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Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease 
characterised by autoantibody production and variable clinical features, ranging 
from mild to severe disease.  Patients with SLE are at increased risk of 
developing accelerated atherosclerosis.  Biomarkers have potential utility in SLE 
as markers of disease or predictors of future clinical events and mortality.   
 
Objective 
The aim of this thesis was to identify serological biomarkers predictive for 
erosive arthritis (EA), cardiovascular events (CVEs), mortality and subclinical 
atherosclerosis in SLE. 
 
Methods 
In chapters 2 to 4, study subjects were SLE patients from Bath.  Anti-cyclic 
citrullinated peptide antibodies (ACPA) and HLA-DR and -DQ were studied for 
markers of EA, and anticardiolipin (aCL) and lipoprotein profiles for markers of 
CVEs and mortality.  In chapters 5 and 6, study subjects were women with SLE 
from Manchester.  B-mode ultrasound scans of subjects' carotid arteries were 
performed at baseline and follow-up time-points to detect atherosclerotic plaque.  
Baseline IgG and IgM antiphospholipid (aPL) antibodies and CV risk factors 
were studied for markers of subclinical atherosclerosis.  Clinical data collected 








ACPA was identified as a marker of a SLE phenotype with EA - "rhupus". 
Patients with major erosive arthritis were HLA-DQB1*0302 carriers.  Increased 
aCL GPL levels and total cholesterol : high density lipoprotein-C (TC : HDL-C) 
ratio were markers for future CVEs, and increased TC : HDL ratio, aCL GPL and 
lipoprotein(a) concentrations were markers for increased mortality.  Lower HDL-
C concentrations and anti-annexin A5 (anti-AnxA5) GPL were markers of carotid 
plaque progression.   
 
Conclusion 
This thesis identified new markers for EA, subclinical atherosclerosis and future 
CVE and mortality risk in SLE.  Strategies to incorporate these new CV markers 
into clinical CV risk assessments may assist in distinguishing the subset of SLE 
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Systemic lupus erythematosus (SLE) is a complex, multi-system, autoimmune 
disease characterised by autoantibody production, immune complex (IC) 
formation and complement activation.  The clinical course is variable, with 
unpredictable disease flares.  The production of multiple autoantibodies with 
differing specificities is a hallmark of the disease and intimately linked to 
mechanisms underlying acute or chronic inflammation which result in target 
organ damage.  Although there may be protean disease manifestations, many 
patients develop characteristic clinical syndromes belonging to distinct disease 
subsets with associated autoantibodies.  The clinical spectrum of disease ranges 
from mild disease such as rash or arthritis, to severe, organ or life-threatening 
disease, such as neuropsychiatric lupus (NP-SLE) or lupus nephritis (LN).  A 
number of clinical features may also be shared with those found in other systemic 
auto-immune diseases, giving rise to the term "overlap syndrome".   
 
SLE predominantly affects females, with a female-to-male ratio of 8:11. The 
overall age-adjusted incidence rate of SLE in the UK from 1989 to 1999 was 
reported as between 3.0 - 4.7 per 100,000 per year.  The female incidence rate 
was 5.3 - 7.9 per 100,000 per year, with male incidence rate of 0.7 - 1.5 per 
100,000 per year1-5.  The highest incidence of SLE occurred in the group of 
females aged 40 to 54 years2, 3, 5.  The overall prevalence rate in the U.K. was 7 - 
26 per 100,000 over the same 1989 to 1999 period2, 3.  Compared with 
Caucasians, SLE occurs more frequently in Afro-Caribbean and South Asian 




100,000 and 20 - 21 per 100,000 for Afro-Caribbeans, South Asians and 
Caucasians respectively2-4, 6.   
 
Biomarkers 
The Biomarkers Working Definitions Group7 defined a biological marker 
(biomarker) as "a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention".  In SLE, biomarkers have great potential 
utility as markers of specific disease characteristics, measures of disease activity 
or severity, or as predictors of future clinical events and mortality.  Such 
biomarkers would provide useful information to guide clinicians' therapeutic 
decisions and monitoring.  Due the nature of SLE with its complex pathogenesis, 
heterogeneous clinical manifestations and unpredictable disease course, multiple 
biomarkers may be required.  However, a major challenge in SLE research is to 
identify a biomarker with high predictive value, yet is cost-effective and feasible 
to perform in routine clinical practice.   
 
Review criteria 
This chapter reviews the published literature on biological factors associated with 
arthritis, accelerated atherosclerosis and long-term outcomes of clinical events 
and mortality in the context of SLE.   
 
The objectives of this chapter were to review: 
1. Associations of auto-antibodies with clinical features shared by SLE and 
other autoimmune diseases 
2. Genetic markers associated with SLE and rheumatoid arthritis (RA) 
3. Traditional cardiovascular (CV) risk factors and SLE-associated risk factors 
predictive of mortality in SLE 
4. Traditional CV risk factors and SLE-associated risk factors predictive of 




5. Traditional CV risk factors and SLE-associated risk factors associated with 
subclinical atherosclerosis in SLE 
6. Inflammatory and autoimmune mechanisms in SLE with potential influence 
on accelerated atherosclerosis 
 
Inclusion criteria for epidemiological studies of SLE patients were systematic 
reviews, meta-analyses, SLE cohort studies and case-control studies with the 
above objectives published in peer-reviewed journals. Case series and case 
reports were excluded. Publications on SLE disease pathogenesis, atherogenesis 
and lipoprotein biology were also included in this review.  
 
Full-text publications published in English between 1970 and 2011 were 
identified from PubMed searches, using the terms (either alone or in 
combination): "systemic lupus erythematosus", "SLE", "Major Histocompatibility 
Complex", "HLA", "genetic", "shared epitope", "antibody", "anti-CCP", 
"rheumatoid arthritis", "erosive arthritis", "Jaccoud's arthritis", "rhupus", 
"antiphospholipid", "lupus anticoagulant", "anticardiolipin", "annexin A5", "β2-
glycoprotein I", "prothrombin", "mortality", "thrombosis", "subclinical", 
"atherosclerosis", "endothelial dysfunction", "Toll-like receptor", "Type I 
interferon", "lipid profile", "lipoprotein lipase", "high density lipoprotein", 
"apolipoprotein-A1" and "lipoprotein(a)".  Further papers were identified by 
searching the reference lists of the selected articles. 
 
The majority of available evidence identified using the above inclusion criteria 
comprised cohort studies (both prospective and retrospective), which would be 
expected for SLE, which is an uncommon disease.  The main limitations of 
cohort studies, in particular retrospective studies, would be selection bias and 
confounding with respect to multiple predictor variables.  These potential effects 
were taken into account in this chapter's tables by summarising results from 
studies that used multivariate analyses to adjust for these effects.  Highly cited 
studies were also included in the tables, with clarification where no statistical 




retrospective cohort and case-control studies reviewed in this chapter. However, 
consistent results were found in several publications, including multi-centre 
studies with large cohorts of patients with differing ethnicities, which reduces 
possible bias.   
 
1.  Autoantibodies as biomarkers in SLE 
1.1.  Autoantibodies as diagnostic biomarkers 
Anti-nuclear antibodies (ANA) are useful for the diagnosis of SLE, since they are 
found in over 95% of patients8, 9.  ANA are usually determined by 
immunofluorescence in the HEp-2000 assay and comprise one of the American 
College of Rheumatology (ACR) 1997 revised SLE classification criteria (see 
Appendix).  However, they are not specific for SLE, as they are also found in 
patients with other autoimmune diseases and in 12% of the healthy population10.  
Apart from a centromere staining pattern, which is associated with limited 
cutaneous systemic sclerosis (SSc), the pattern and titre of a positive ANA result 
are not specific for SLE and other antibodies would be more diagnostic for a case 
of suspected SLE.  Anti-double-stranded DNA (anti-dsDNA) and anti-Smith 
(anti-Sm) are highly specific for SLE and are present in up to 80% and 55% of 
patients respectively, but in less than 1.1% of the healthy population9, 11-13.  
 
1.2.  Pathogenicity of autoantibodies in SLE 
Arbuckle et  al. found the presence of autoantibodies in sera of patients with SLE 
up to 9.4 years before their diagnosis12.  There was a temporal order of 
autoantibody appearance, with anti-Ro/SSA, anti-La/SSB, ANA and 
antiphospholipid antibodies (aPL) appearing first, followed by anti-dsDNA, and 
finally anti-Sm and anti-U1 ribonucleoprotein (anti-U1RNP).  Animal studies, as 
well as human clinical and tissue-based studies, have provided evidence for the 
pathogenicity of these autoantibodies11.  IgG anti-Ro/SSA from sera of mothers 




heart tissue14.  Passive transfer of human monoclonal IgG aPL into pregnant mice 
caused fetal loss15, 16.  Mechanisms by which aPL cause fetal loss include 
placental vessel thrombosis, complement activation and disruption of the annexin 
A5 (AnxA5) anticoagulant shield on syncytiotrophoblasts and umbilical vein 
endothelial cells16-19.  Further evidence of autoantibody pathogenicity was 
provided by studies demonstrating deposition of human monoclonal IgG anti-
dsDNA in murine glomeruli with induction of proteinuria20, 21.  In humans, more 
severe types of LN were associated with higher levels of IgG anti-dsDNA, but 
not with IgM anti-dsDNA or IgG anti-single-stranded DNA antibodies (anti-
ssDNA)22.  Higher anti-dsDNA titres were associated with increased disease 
activity, as defined by exacerbations of SLE clinical manifestations23.  In 
contrast, some SLE patients may have elevated IgG anti-dsDNA accompanied by 
low complement levels for years, without  developing disease exacerbations24.  
This suggests that only certain autoantibody subsets are pathogenic in SLE.  This 
factor should be taken into account with respect to studies correlating quantitative 
measurements of antibodies with clinical outcome measures.   
 
1.3  Autoantibodies as biomarkers of SLE clinical disease subsets 
Several studies have demonstrated auto-antibody associations with SLE disease 
subsets (Table 1.1). The Euro-lupus cohort comprised 1000 European SLE 
patients studied prospectively from 1991 to 200025-27.  Patients with high titres of 
anti-dsDNA antibodies were more likely to have arthritis, active LN and 
haemolytic anaemia, and less likely to have a discoid rash.  Patients with anti-
Ro/SSA antibodies more frequently had subacute cutaneous lupus (SCLE) and 
patients who were rheumatoid factor (RF) positive had a lower incidence of 
active LN and thrombosis.  Thrombosis and thrombocytopenia occurred more 
frequently in patients with IgG anticardiolipin antibodies (aCL GPL) or lupus 
anticoagulant (LA).  Arthritis occurred less frequently in aCL GPL positive 
patients.  In other studies, anti-Sm was associated with renal involvement, NP-
SLE and lymphopenia27, 28.  Witte et al. found that RF-positive SLE patients were 




LN29. David-Bajar et al. found a distinctive pattern of staining on direct 
immunofluorescence termed "particulate epidermal IgG deposition" in lesional 
skin biopsies from seven anti-Ro/SSA positive patients with SCLE.  Infusion of 
anti-Ro/SSA into human skin-grafted mice reproduced this staining pattern, 
which was absent in patients with discoid lupus erythematosus (DLE)30.   
 
Several auto-antibodies are more characteristic of other autoimmune diseases, 
although they may share similar clinical subsets with SLE.  Anti-Ro/SSA and 
anti-La/SSB are markers of Sjögren's syndrome (SS).  Babies born to mothers 
with SLE or SS and anti-Ro/SSA or anti-La/SSB antibodies have an increased 
risk of developing neonatal lupus, including congenital heart block (CHB)31, 32.  
Alexander et al. found that anti-Ro/SSA positive patients with primary or  
secondary SS (including SS secondary to SLE) had more frequent extra-glandular 
manifestations such as vasculitis, purpura, and lymphadenopathy, as well as 
haematological abnormalities of anaemia, leucopenia, and thrombocytopenia33.  
In the Euro-lupus cohort, anti-Ro/SSA was associated with a higher prevalence of 
SCLE and the sicca syndrome and a lower prevalence of thrombocytopenia27, 
while anti-La/SSB was associated with arthritis, serositis and cutaneous 
manifestations of malar rash, SCLE, and photosensitivity27.  Anti-U1RNP is an 
antibody associated with mixed connective tissue disease (MCTD).  In SLE 
patients, it is associated with Raynaud's phenomenon, arthritis, myositis, pleurisy 
and pulmonary arterial hypertension (PAH), features characteristic of MCTD26, 34-
36.  Antibodies associated with overlapping autoimmune disease manifestations 
could therefore be studied as potential SLE biomarkers.   
 
1.4.  Antiphospholipid antibodies 
Antiphospholipid antibodies (aPL) are a group of autoantibodies directed against 
complexes of phospholipids (PL) with phospholipid-binding proteins, such as β2-
glycoprotein I (β2GPI) or prothombin (PT)37.  Targeted phospholipids include 





The antiphospholipid syndrome (APS) is a clinical syndrome in which the 
presence of persistent aPL is associated with arterial or venous thrombosis, 
thrombocytopenia and pregnancy morbidity, including spontaneous fetal loss25, 27, 
38.  APS may occur alone (primary APS), or in association with SLE and other 
auto-immune diseases39, 40, and its prevalence has been reported to be between 
23% and 42% in different SLE cohorts41-43.   
 
ACL, anti-β2GPI  and LA are the 3 types of aPL included in the updated 2006 
classification criteria for APS44 (see Appendix).  β2GPI is the main co-factor for 
antibody binding to cardiolipin45.  ACL, anti-β2GPI and other APL are usually 
determined by enzyme-linked immunosorbent assays (ELISAs) of serum 
samples, whereas LA is determined by functional coagulation assays, including 
the activated partial thromboplastin time (aPTT), dilute Russell's viper venom test 
(dRVVT) and kaolin clotting time (KCT).  LA activity is due to a set of 
heterogeneous autoantibodies comprising aPL directed against cardiolipin, β2GPI 
and other phospholipid-binding proteins such as PT, PS and annexin A5 
(AnxA5).  ACL and anti-β2GPI are therefore significantly associated with LA42, 
46, 47. The overall prevalence of aCL and LA in SLE has been reported as up to 
44% and 34% respectively42.   
 
1.4.1.  APL as predictors of future thrombosis 
Previous studies have confirmed the utility of aPL (including LA, aCL and anti-
β2GPI) as predictors for future arterial thrombosis, including stroke and 
myocardial infarction (MI), venous thrombosis and APS38, 41, 48-57.  In a study of 
21 aCL-positive patients attending a London tertiary referral centre, 11 (52%) 
developed APS during the 10-year follow-up period51.  Several studies have 
shown that thrombosis occurs less frequently in non-SLE cohorts with LA than in 
SLE patients with LA42.  LA is the strongest aPL predictor for both arterial and 
venous thrombosis38, 46, 48, 50, 58, 59.  However, in the Euro-lupus cohort, only 43% 
of SLE patients positive for LA developed thrombotic episodes25.  In SLE 
populations, high-titre aCL are predictors for future thrombosis42, 52 including 




Danowski et al. showed that anti-β2GPI GPL increased the risk for arterial and 
venous thrombosis and anti-β2GPI MPL increased the risk of arterial thrombosis 
among patients with SLE and primary APS62.  In contrast, no associations were 
found between aPL/LA and thrombosis in the LUpus in MInority populations: 
NAture versus nurture (LUMINA) cohort63.  The LUMINA cohort comprises a 
multi-ethnic (Hispanic, African-American and Caucasian) cohort of 442 
American SLE patients followed prospectively.  The "2 hit hypothesis" has been 
proposed to provide an explanation for the observation that thrombotic events 
occur only occasionally, despite the persistence of aPL64.  According to the 
hypothesis, aPL constitute the first hit by inducing a pro-thrombotic state, 
however, thrombosis only occurs in the presence of a second pro-thrombotic 
condition (the second hit).  Rauch et al. suggested that the second hit may involve 
activation of the innate immune system, possibly through triggering of Toll-like 
receptors (TLRs) such as TLR465.  Another possible explanation is that not all 
aPL are pathogenic, due to differences in autoantibody specificities.  For 
example, anti-β2GPI with LA activity correlate better with thrombosis, due to 
increased specificity of aPL that bind domain I on β2GPI.  One likely pathogenic 
mechanism is that anti-β2GPI directed against domain I confer increased 
resistance to the anticoagulant properties of AnxA566.  However, the specificity 
of LA may vary depending on different laboratory assay methods, which may in 
turn affect the predictive ability of aPL for APS manifestations.  The likelihood 
of detecting pathogenic aPL may be increased if moderate to high aPL titres are 
present67.  
 
Other factors have been found to be protective for thrombosis.  The presence of 
anti-nuclear lamin B1 (anti-LB1) is associated with protection against thrombosis 
in SLE patients who are LA positive68.  A recent multi-ethnic study of 1930 SLE 
patients found that hydroxychloroquine (HCQ) had an independently protective 
effect for thrombosis69, a finding that was also reported by another group70.  
These results provide further evidence of the complexity of the pathogenesis of 
thrombosis in SLE, where multiple interacting factors may modify the final 




1.4.2  APL in atherosclerosis  
There is emerging evidence suggesting pro-atherogenic roles for aPL in 
atherosclerosis.  The increased risk of thrombotic events and CVEs in SLE 
patients with aPL may partly be due to cross-reactivity between aCL and anti-
oxLDL antibodies, reflecting a state of pro-atherogenic oxidative stress71.  
Cardiolipin is a component of lipoproteins such as LDL and HDL and hence aCL 
may play a role in lipoprotein lipid peroxidation72.  However, although pro-
atherogenic actions of aPL have been described, the evidence for aPL as clinical 
biomarkers of atherosclerosis is less clear.  IC have been reported to be risk 
factors for atherosclerosis in the general population.  In a prospective study of 
257 healthy, 50-year old men, increased levels of circulating IC and aCL GPL 
independently predicted future MI73.  ACL has been associated with MI in 
several studies56, 74.  Vaarala et al. prospectively followed middle-aged men 
prospectively and found that elevated aCL levels were independent predictors for 
future MI or cardiac death56.  Bili et al. showed that elevated aCL GPL and low 
aCL MPL levels were independent risk factors for recurrent cardiac events in 
post-MI patients75.  Hamsten et al. found that 21% of post-MI patients aged under 
45 years had persistent aCL, a predictor for recurrent CVEs76.  In this study, high 
aCL levels were also positively correlated with anti-oxLDL levels.  In the 
Honolulu Heart Program, β2GPI-dependent aCL GPL was associated with future 
ischaemic stroke and MI77.  In contrast, in a cross-sectional study of patients with 
acute coronary syndromes (ACS), Edwards et al. found no association with aCL 
GPL or MPL78.  Other studies have also reported similar negative results79, 80.  
Within the general population, aPL are also strong predictors for initial ischaemic 
stroke79, 81, 82.   
 
In SLE patients, the role of aPL in atherosclerosis remains unclear.  Gustafsson et 
al. prospectively followed 182 SLE patients and showed that aPL was an 
independent predictor for initial CVEs83.  APL was also an independent predictor 
for future CVEs in the LUMINA cohort84.  In the Hopkins Lupus Cohort, LA was 
associated with stroke and MI, however, other aPL were associated with stroke, 




associated with the presence of carotid plaque in women with SLE85.   In 
contrast, other studies of SLE patients found no independent associations for aPL 
with the subclinical atherosclerosis markers of carotid plaque, carotid IMT, or 
coronary calcification86-88.  Possible explanations for these inconsistent results 
include the presence of non-pathogenic aPL which may dilute the overall clinical 
effect of pathogenic aPL, a non-pro-coagulant state, or low disease activity.  
Furthermore, it remains to be determined whether specific aPL, such as anti-
β2GPI, are able to exert differential effects in various stages of the atherosclerotic 
process.   
 
1.4.3.  Anti-β2-glycoprotein I  
β2GPI is a highly-conserved, single-chain glycoprotein with 5 domains which 
binds to negatively-charged PLs via its fifth domain89.  β2GPI also binds other 
negatively charged structures such as heparin, DNA, oxLDL, lipoprotein(a) 
[Lp(a)], and apoptotic cell membranes and syncytiotrophoblasts via exposed 
PS89.  β2GPI forms stable complexes with oxLDL, possibly providing an anti-
oxidant effect, and inhibits oxLDL uptake by murine macrophages via scavenger 
receptors90, 91.  Moreover, β2GPI binds to cell surfaces of activated ECs, 
monocytes, and platelets92.  β2GPI is thought to play a regulatory function in the 
coagulation cascade, through inhibition of activation of Factors XI and XII, 
interference with thrombin generation by the prothrombinase complex89, and 
inhibition of platelet adhesion and aggregation by binding to vWF93.   
 
Multiple studies have demonstrated pro-thrombotic and pro-atherogenic effects 
for anti-β2GPI.  Kobayashi et al. found that murine macrophage uptake of oxLDL 
was enhanced in the presence of both β2GPI and anti-β2GPI GPL, most likely 
mediated by Fcγ receptors94.  In contrast, IgM anti-oxLDL reduced macrophage 
oxLDL uptake, suggesting opposing effects of aPL GPL and MPL90. β2GPI  has 
been detected in human atherosclerotic plaques, where it is co-located with T 




β2GPI complexes promote atherogenesis by enhancing macrophage oxLDL 
uptake and subsequent foam cell formation94.   
 
Anti-β2GPI binds β2GPI adherent to EC cell membranes via a TLR 4/annexin A2-
containing multiprotein complex to activate EC expression of adhesion molecules 
and chemokine production92, 96-99.  Anti-β2GPI has been shown to promote 
monocyte release of TNF-α and TF, possibly via triggering of TLR2 or TLR4 - 
mediated NF-κB activation100.  Furthermore, Lambrianides et al. found that anti-
β2GPI GPL from APS patients with venous thrombosis activated monocyte 
production of TF via TLR4101.  These studies highlight the complexity of anti-
β2GPI interactions with innate immune mechanisms in atherogenesis. 
 
Clinical studies have also provided support for the pro-atherogenic effects of anti-
β2GPI in the general population.  The presence of anti-β2GPI GPL or MPL was 
found to be an independent risk factor for MI in young premenopausal women102.  
IgA anti-β2GPI was associated with ACS103.  Greco et al. showed that anti-β2GPI 
was the most frequent aPL type in patients with ACS, occurring in 54% of aPL 
positive patients with IHD104.  Antibodies to oxLDL-β2GPI complexes occurred 
in 48% of aPL positive patients with IHD.  Moreover, anti-β2GPI and/or anti-
oxLDL-β2GPI were associated with increased IHD severity and adverse 
outcomes, providing support for a pro-atherogenic role for these autoantibodies.   
 
Elevated levels of oxLDL-β2GPI complexes and anti-oxLDL-β2GPI GPL have 
also been found in patients with SLE and APS, and were associated with an 
increased risk of arterial thrombosis105, 106.  However, Lopez et al. found no 
associations of anti-oxLDL-β2GPI GPL or MPL with carotid plaque or IMT in 
patients with SLE106.   
 
1.4.4.  Anti-prothrombin  
Prothrombin (PT) is a vitamin K-dependent glycoprotein which binds to 




prothrombinase complex (comprising activated Factors X and V, calcium and 
PLs), and converted to thrombin.  Thrombin has several anticoagulant actions, 
including converting fibrinogen into fibrin and binding to thrombomodulin on the 
EC surface to activate protein C.  In turn, activated protein C exerts a negative 
feedback effect on the prothrombinase complex and therefore PT.  PT also acts 
on Factors V, VIII, and XIII and platelets107 and binds to apoptotic cells, serving 
as a target for LA108.  Anti-PT antibodies may be determined by ELISA using PT, 
or PT bound to PS as the antigen109.  Anti-PTs targeting PS-PT complexes have 
been found to correlate best with arterial and venous thrombosis in patients with 
SLE110, 111.  Anti-PT has also been associated with atherosclerosis.  High anti-PT 
levels were predictive for MI or cardiac death in middle-aged, dyslipidaemic 
men112.   
 
1.4.5.  Anti-annexin A5 
Annexin A5 (AnxA5) belongs to the annexin family of proteins which bind 
negatively charged PLs in a Ca2+ dependent manner113.  AnxA5 binds with high 
affinity to PS, a potent, pro-coagulant PL.  PS is usually confined to the inner 
leaflet of the cell membrane, however, during cell apoptosis, it is translocated to 
the external cell membrane and is found on the highly immunogenic surface 
blebs of apoptotic cells113, 114.  After binding PS on the cell surface, AnxA5 self-
assembles into two-dimensional (2D) crystalline arrays113,  forming a shield 
which inhibits coagulation and apoptosis115, 116 and promotes repair of disrupted 
cell membranes117.  During placental development, villous syncytiotrophoblasts 
express surface PS, to which AnxA5 binds and forms 2D arrays, preventing 
coagulation115.   Plasma from patients with APS demonstrate inhibition of AnxA5 
binding to ECs118 and resistance to AnxA5 anticoagulant activity119, 120.  APL can 
also disrupt the organisation of cell surface AnxA5 2D arrays18.  These 
mechanisms may explain the association of anti-AnxA5 with arterial and venous 





AnxA5 may also have a protective role in atherosclerosis.  In vitro, AnxA5 binds 
to negatively charged PLs within oxLDL, which suggests that AnxA5 may 
directly inhibit the pro-coagulant and pro-inflammatory effects of oxLDL122.  
Endothelial dysfunction is present early in the atherosclerotic process and AnxA5 
improves endothelial dysfunction by acting on NO signalling, reducing leucocyte 
adhesion to activated endothelium, and reducing expression of the pro-
inflammatory cytokines MCP-1 and TNF-α123. Cederholm et al. demonstrated 
that AnxA5 was abundant at sites prone to rupture in advanced atherosclerotic 
plaques, suggesting that AnxA5 may act to stabilise atherosclerotic plaque124.   
They also reported that plasma containing aCL from SLE patients with CVD 
inhibited AnxA5 binding to endothelium124.  Hydroxychloroquine inhibits aPL 
disruption of AnxA5 binding to ECs and hence increases the anticoagulant effects 
of plasma AnxA5 from patients with APS125.  
 
1.5.  Summary 
There are several aspects to consider about autoantibodies as SLE biomarkers. 
• Diagnostic biomarkers -  ANA is not a specific marker, whereas anti-
dsDNA and anti-Sm are.  
• Autoantibody pathogenicity - certain autoantibodies cause specific organ 
damage e.g. anti-dsDNA and lupus nephritis, aPL and fetal loss. 
• Biomarkers of disease subsets - some autoantibodies are markers of SLE 
disease subsets common to other auto-immune diseases e.g. anti-Ro/SSA 
or anti-La/SSB and sicca symptoms, neonatal lupus or congenital heart 
block. 
• APL - LA, aCL, anti-β2GPI are associated with arterial and venous 
thrombosis, however not all aPL are pro-thrombotic and it has been 
proposed that an additional condition is required for a thrombotic event to 
occur, possibly involving the immune system. 
• APL in atherosclerosis - aPL are associated with CVEs in the general 




populations, including associations of aPL with IHD and subclinical 
atherosclerosis. 
• Anti-β2GPI has both pro-thrombotic and pro-atherogenic effects. 
Circulating anti-oxLDL-β2GPI GPL complexes have been associated with 
arterial thrombosis in SLE. 
• Anti-PT predicts both arterial and venous thrombosis in SLE. 
• Anti-AnxA5 - AnxA5 has a protective role against thrombosis and in 
atherosclerosis, through its ability to form crystalline arrays on 
endothelial cell surfaces. Anti-AnxA5 exerts a pathogenic effect in 
atherosclerosis through its inhibition of AnxA5 binding to endothelium. 
 
Table 1.1 below presents the associations of autoantibodies with distinct clinical 






Table 1.1.  Associations of antibodies with SLE clinical features 




sample size  Antibody Associated SLE clinical features 
Cervera et al (1993)25 prospective cohort - 
cross-sectional (Euro-
lupus) 
- 1000 anti-dsDNA LN, haemolytic anaemia, fever; less thrombosis, sicca 
   anti-Ro/SSA SCLE, sicca; less thrombocytopenia 
   anti-La/SSB malar rash, SCLE, photosensitivity, arthritis, serositis, thrombosis; less 
lymphadenopathy 
    anti-U1RNP Raynaud's phenomenon, myositis, lymphadenopathy 
    anti-Sm oral ulcers, myositis; less sicca 
    aCL GPL thrombosis, spontaneous fetal loss, thrombocytopenia,  
livedo reticularis 
    aCL MPL thrombosis, thrombocytopenia, haemolytic anaemia 
    LA thrombosis, spontaneous fetal loss, thrombocytopenia, chorea 
    RF discoid rash, sicca; less LN 
Cervera et al (1999)26 prospective cohort  
(Euro-lupus) 
5 1000 anti-dsDNA arthritis, active LN, haemolytic anaemia; less discoid rash 




                                          anti-U1RNP  Raynaud's phenomenon, myositis 
    aCL GPL thrombosis, fetal loss, thrombocytopenia; less arthritis 
    aCL MPL haemolytic anaemia 
    LA thrombosis, thrombocytopenia 
    RF less active LN, thrombosis 
Cervera et al (2009)27   prospective cohort  
(Euro-lupus) 
10 1000 anti-dsDNA LN, haemolytic anaemia, fever; less sicca, thrombosis 
  anti-Ro/SSA SCLE, sicca; less thrombocytopenia 
                                           anti-La/SSB malar rash, SCLE, photosensitivity, arthritis, serositis, thrombosis  










sample size  Antibody Associated SLE clinical features 
Cervera et al (2009)27          prospective cohort 
(Euro-lupus)                          
10  1000 anti-Sm oral ulcers, myositis; less sicca 
  aCL GPL thrombosis, fetal loss, thrombocytopenia 
                                               aCL MPL thrombosis, fetal loss, thrombocytopenia, haemolytic anaemia 
    RF sicca, less LN 
Bastian et al (2002)126  prospective multi-
ethnic cohort (LUMINA) 
up to 7 353 anti-dsDNA,  
anti-RNP 
LN 
Hitchon & Peschken 
(2007)28     
retrospective cohort - 330 anti-dsDNA renal disease 
  anti-Ro/SSA discoid rash, hypocomplementaemia, leucopenia, lymphopenia 
    anti-La/SSB hypocomplementaemia, leucopenia, lymphopenia 
    anti-RNP renal disease, NP-SLE (psychosis, neuropathy), proteinuria, pleuritis, 
vasculitis, scarring alopecia, deforming arthritis 
    anti-Sm renal disease, proteinuria, NP-SLE (seizures, psychosis), vasculitis, 
lymphopenia, fever 
Hanly et al (2011)58 inception cohort 
(SLICC) 
mean 3.6  1047 anti-ribosomal P psychosis 
   LA intracranial thrombosis 
Mittoo et al (2010)35                                                       prospective cohort - 876 anti-U1RNP, anti-
Sm 
pleurisy 
Lian et al (2012)34                                                  retrospective case-
control 
9  41 PAH cases 
+ 106 controls 
anti-U1RNP pulmonary arterial hypertension 
Love (1990)42 systematic review  29 published 
reports  
(total n > 1000) 
aCL, LA thrombosis, neurological disease, thrombocytopenia 
Horbach (1996)48 retrospective case-
control 
 175 + 23 
controls 
high titre aCL GPL / 
MPL, high titre IgG / 











sample size  Antibody Associated SLE clinical features 
Somers et al (2002)38 prospective cohort 
(Hopkins) 
up to 14  352 high titre aCL GPL / 
MPL, LA 
venous thrombosis 




 105 aCL GPL > 40 venous thrombosis 




 413 IgG anti-β2GPI arterial & venous thrombosis, livedo reticularis 
  IgM anti-β2GPI arterial thrombosis 
Bertolaccini (1998)127    207 anti-PT thrombosis 
Lakos et al (2000)128 retrospective case-
control 




IgG anti-β2GPI, IgG 
anti-PT,  
IgG anti-AnxA5 
venous thrombosis, APS 
Kaburaki et al 
(1997)121 
retrospective cohort up to 20 140 anti-AnxA5 arterial or venous thrombosis, fetal loss 
Witte et al (2000)29 retrospective cohort  352 RF active arthritis, sicca, Raynaud's phenomenon; less LN,  
livedo racemosa 
Chan et al (2008)129 retrospective cohort + 
controls (Bath) 
 104 + 130 
serum controls  
ACPA erosive arthritis 
Qing (2009)130 retrospective cohort  267 ACPA erosive arthritis 






2. Genetic biomarkers of SLE 
Genetic predisposition to the development of SLE is an important factor in the 
pathogenesis of SLE.  Genetic markers of SLE disease susceptibility have been 
shown to code for proteins involved in innate and adaptive immunity, including 
autoantibodies.   
 
The extended Major Histocompatibility Complex (MHC) comprises three 
genomic regions (class I, II and III) found on chromosome 6.  In humans, the 
MHC class I and II regions encode human leukocyte antigen (HLA) molecules, 
which present peptides to CD8+ and CD4+ T lymphocytes respectively.  MHC 
class I molecules are ubiquitously expressed, whereas MHC class II molecules 
are primarily expressed by professional antigen presenting cells (APC), such as 
dendritic cells (DC), macrophages and B cells.  In general, MHC class I 
molecules present intracellularly-derived peptides and MHC class II molecules 
present exogenous peptides.  MHC class I α chains are encoded by three classical 
HLA genes, HLA-A, HLA-B and HLA-C.  MHC class II α and β chains are 
encoded by HLA-DR, HLA-DQ and HLA-DP.  All six genes exhibit a high degree 
of polymorphism.  MHC class III genes encode cytokines such as TNF, early 
complement components, heat shock proteins and other proteins with potential 
immunomodulatory function132, 133.   
 
Haplotypes refer to closely-linked clusters of genes that are inherited together.  
Ancestral haplotypes (AH) contain conserved continuous gene sequences which 
appear to be derived from a common remote ancestor134.  The most well-known 
genetic susceptibility factors for Caucasian SLE patients are the MHC haplotypes 
HLA-B8, DR3 (DRB1*03) and HLA-B7, DR2 (DRB1*1501)135-137.  HLA-B8, DR3 
(DRB1*03) forms part of the ancestral haplotype AH8.1, comprising HLA-A1, 
Cw7, B8, TNFAB*a2b3, TNFN*S, C2*C, Bf*S, C4A*Q0, C4B*1, DRB1*0301, 
DRB3*0101, DQA1*0501, DQB1*0201.  AH8.1 is commonly found in Northern 




diseases, including SLE138.  A microsatellite mapping study of 334 families of 
predominantly Caucasian SLE patients identified three MHC class II risk 
haplotypes - DRB1*1501(DR2) / DQB1*0602, DRB1*0801(DR8) / DQB1*0402, 
and DRB1*0301 (DR3) / DQB1*0201139.  The estimated relative risk (RR) for 
developing SLE for each of the three haplotypes was between 1.3-fold and 2.3-
fold in a gene dose-dependent fashion, with DRB1*0301 (DR3) / DQB1*0201 
conferring a higher risk than the other haplotypes.  Compound heterozygotes 
exhibited the highest risk of 5.2-fold for developing SLE.  
 
Two MHC class III alleles, C4 "null" (C4A*Q0) and TNF-α -308A, have been 
proposed as susceptibility alleles140.  Hereditary deficiencies of early components 
of the classical complement pathway (C2 and C4) are associated with SLE 
susceptibility141 and a significant association of the TNF-α -308A allele with 
SCLE was also reported142-144. However, as both alleles are inherited in linkage 
disequilibrium and form part of the AH8.1 haplotype135, 145, it is difficult to be 
certain of the independent causality of these alleles, thus limiting interpretation of 
these data. 
 
The MHC class II genes HLA-DR2 and HLA-DR3 confer a 2-fold RR for 
developing SLE in Caucasian populations146.  However, there are differences in 
the autoantibody associations with both haplotypes.  Several studies have 
confirmed the association of HLA-DR3 with the production of both anti-Ro/SSA 
and anti-La/SSB antibodies147, 148.  The HLA-DR2 haplotype is associated with 
anti-Ro/SSA, anti-Sm and anti-dsDNA, but not with anti-La/SSB145, 147-151.  
Compound heterozygotes for HLA-DR2 / HLA-DR3 have the highest risk for 
developing anti-Ro/SSA, with a RR of up to 15-fold149, 151, 152.  Moreover, there 
are differences in the clinical phenotypes associated with both haplotypes.  
Babies born to anti-Ro/SSA positive mothers with the HLA-A1, B8, DR3 
haplotype are at increased risk of developing neonatal lupus, compared with 
babies born to anti-Ro/SSA positive mothers with the HLA-DR2 haplotype153.  
The HLA-A1, B8, DR3 haplotype with anti-Ro/SSA antibodies is also associated 




DR3 haplotype are more likely to be older at disease onset, with sicca symptoms 
and less renal involvement151.  Other HLA associations with SLE have also been 
reported.  In the LUMINA cohort, patients with LN were more likely to carry 
HLA-DRB1*13 and less likely to carry HLA-DQB1*0201126.  The HLA-DR4 
haplotype was reported to be protective against the development of SLE150, 
however it has been associated with aCL and anti-β2GPI in other SLE studies152, 
156-158.  HLA-DQB1*0301 (HLA-DQw7) was found to be associated with the 
presence of LA in SLE and in primary APS159.  
 
Candidate gene studies in SLE have yielded non-MHC genes related to type I 
interferon (IFN) production, including signal transducer and activator of 
transcription 4 (STAT4) and interferon regulatory factor 5 (IRF5)160.  The type I 
IFN system constitutes a family of cytokines, including IFN-α and IFN-β, that 
can be produced by all nucleated cells upon recognition of conserved viral and 
bacterial structures161.  Protein products of type I IFN-inducible genes have 
complex regulatory roles in immunological pathways involved with chronic 
inflammation161.  Studies of patients with SLE have demonstrated elevated serum 
levels of type I IFN and type I IFN-inducible genes162, which were associated 
with high disease activity, LN, NP-SLE, cutaneous lupus and the presence of 
autoantibodies such as anti-dsDNA, anti-Ro/SSA, anti-U1RNP and anti-Sm162, 
163.   
 
Recent genome-wide association studies (GWAS) have further identified 
susceptibility loci for SLE that encode proteins involved in innate and adaptive 
immune responses and IC clearance164.  These loci include the B-lymphoid 
tyrosine kinase (BLK) promoter region, integrin alpha M (ITGAM) and tumour 
necrosis factor alpha-induced protein 3 (TNFAIP3)160, 165.  A recent meta-
analysis confirmed the independent associations of genetic variants at the IRF5, 
STAT4, BLK, ITGAM and TNFAIP3 loci with SLE166.  IRF5, when activated by 
triggering of intracellular TLRs, TLR7 or TLR9, induces transcription of type I 
IFNs and pro-inflammatory cytokines such as TNF-α, interleukin-6 (IL-6) and 




three alleles conferring increased risk for SLE and two others conferring 
protection160, 167, 168.  Niewold et al. found that high-risk IRF5 genotypes were 
associated with higher serum IFN-α activity in Caucasian SLE patients and this 
effect mainly occurred in patients positive for anti-Ro/SSA and/or anti-La/SSB, 
or anti-dsDNA autoantibodies.  These antibodies were proposed as activators of 
IRF5 through TLR7 or TLR9 binding, causing differing downstream effects on 
cytokine production167, 169.  STAT4 encodes a nuclear transcription factor that 
transmits signals induced by several cytokines, including type I IFNs and IL-
12/IL-23170.  Activated STAT4 stimulates transcription of specific genes involved 
in the T helper-1 (Th1)-type immune response, including IFN-γ171.  The STAT4 
risk gene increases the risk of developing severe manifestations of SLE, 
including renal disease172.  ITGAM is a major susceptibility gene for SLE which 
encodes the α-chain of αMβ2-integrin (also known as Mac-1, CD11b/CD18, or 
complement receptor type 3 [CR3]), a cell-surface receptor mediating immune 
cell adhesion, IC processing and apoptosis regulation173. ITGAM risk alleles are 
significantly associated with discoid rash in SLE174, and impaired αMβ2-integrin 
function may be involved the upregulation of apoptosis genes within evolving 
discoid lesions175.  Furthermore, the ITGAM SNP rs9888739 is associated with 
less frequent arthritis in SLE176.  STAT4 and ITGAM risk alleles are associated 
with anti-dsDNA production in SLE176.  BLK encodes a Src tyrosine kinase 
specifically expressed in B-cell lines.  BLK influences the proliferation, 
differentiation and tolerance of B cells140.  The SLE risk allele is found in the 
BLK promoter region and causes reduced BLK expression, resulting in impaired 
B-cell signalling177.  TNFAIP3 encodes A20, a de-ubiquitinating protein that 
negatively regulates nuclear factor-κB (NF-κB)-induced pro-inflammatory 
responses that are stimulated upon triggering of TLRs.  A20 has anti-apoptotic 
and anti-inflammatory effects, which are impaired in SLE178.  Considered 
together, these genetic studies provide new insights into the auto-immune and 






2.1  Summary 
• Recently discovered genetic markers have provided new markers of SLE 
disease susceptibility, in addition to the known MHC Class II genes HLA-
DR2 and HLA-DR3 and Class III genes C4A*Q0 and TNF-α -308A. 
• Recently defined SLE susceptibility genes include non-MHC genes 
related to type I IFN production (e.g. STAT4, IRF5), and innate and 
adaptive immune responses (e.g. BLK, ITGAM, TNFAIP3). 
• Some of these susceptibility genes are also associated with SLE clinical 
features, e.g. STAT4 and lupus nephritis. 
 
Table 1.2 below summarises the known associations of immunogenetic markers 









Table 1.2.  Clinical associations of genetic markers in SLE 
Authors (year) Gene  
Marker / 







  MHC Class II  
       
Hochberg et al (1985)147 HLA-DR3 / HLA-
DRB1*03 
 HLA-DR3 / HLA-
DRB1*03 / 
DQB1*0201 
6p DR3 anti-Ro/SSA & 
anti-La/SSB 
(Caucasians) 
older age at 
disease onset  
  
 HLA-DR2 / HLA-
DRB1*15 
 HLA-DR2 /  HLA-
DRB1*1501 / 
DQB1*0602 





younger age at 
disease onset  
  
Watson et al (1984)153 HLA-DR3 / HLA-
DRB1*03 
 HLA-A1, B8, DR3, 
DR52 (MT2), DQ2 
(MB2)  
6p DR3 anti-Ro/SSA  neonatal lupus 
in offspring 
  




 HLA-DR3 / HLA-
DRB1*03 / 
DQB1*0201 
6p DR3, DR2 anti-Ro/SSA &/or 
anti-La/SSB 
   
 HLA-DR1  or 
DR4 
 HLA-DR1 or HLA-
DR4  
6p DR1, DR4 anti-Sm &/or anti-
RNP 
   
Hamilton et al (1988)151 HLA-DR3 / HLA-
DRB1*03 
 HLA-B8, DR3, DR52 
(MT2), DQ2 (MB2) 
6p DR3 anti-Ro/SSA & 
anti-La/SSB 
sicca, older 
age at disease 







Authors (year) Gene  
Marker / 








MHC Class II 
       
Hamilton et al (1988)151 HLA-DR2/ HLA-
DRB1*15 
 HLA-DR2, DQ1 6p DR2 anti-Ro/SSA less LN   
Provost et al (1988)155 HLA-DR3 / HLA-
DRB1*03 
 HLA-B8, DR3, 
DRw6, DR52 (MT2), 
DQ2 (MB2) 
6p DR3 anti-Ro/SSA SCLE, sicca   
Sontheimer et al (1981)154 HLA-DR3 / HLA-
DRB1*03 
 HLA-A1, B8, DR3 6p DR3  SCLE   
Taylor et al (2011)176 HLA-DR3 / HLA-
DRB1*03 
rs2187668  6p DR3 anti-dsDNA renal disease   
Savi et al (1988)179 HLA-DR7 / HLA-
DRB1*0701 
 HLA-DR7 6p DR7 aCL (Northern 
Italian cohort) 
    
McHugh et al (1989)152 HLA-DR4 / HLA-
DRB1*04 
 HLA-DR4 6p DR4 aCL GPL  
(British cohort) 
   





 HLA-DR4, DQ7; 
HLA-DR7 





   
Hartung et al (1992)158 HLA-DR4    HLA-DR4 , DRw53 6p DR4, DR53 aCL MPL    
 HLA-DRw53    HLA-DR4 / HLA-DR7 
/ HLA-DR9, DRw53 
6p DR4/DR7/DR9, 
DR53 
aCL GPL APS   
Bastian et al (2002)126 HLA-DRB1*13  HLA-DRB1*13 6p DR13  LN   






Authors (year) Gene  
Marker / 








MHC Class II 
       
Arnett et al (1991)159 HLA-DQB1*0301  DQB1*0301 6p DQ7 LA    
Arnett et al (1999)156 DQB1*03, 
DQB1*0302 
 DQB1*03 6p DQ7, DQ8 anti-β2GPI    
  MHC Class III 
        
Racila et al (2003)180, 
Sontheimer (2005)143 
C1qA Gly70GGA  6p C1q C1q deficiency SCLE   
Pickering & Walport 
(2000)141 
C2 C2*Q0  6p C2 C2 deficiency    
Deng & Tsao (2010)140, 
Pickering & Walport 
(2000)141 
C4 C4A*Q0 HLA-A1, B8, 
C4A*Q0, C4B1, 
DR3, DQ2 
6p C4 C4 deficiency    
Millard et al (2001)142 TNF-α -308A  6p TNF-α  SCLE   
Werth et al (2000)144 TNF-α -308A  6p TNF-α ↑TNF production SCLE   
  Innate immunity 
       
Harley et al (2008)160, 
Graham et al (2009)166,  
Hom et al (2008)177,  
Rhodes & Vyse (2008)173 
ITGAM rs9888739, 
rs1143679 















Authors (year) Gene  
Marker / 









      















anti-Ro/SSA discoid rash, 
renal disease 
Graham et al (2009)166 TNFAIP3 rs5029937  6q A20   IFN & TLR 7/9 
signalling 
Niewold et al (2008)169 IRF5 rs3807306, 
rs10488631  





 IFN & TLR 7/9 
signalling 
 
Harley et al (2008)160, 
Graham et al (2009)166 
IRF5 rs12537284  7q IRF5   
  Adaptive immunity 
     
  
Graham et al (2009)166, 
Hom et al (2008)177 








Authors (year) Gene  
Marker / 







  Adaptive immunity 
       
Karassa et al (2003)181  FcγRIII-R F158  1q FcγRIIIA-R 
(CD16) 
 LN Fc receptor -IC 
clearance 
 
Manger et al (2002)182 FcγRIIA-R R131  1q FcγRIIA-R  LN 
Harley et al (2008)160, 
Graham et al (2009)166, 
Remmers et al (2007)171, 
Rhodes & Vyse (2008)173 
STAT4 rs7574865  2q STAT4   Mediation of Th1 -
type cell cytokine 
production 
 
Taylor et al (2008)172,  
Taylor et al (2011)176 
STAT4 rs7574865   2q STAT4 anti-dsDNA ↑disease 
severity - LN, 







3.  Arthritis in SLE 
Joint involvement is a common feature of SLE, occurring in up to 91% of 
patients25, 183.  Clinical manifestations range from recurrent, transient 
polyarthralgia to deforming, rheumatoid-like arthritis, with synovitis affecting 
metacarpophalangeal (MCP) or proximal interphalangeal (PIP) joints.  Jaccoud's 
arthropathy is a type of deforming, nonerosive arthritis (NEA) first described in 
patients with recurrent rheumatic fever.  This pattern of arthritis was first 
recognised by Bywaters in patients with SLE184.  Jaccoud's arthropathy is 
uncommon, occurring in 3% to 13% of SLE patients184-187.  It is characterised by 
the deformities of ulnar deviation at the MCP joints and subluxation of the MCP 
and PIP joints, which are correctable in the early stage of the arthropathy.  Swan-
neck, boutonniere and Z-thumb deformities may occur at later stages.  Typical 
RA-like erosions are absent on radiographs, although "hook-like" erosions of the 
metacarpal heads may be present in late disease.  Erosive arthritis (EA) is also 
uncommon in SLE, affecting 5% - 11% of patients129, 187-189.  A further clinical 
subset exists, consisting of patients with radiological RA-like joint erosions, who 
fulfil both clinical features of RA and SLE.  This disease subset has been termed 
"rhupus"190.  Apart from polyarthritis, the clinical features that occur more 
frequently in rhupus patients include malar rash, DLE, photosensitivity, LN, 
anaemia, leucopenia, and thrombocytopenia191.  As EA is associated with worse 
functional outcome and disability, determining a biomarker that can identify the 
subset of patients at risk of developing EA would enable clinicians to make 
informed decisions about initiating aggressive disease-modifying therapy for 
arthritis.   
 
3.1. Antibodies as biomarkers of arthritis in SLE 
RFs are polyclonal autoantibodies directed at epitopes within the Fc portion of 
human IgG.  RF is the major antibody associated with RA and its presence is a 




Rheumatism (EULAR) RA classification criteria192-194 (see Appendix).  The 
sensitivity of RF for predicting RA is relatively low, as 75% of patients with RA 
are RF-positive195.  Furthermore, RF is not specific for RA, as it is also detected 
in patients with SLE, SS, SSc and inflammatory myositis195.  Mediwake et al. 
found that RF was unhelpful in distinguishing RA patients from SLE patients 
with EA187. 
 
The anti-cyclic citrullinated peptide antibody (ACPA) has been reported to be a 
more reliable serological marker for RA than RF. ACPAs are present years 
before the onset of disease196.  In patients presenting with early, undifferentiated 
arthritis, ACPA predicts disease evolution into RA197, 198.  ACPA has been 
reported to be highly specific for RA199, however, it has also been detected in 
other autoimmune diseases, including psoriatic arthritis (PsA)200, juvenile 
idiopathic arthritis (JIA)201 and SLE129, 187.  In both RA and PsA, ACPA is 
associated with EA and radiographic disease progression200, 202.  Furthermore, we 
and others have reported the association of ACPA with EA in SLE129-131, 187, 203 
(see chapter 2).  These SLE patients with EA and ACPA may represent a subset 
of rhupus patients.  
 
3.2.  Genetic markers of arthritis in SLE 
ACPA production is associated with the shared epitope (SE)204, 205, a highly-
conserved, 5-amino acid sequence found in the third hypervariable region of the 
HLA-DRB1 molecule.  The SE binds citrullinated arginine-containing peptides 
with high affinity, thereby facilitating the generation of antibodies to these 
peptides from synovium206.  The SE is encoded by specific MHC class II HLA-
DRB1 alleles that are predictive for progressive, erosive disease in RA207.  
Recently, Huizinga et al. proposed the theory that SE alleles may not be specific 
for RA, but are associated with the production of antibodies to citrullinated 
peptides which play a pathogenic role in the development of more severe, erosive 
arthritis208.  Furthermore, HLA-DQB1*0302, which is in linkage disequilibrium 




associated with ACPA production209.  Similarly, we found an association of HLA-
DQB1*0302 with EA in SLE patients129 (see chapter 2).  
 
Several single nucleotide polymorphisms (SNPs) at the IRF5, STAT4, BLK and 
TNFAIP3 loci are shared by SLE and RA171, 210, 211.  Genetic variants at the IRF5, 
STAT4 and BLK loci are also shared by SLE and SSc140, 210.  Ablation of 
TNFAIP3 in the myeloid cells of A20-deficient mice resulted in development of a 
destructive, erosive polyarthritis which was dependent on TLR4-MyD88 
signalling pathways and IL-6, but not dependent on TNF212.  A recent study of 
Norwegian patients demonstrated that the rs2004640 SNP at the IRF5 locus was 
shared by patients with SLE and the RF-negative polyarthritis subtype of JIA213.  
The sharing of genetic loci between SLE and RA and/or SSc suggests the 
existence of common pathways in the pathogenesis of several autoimmune 
diseases, providing further support for the potential application of biomarkers of 
other autoimmune diseases to SLE disease subsets such as arthritis.   
 
3.3.  Summary 
• Clinical manifestations of lupus arthritis include polyarthralgia, transient 
synovitis, Jaccoud's arthropathy, EA and rhupus.  
• EA is uncommon, affect up to 11% of SLE patients.  
• RF is not specific for RA. 
• ACPA has a much higher specificity for RA but has been detected in 
other autoimmune diseases, including SLE. ACPA is associated with EA 
in SLE and may also predict for the rhupus subset. 
 
4. Mortality in SLE 
Survival rates of patients with SLE have improved significantly since the 5-year 
survival rate of less than 50% reported in 1955214.  Ginzler et al. studied 1,103 




and 71% respectively215.  Wallace et al. followed 609 private patients between 
1950 and 1979 and found 5-, 10- and 15-year survival rates of 88%, 79% and 
74% respectively216.   The same group later reported a significant improvement in 
the 5-, 10- and 15-year survival rates to 97%, 93% and 83% respectively, for 507 
patients followed between 1980 and 1989183.  In a series of 110 English patients 
with LN followed between 1963 and 1986, overall 5-, 10- and 15-year survival 
rates were 84%, 72% and 62% respectively217.  Survival improved significantly 
for the cohort diagnosed between 1976 and 1986, compared with the cohort from 
1963-1975, with survival rates of 90% vs 78% at 5 years, 81% vs 56% at 10 
years and 76% vs 43% at 15 years.  In a study of 100 SLE patients attending a 
tertiary rheumatology clinic in London, the 5- and 10-year survival rates for the 
period 1978 - 1988 were 88% and 86% respectively137.  An extension of this 
study comprising 165 adult-onset and juvenile SLE patients found an 
improvement in the 5-year survival rate to 93% for the period 1978 - 1993, with 
the 10-year survival rate unchanged at 86%218.  During the 1990s, survival rates 
improved further to 93% - 97% at 5 years, 83% - 92% at 10 years and 78% - 79% 
at 15 years50, 218-221.  More recent studies have demonstrated survival rates of 95% 
- 97% at 5 years and 93% at 10 years222-224.  Improvement in survival rates over 
the last 6 decades may be attributed to more careful use of glucocorticoids, the 
availability of newer immunosuppressive agents, the advent of renal dialysis and 
transplantation, and advances in general medical therapy, including treatment of 
infections.  
 
Nevertheless, the mortality rate in SLE remains significantly higher, with up to a 
4-fold increased rate compared with age- and sex-matched controls or with the 
general population50, 225-228.  In an international, multi-centre cohort comprising 
9,547 patients studied between 1970 and 2001, Bernatsky et al. reported an 
overall standardised mortality ratio (SMR) of 2.4 (95% CI 2.3, 2.5), with a 60% 
decrease in the SMR from 4.9 between 1970 and 1979, to 2.0 between 1990 and 
2001227.  In a cohort of 1,241 SLE patients attending a tertiary rheumatology 
service in Toronto, the overall SMR reduced significantly from 12.6 (95% CI 9.1, 




2005229.  Similarly, in a cohort of 300 SLE patients attending a tertiary 
rheumatology clinic in London and followed between 1978 and 2000, the overall 
SMR was 4.0 (95% CI 2.8, 5.2)226.   
 
4.1. Causes of death in SLE 
Major causes of death include those related to active SLE disease, complications 
of therapy, or other co-morbid conditions.  In a multi-centre US study of 1,103 
SLE patients followed between 1965 and 1978, the major causes of death were 
active SLE-related organ disease and infection230.  Active SLE disease as a major 
primary cause of death is well-documented in other studies26, 216, 219, 231-235.  
Infection also remains a major cause of death, with a SMR of 4.9 - 5.0217, 227, 228, 
235, 236.  In 1976, Urowitz et al. first described the "bimodal mortality pattern" in 
SLE231,  reporting that deaths early in the course of SLE were mostly due to 
active disease such as LN, or treatment-related complications such as infection, 
whereas late deaths were mostly due to atherosclerosis-related MI, at a time when 
SLE was relatively quiescent.  Several authors have since confirmed Urowitz et 
al.'s findings of early deaths related to active SLE and infections, and late deaths 
from CV causes216, 220, 221, 226, 237, 238.  In the last 4 decades, all-cause mortality has 
declined, together with infection- and renal-related deaths227, however, the 
incidence of ischaemic heart disease (IHD) has risen229 and the risk of MI-related 
death has also tended to increase, with SMRs between 1.7 and 3.0227, 236. 
 
Patients with SLE are at increased risk of developing certain types of 
malignancies, which are significant causes of death in SLE226, 227, 239.  In 
Bernatsky et al.'s cohort, the standardised incidence ratio (SIR) of observed-to-
expected cancers was 1.2 (95% CI 1.1, 1.3) for all cancers, 2.8 (95% CI 2.1, 3.5) 
for all haematological malignancies, 3.6 (95% CI 2.6, 4.9) for non-Hodgkin’s 
lymphoma (NHL) and 1.4 (95% CI 1.1, 1.8) for lung cancer240.  A previous 
Swedish study of 5,715 SLE patients also found an increased SIR of 2.9 (95% CI 




0.8 (95% CI 0.6, 1.0) was lower for cancer, SMRs were higher for NHL and lung 
cancer, at 2.8 (95% CI 1.2, 5.6) and 2.3 (95% CI 1.6, 3.0) respectively227.   
 
4.2.  Predictors of mortality 
Table 1.3 summarises factors predictive of early mortality in patients with SLE, 
which were mostly determined from cohort studies.  The independent predictor 
factors listed in this table were derived from studies that employed multivariate 
analyses to adjust for possible confounding due to multiple predictor variables 
and selection bias.   
 
Non-SLE related predictors of premature death in SLE include older age at 
disease onset242-245, male gender50, 183, 216, 228, 229, 243, 246, 247, non-Caucasian 
ethnicity28, 244, 248, and low socioeconomic status215, 223, 243, 248-250.  As might be 
expected, patients who are older at disease onset are more likely to die from CV-
related causes and age-related co-morbidities242, 245.  Male patients have more 
severe disease (such as LN) and increased damage accrual, resulting in a poorer 
prognosis and a higher than expected male/female age-adjusted mortality ratio 
when compared with the general population183, 243, 251-253.  Various authors have 
related low socioeconomic status to lack of health insurance in USA, poverty, 
and varying patients' health-related attitudes and behaviours, which are more 
likely to contribute to early mortality. 
 
SLE-related predictors of poor survival include  higher disease activity223, 254 
including higher SLEDAI scores223, 229, 254, 255, renal disease26, 50, 183, 215, 216, 228, 256, 
257, NP-SLE256, 258, lung involvement254, pleurisy255, 259, haemolytic anemia243, 258, 
259, thrombocytopenia183, 244, 254, 256, 259, and APS259.   Organ damage, whether 
early in the disease course249, 260, or from accrual of damage (as measured by the 
Systemic Lupus Erythematosus Disease Activity Index [SLICC DI]) is also a 





The clinical factors listed above in general reflect subsets of patients with more 
severe disease and hence a poorer prognosis.  Higher disease activity as a 
predictor suggests that persistent chronic inflammation is important mechanism 
in the development of organ damage and accelerated atherosclerosis resulting in 
premature death.  In contrast, Ward et al. reported that leucopenia was protective 
against mortality, a surprising finding given that leucopenia is a manifestation of 
increased disease activity256.   They found that this protective effect mainly 
occurred in Caucasian patients compared with African American patients, which 
suggests that genetic factors may be involved.  This theory is supported by the 
increased risk of mortality in non-Caucasian patients28, 244, 248.  One possible 
explanation for the protective effect of leucopenia is that the immunogenetic 
mechanisms causing leucopenia may also reduce mortality risk, however when 
combined with other pathogenic mechanisms that contribute to increased disease 
activity, the overall effect would be to increase mortality risk.  Moreover, 
leucocytosis is associated with progression of subclinical atherosclerosis in 
SLE267, another mechanism for increased mortality risk.  Several authors have 
shown that accumulation of damage (by SLICC-DI) is an important predictor of 
mortality (see Table 1.3).    
 
Hydroxychloroquine therapy was reported in several studies to have an 
independent protective effect on survival70, 229, 268, 269.   Patients with milder 
disease tend to be treated with hydroxychloroquine, which may have introduced 
selection bias to this result.  Nevertheless, hydroxychloroquine has several 
mechanisms of action that could contribute to a protective effect against 
mortality.  These effects include an anti-thrombotic effect, possibly through 
platelet inhibition, improvement of lipid profiles by decreasing total cholesterol 
(TC) and low-density lipoprotein cholesterol (LDL-C) levels, reduction in disease 








4.3.  Antibodies as predictors of mortality 
Anti-Sm was reported to be an independent predictor of mortality in SLE28.  Two 
studies reported anti-dsDNA was a predictor of early mortality28, 228, however, 
another study found it had a protective effect255.  Pathogenic anti-Sm and anti-
dsDNA antibodies that cause LN may partly account for their association with 
reduced survival in SLE.  Anti-Sm or anti-dsDNA antibodies with specificities 
for non-renal antigens may not have significant associations with mortality, 
which may account for the lack of data from other studies.   
 
Similarly, the paucity of data demonstrating associations of aPL with mortality 
may be due to difficulties identifying pathogenic aPL that cause thrombosis, 
thrombocytopenia and APS, established predictive factors for mortality253, 259.  
Furthermore, APS is associated with increased damage accrual, another important 
predictor of mortality253.  Gómez et al. showed that aCL was associated with 
increased mortality270, while Gulko et al. found that only aCL MPL was 
associated with increased mortality271.    
 
In a single-centre study of 338 German SLE patients followed for up to 15 years, 
no deaths were observed in patients who had anti-Ro/SSA and anti-U1RNP at 
disease onset50.  As anti-Ro/SSA and anti-U1RNP are markers of patient subsets 
with less LN, this may explain in part their protective effect against mortality.  In 
contrast, no associations of antibodies with mortality were found in other SLE 
cohorts243, 249, 259, 272. 
 
4.4.  Summary 
Despite recent advances in the medical treatment of SLE, patients still have 
higher mortality rates compared with the general population, with the SMR 
between 2.4 and 3.5.   
• Major causes of death early in the course of SLE include active disease 




• Late deaths in SLE are mostly due to atherosclerosis-related causes and 
malignancy. 
 
Table 1.3 presents the associations of independent predictive factors for early 
mortality in patients with SLE.  
• Important non-SLE related factors include older age at disease onset, male 
gender and low socio-economic status.  
• Major SLE-related factors include higher disease activity, organ damage 
accrual, more severe disease manifestations (e.g. renal and 
neuropsychiatric involvement), and APS.  
• Hydroxychloroquine has a protective effect against mortality. 
• There is very little data published on the associations of autoantibodies 






Table 1.3.  Predictors of mortality in SLE 





sample size  Study site(s) 
SLE-related baseline predictor 
variables* 




Cervera et al (1999)26 prospective cohort 
(Euro-lupus) 
5 1000  multi-centre, 
Europe 
renal disease  yes 




21 330 Manitoba, 
Canada 
renal disease, ↑SLICC DI scores, 
anti-Sm 




Manger et al (2002)50 retrospective 
cohort 
15 338 Erlangen, 
Germany 
older age at diagnosis, LN, SLICC 
DI early damage accrual; 
protective - anti-Ro/SSA, anti-
U1RNP 
male gender yes 
Ruiz-Irastorza et al 
(2006)70 
prospective cohort 15 232 Bizkaia, Spain protective - HCQ  yes 
Pistiner et al (1991)183 retrospective 
cohort 
10 503 Los Angeles CA, 
USA 
LN, thrombocytopenia male gender no 
Ginzler et al (1982)215 retrospective 
cohort 
10 1103 multicentre, USA anaemia, renal disease low socioeconomic status yes 
Wallace et al (1981)216 retrospective 
cohort 
10 609 Los Angeles CA, 
USA 
renal disease male gender no 





1.7 1214 multicentre, Latin 
American 
countries 
↑SLEDAI score, SLICC DI damage 
accrual 











sample size  Study site(s) 
SLE-related baseline predictor 
variables* 




Campbell et al (2008)228 prospective case-
control 
5 265 + 355 
controls 
N & S Carolina, 
USA 
LN, anti-dsDNA male gender yes 
Urowitz et al (2008)229 prospective cohort 
(University of 
Toronto) 
36 1241 Toronto, Canada ↑SLEDAI scores,  SLICC DI 
damage accrual, 
immunosuppressive use; 
protective - HCQ 
male gender, IHD yes 






 > 10  73 + 144 
contols 
multicentre, USA older age at disease onset  yes 
Kasitanon et al (2006)243 prospective cohort 
(Hopkins) 
median 6.1 1378 Baltimore MD, 
USA 
older age at diagnosis, haemolytic 
anaemia, low C3 
male gender, low 
socioeconomic status 
yes 
Reveille et al (1990)244 retrospective 
cohort 
10 389 Birmingham AL, 
USA 
older age at disease onset, 
thrombocytopenia 
African-American ethnicity yes 




mean 5.8 - 
8.6 
161 + 714 
controls 
Paris, France older age at disease onset  no 
Alamanos et al (2003)246 retrospective 
cohort 
10 185 NW Greece  male gender yes 











sample size  Study site(s) 
SLE-related baseline predictor 
variables* 




Alarcón et al (2001)249 multi-ethnic 
prospective cohort 
(LUMINA) 
5 288 multi-centre USA  ↑SLAM & SLICC DI scores poverty yes 
Studenski et al (1987)248 retrospective 
cohort 
15 411 N Carolina, USA  low socioeconomic status, 
non-Caucasian ethnicity 
yes 




 4779 Bethesda MD, 
USA 
 low socioeconomic status (< 
12 yrs education) 
no 
Abu-Shakra et al 
(1995)254 
prospective cohort 20 665 Toronto, Canada age > 50 at diagnosis, renal 
damage, thrombocytopenia, 
SLEDAI > 20 at presentation,   
lung involvement; protective - LN 
 yes 
Ward et al (1996)256 retrospective 
cohort 
median 11 408 Durham NC, 
USA 
(not baseline) LN, seizures, 
thrombocytopenia; protective - 
leucopenia 
 yes 
Seleznick & Fries 
(1991)257 
prospective cohort 12 310 Stanford CA, 
USA 
renal impairment, mouth ulcers ↑systolic BP yes 
Jacobsen et al (1998)258 retrospective 
cohort  
mean 8.2 513 multicentre, 
Denmark 
renal impairment, NP-SLE, 
haemolytic anaemia, myocarditis 
hypertension, IHD yes 
Drenkard et al (1994)259 ambispective 
cohort 
10 667 Mexico City, 
Mexico 
(not baseline) pleurisy, disease 












sample size  Study site(s) 
SLE-related baseline predictor 
variables* 








mean 9.7 202 Bizkaia, Spain APS, SLICC-DI > 1  yes 
Cook et al (2000)255 prospective cohort median 6.6 806 Waterloo & 
Toronto, Canada 
(not baseline) higher SLEDAI 
scores; SLEDAI organic brain 
syndrome, retinal changes, cranial 
nerve involvement, proteinuria, 
pyuria, pleurisy, fever, 
thrombocytopenia, leucopenia; 
protective -new rash, anti-dsDNA 
 yes 
Rahman et al (2001)260 inception cohort 10 263 Toronto, Canada SLICC DI - early damage, SLICC 
DI - renal damage 
 no 
Chambers et al (2009)261 retrospective 
cohort 
 > 10 232 London, UK SLICC DI damage accrual  no 
Danila et al (2009)262 multi-ethnic 
prospective cohort 
(LUMINA) 
 > 10 635 multicentre USA SLICC DI damage accrual, SLICC 
DI renal damage 
poverty yes 
Mok et al (2003)263 prospective cohort 3 242 Hong Kong, 
China 
SLICC DI damage accrual  yes 
Gladman et al (2000)264 prospective cohort 
(SLICC) 
 > 10 1297 multicentre, 
Europe, N 
America 
↑SLICC DI scores   no 
Nived et al (2002)265 prospective cohort 
(SLICC) 
median 7 80 multicentre, 
Europe, N 
America 
↑SLICC DI scores 5 yrs after 













sample size  Study site(s) 
SLE-related baseline predictor 
variables* 




Stoll et al (1996)266 retrospective 
inception cohort 
10 80 London, UK ↑SLICC DI scores   no 




median 3.3 608 multicentre USA protective - HCQ, less severe 
disease 
 yes 




median 4.6 1480 multicentre, Latin 
American 
countries 
protective - HCQ  yes 
Gómez et al (2006)270 retrospective 
cohort 
 > 10 363 Asturias, Spain older age at disease onset, renal 
disease, aCL 
 yes 
Gulko et al (1993)271 retrospective 
cohort 
16 139 Birmingham AL, 
USA 
older age at diagnosis, aCL MPL, 
HLA-DQ7, major infection, 
thromboembolic events 
 yes 




median 22 37 + 37 
controls  
Helsinki, Finland LA, DVT, LN   no 
 




5. Atherosclerosis in SLE 
Although overall survival in SLE has increased dramatically since the 1950s, 
atherosclerosis has remained a significant cause of mortality.  In Bernatsky et al.'s 
cohort of 9,547 SLE patients, the incidence of CV-related mortality increased 
slightly over 3 decades from 1970, despite a fall in the incidence of renal and 
infection-related deaths227.  A post-mortem study published in 1975 found that in 
42% of SLE patients who had received glucocorticoids for over 1 year, 
atherosclerotic plaques caused over 50% stenosis in at least one major coronary 
artery274.  The estimated incidence of new cardiovascular events (CVEs) 
attributed to atherosclerosis in patients with SLE is approximately 1.5% per 
annum275, with prevalence ranging from 6.6% to 10.9% in 3 North American 
cohorts276-278.  In a population-based case-control study, using the UK-based 
General Practice Research Database, the RR of developing MI was 2.7 for 
patients with SLE279.  Similarly, the Nurses' Health Study reported an adjusted 
RR of 2.3 for CVEs280.  Other studies have found up to a 10-fold increased risk of 
MI or stroke in patients with SLE compared with the general population238, 275, 281.  
Furthermore, CVEs occur at an earlier age in patients with SLE278.  Manzi et al. 
reported that women with SLE aged between 35 and 44 years had a 52-fold 
increased risk of MI, compared with an age-matched women from the 
Framingham Offspring Study278. Ward found that women with SLE aged 
between 18 and 44 had a 2.3-fold increased risk of hospitalisation for MI 
compared with age-and sex-matched controls, and a 2.1-fold increased risk of 
hospitalisation for stroke281.  Shah et al. showed that patients with SLE who were 
hospitalised for MI were more likely to have prolonged admissions and had a 
higher risk of inpatient mortality than patients without SLE or diabetes mellitus 
(DM)282.  Possible explanations for this increased mortality risk post-MI include 
a chronic inflammatory and pro-coagulant state due to the presence of aPL, 






5.1. Risk factors for cardiovascular events in SLE 
Prospective studies of patients with SLE have demonstrated that CVEs occur at 
an average of 6 to 9 years after the initial diagnosis of SLE83, 84, 277.  Several 
studies, including 5 large cohort studies (LUMINA84, Hopkins Lupus Cohort276, 
University of Pittsburgh278, SLICC Registry for Atherosclerosis [SLICC-RAS]283 
and University of Toronto inception cohorts277) have consistently shown that 
traditional CV risk factors are independent predictors for CVEs in SLE (Table 
1.4).  These factors include older age at diagnosis83, 276, 278, hypertension275, 276, 284-
287, hypercholesterolaemia275, 276, 278, 284, 287, hypertriglyceridaemia288 and 
smoking84, 277.  Other CV risk factors that have been identified include male 
gender283, 286, obesity276, DM284, elevated homocysteine and lipoprotein(a) [Lp(a)] 
levels289 and post-menopausal status278.  Elevated levels of circulating oxLDL are 
significantly associated with IHD in the general population290, 291.  Elevated 
oxLDL levels and anti-oxLDL have also been reported in SLE patients with CV 
disease (CVD)289, 292.  
 
Although traditional CV risk factors are important, they do not fully account for 
the increased atherosclerotic risk in patients with SLE293.  Furthermore, SLE 
patients with a cardiac event have on average one less traditional risk factor than 
non-SLE patients with premature IHD294.  The risk of MI in SLE remains 
elevated, even after adjustment for conventional CV risk factors, suggesting that 
SLE-related factors or SLE itself may be independent risk factors for 
atherosclerosis275, 279, 288.  Several longitudinal studies have identified non-
traditional factors and other SLE-related factors as predictors of CVEs.  These 
factors include longer SLE disease duration278, longer duration of glucocorticoid 
use276, 278, azathioprine use286, the presence of aPL83, 84, NP-SLE277, and 
vasculitis277.  However, with regard to glucocorticoid and azathioprine use, it is 
unclear whether they are truly independent predictive factors or markers of 
disease severity and/or activity.  Glucocorticoids are often used in the treatment 
of active disease, however they may also have deleterious effects.  Karp et al. 
found that a 10 mg increase in the daily prednisolone - equivalent dose in the 




(HDL-C) levels  and increased systolic blood pressure (BP), triglyceride (TG) 
and blood glucose levels, and 2-year coronary heart disease risk295.  As 
Azathioprine is used for long-term disease control, it too may be a marker of 
active disease requiring therapy, rather than a true predictor of CVEs.  Markers of 
inflammation, such as elevated CRP84, have also been implicated.  A recent study 
found that von Willebrand factor (vWF), a marker of endothelial activation, was 
independently associated with CVEs83.   
 
Not only are patients with SLE at increased risk of future CVEs, the prevalence 
of traditional CV risk factors is also increased in these patients.  These CV factors 
include hypertension, hypercholesterolaemia, obesity296, DM297, and the 
metabolic syndrome (MetS)298, 299.  The most recent consensus definition for the 
MetS was published in 2009, in a joint interim statement from the International 
Diabetes Federation Task Force on Epidemiology and Prevention, the National 
Heart, Lung, and Blood Institute, the American Heart Association, the World 
Heart Federation, the International Atherosclerosis Society, and the International 
Association for the Study of Obesity300.  The MetS doubles the risk of CVD and 
the diagnosis is based on the presence of 3 or more of 5 criteria of elevated waist 







Table 1.4.  Factors predictive of cardiovascular events in SLE 




sample size  Study site(s) CVE(s) 
Independent SLE-related 
predictor variables 








3 229 Baltimore MD, 
USA 
MI, angina,  death older age at diagnosis, 
↑duration of glucocorticoid 
use 
hypertension, ↑TC, obesity yes 




mean 8.6 263 multi-centre 
Canada 
MI,  angina, CCF, 
stroke, death 
 age, ↑systolic & diastolic 
BP, ↑TC 
yes 











MI, angina, TIA, 
stroke, PVD, 
death 
total -NP-SLE, vasculitis; 
inception - NP-SLE 
total - ↑number of CV risk 
factors; inception - smoking 
yes 





14 498 women Pittsburgh PA, 
USA 
MI, angina older age at diagnosis, 
↑disease duration, 
↑duration of glucocorticoid 
use 
↑TC, post-menopause yes 
Gustafsson et al 
(2009)83 
prospective cohort > 20 182 Stockholm, 
Sweden 
MI, angina, TIA, 
stroke, PVD, 
death 
older age at diagnosis, 
aPL, vWF; protective - 
thrombocytopenia 
 yes 









aPL, ↑CRP older age, smoking, ↑no. of 
CV risk factors, longer 
follow-up time 
yes 





8 1249 multi-centre, 





TIA, stroke, PVD 










sample size  Study site(s) CVE(s) 
Independent SLE-related 
predictor variables 





















> 10 507 Toronto, 
Canada 
MI, angina pericarditis, myocarditis CCF, hypertension, TC > 
7.0 mmol/L, TG > 1.8 
mmol/L, glucose > 8.0 
mmol/L, DM 
not stated 










 hypertension yes 





mean 11 53 + 96 
controls 
multi-centre UK MI, angina azathioprine age, hypertension, male 
gender, family history 
yes 
Mikdashi et al 
(2007)287 
prospective cohort mean 8 238 Baltimore MD, 
USA 














↑ESR, ↑CRP, LA, α-1 
antitrypsin, ↑cumulative 
glucocorticoid use, ↑IgG 
anti-oxLDL  




Frostegård et al 
(2005)118 
retrospective 
cohort & controls 












5.2.  Pathogenesis of atherosclerosis 
It is now well established that atherosclerosis is a chronic inflammatory 
disease301.  Moreover, it is likely that the inflammatory and immunological 
mechanisms of SLE enhance the complex interaction of classic CV risk factors 
with inflammatory pathways of atherogenesis.  All these factors may interact to 
accelerate the atherosclerotic process within the vasculature of patients with SLE.  
 
The atherosclerotic process is initiated by endothelial dysfunction or damage 
through a variety of mechanisms such as free radicals caused by cigarette smoke, 
hypertension,  diabetes mellitus and elevated homocysteine concentrations301.  
Impaired endothelial repair mechanisms lead to the subendothelial accumulation 
of LDL, through binding by apolipoprotein B100 (apoB100) within LDL to 
proteoglycans in the artery wall302.  Cytokines, such as TNF-α and IL-1, increase 
binding of LDL to endothelium and smooth muscle301.  LDL becomes oxidised 
by reactive oxygen species or enzymes such as myeloperoxidase or 
lipoxygenases released from local inflammatory cells303.  Oxidized PLs (oxPL) 
and oxLDL then activate endothelial cells to express adhesion molecules and 
secrete chemokines such as monocyte chemotactic protein-1 (MCP-1), resulting 
in the recruitment of neutrophils, monocytes and T cells and their subsequent 
migration into the intima301, 304.  HDL plays an anti-inflammatory role in this 
process by inhibiting endothelial cell expression of adhesion molecules and 
production of MCP-1305, 306 (Figure 1.1).  Monocytes differentiate into 
macrophages, which internalise oxLDL via scavenger receptors and  later 
transform into foam cells307.  Early fatty-streak lesions in the vasculature consist 
of T cells and foam cells loaded with lipids308.  Successive accumulation of 
apoptotic cells, debris and cholesterol crystals lead to the formation of a necrotic 
core within the atheromatous plaque.  Smooth muscle cells then proliferate and 
produce collagen to form a fibrous cap on the plaque.  The shoulder regions of 
the cap are heavily infiltrated by T cells and macrophages, which produce 




thinning of advanced plaques and ultimately, to plaque rupture, thrombosis and 























HDL Inhibits Adhesion Molecule Expression
Foam 
Cell
HDL Promotes Cholesterol Efflux
 
Reprinted with permission from the Lipids Online Slide Library. © Copyright 2000–2012 Baylor College of 
Medicine.  All rights reserved.  (Available from: http://www.lipidsonline.org [Accessed 19 March 2012]). 
Figure 1.1. 
OxPLs and oxLDL/modified LDL activate endothelial cells to express adhesion 
molecules and secrete chemokines such as MCP-1, resulting in the recruitment of 
neutrophils, monocytes and T cells and their subsequent migration into the intima.  HDL 
plays an anti-inflammatory role in this process by inhibiting endothelial cell expression of 
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Reprinted with permission from the Lipids Online Slide Library. © Copyright 2000–2012 Baylor College of 
Medicine.  All rights reserved.  (Available from: http://www.lipidsonline.org [Accessed 19 March 2012]). 
Figure 1.2. 
The early fatty-streak lesion consists of T cells and foam cells loaded with lipids.  
Successive accumulation of apoptotic cells, debris and cholesterol crystals lead to the 
formation of a necrotic core within the atheromatous plaque.  Smooth muscle cells then 
proliferate and produce collagen to form a fibrous cap on the plaque.  The shoulder 
regions of the cap are heavily infiltrated by T cells and macrophages, which produce 
enzymes and pro-inflammatory mediators that contribute to destabilisation and thinning 
of advanced plaques and ultimately, to plaque rupture, thrombosis and vessel occlusion 




5.3.     Inflammatory mechanisms and autoimmunity in SLE and 
atherosclerosis 
 
5.3.1.  Endothelial dysfunction  
It has been proposed that endothelial injury and dysfunction are pivotal steps in 
the initiation and progression of atherosclerotic CVD304.  Repair of damaged 
endothelium or restoration of endothelial function are mediated by migration and 
proliferation of local endothelial cells (ECs) and recruitment of circulating 
endothelial progenitor cells (EPCs), which then differentiate into ECs311.  EPC 
levels correlate positively with endothelial function312, and low EPC numbers are 
associated with increased CVEs and CV-related mortality in patients with IHD313, 
314.  Endothelial dysfunction has been demonstrated in patients with SLE315-318 
and is associated with increased disease activity318.  Rajagopalan et al. found that 
elevated levels of apoptotic ECs correlated strongly with elevated tissue factor 
(TF) levels in women with SLE315.  As TF is a strong initiator of thrombosis, this 
provides a possible explanation for endothelial dysfunction as a predictor of 
CVEs319, 320.  Recent studies in SLE patients also reported reduced circulating 
EPC numbers321-324.  Moreover, EPCs from SLE patients demonstrated impaired 
endothelial repair function and produced IFN-α, which induced EPC apoptosis322, 
325.  Ferro et al. showed that 70% of aPL positive SLE patients had endothelial 
perturbation, as defined by elevated plasma levels of vWF and tissue-type 
plasminogen activator (tPA).  Endothelial perturbation was associated with 
increased disease activity, aPL and anti-endothelial cell antibodies (AECAs).  
Moreover, in aPL positive SLE patients, a pro-thrombotic state (defined by 
elevated circulating prothrombin fragments) occurred only in the presence of 
endothelial dysfunction326.  The prevalence of AECAs in SLE sera ranges from 
15% to 88%, and their levels correlate with SLE disease activity327.  AECAs from 
patients with SLE are associated with aCL328, bind to ECs, inducing EC 
apoptosis329, and promote macrophage phagocytosis of apoptotic ECs330.  These 




compromise EC-mediated vascular repair and contribute to a pro-coagulant state, 
thereby accelerating atherosclerosis.  
 
5.3.2.  Innate immunity  
There is accumulating evidence that innate immunity plays a role in both the 
pathogenesis of SLE and in atherosclerosis.  TLRs are a major class of pattern 
recognition receptors (PRRs) that recognise conserved molecular motifs on 
microbial pathogens, known as pathogen-associated molecular patterns 
(PAMPs)331.  The human TLR family currently includes 10 members, each with 
specificities for important PAMPs332.  TLR2 and TLR6 recognise peptidoglycan 
(PGN) on gram-positive bacteria, other bacterial lipoproteins and fungal cell wall 
components, while TLR4 recognises lipopolysaccharide (LPS) on gram-negative 
bacteria, heat-shock proteins (HSPs) and some viral proteins.  TLR3, TLR7 and 
TLR9 recognise double-stranded RNA, single-stranded RNA, and unmethylated 
CpG DNA, respectively333. TLR2 and TLR4 are found on the cell surface and 
TLR3, TLR7 and TLR9 are located within intracellular compartments such as 
endosomes334.  The TLR–PAMP interaction triggers an intracellular signalling 
cascade involving activation of adaptor molecules such as MyD88 that induce 
NF-κB transcription, resulting in production of pro-inflammatory cytokines and 
chemokines333.   
 
In SLE, activation of TLR7 and TLR9 on DCs and B cells is thought to initiate 
inflammatory pathways leading to the production of type I IFNs and 
autoantibodies such as ANA333, 335.  Wong et al. demonstrated increased 
expression of TLRs in B cells, T cells and monocytes in patients with SLE, 
compared with controls336.  Moreover, expression of TLR4 on T cells and TLR6 
on B cells correlated positively with disease activity.  Other studies have shown 
increased expression of TLR2, TLR4 and TLR7 in human atherosclerotic 
plaques335, 337.  Enhanced TLR4 expression in murine atheromatous plaques is 
associated with activation of NF-κB, suggesting that TLR4 is an important factor 




upregulates TLR4 expression and amplifies the production of cytokines 
implicated in plaque destabilisation, including TNF-α and IL-12340.  IFN-α has 
also been shown to promote macrophage uptake of oxLDL and foam cell 
formation in patients with SLE341.  These studies together suggest that innate 
immune pathways in atherosclerosis are shared with SLE. 
 
5.4.  Subclinical atherosclerosis in SLE 
Although clinical cardiovascular events occur more frequently in patients with 
SLE compared with the general population, subclinical atherosclerosis is even 
more common.  External carotid artery intima-media thickness (IMT) and the 
presence of atherosclerotic plaque may be used as markers for subclinical 
atherosclerosis and are assessed using the non-invasive technique of B-mode 
ultrasonography342, 343.  IMT and carotid plaque are thought to reflect different 
stages of atherogenesis344.  IMT is thought to represent an earlier stage of arterial 
intimal and medial cell hypertrophy in response to lipid infiltration or 
hypertension, whereas plaque is thought to represent a later stage of 
atherogenesis344.  Both the presence of carotid plaque and increased IMT are 
strong predictors for CVEs in the general population345-347.  Several groups have 
reported an increased prevalence of carotid plaque, ranging from 29% to 45% in 
patients with SLE, compared with 15% to 22% in controls85, 86, 348-352.  
Furthermore, carotid plaque occurs at an earlier age in SLE patients compared 
with age and sex-matched controls, with a prevalence of 33% to 35% in patients 
younger than 55 years85, 86.  Accelerated progression of plaque size and/or 
number occurs over time in patients with SLE353.  Carotid IMT is also increased 
in patients with SLE354-356 and progresses at an increased rate compared with 
controls354, 357.  Svenungsson et al. reported that carotid IMT was increased in 
SLE patients with CVD than in SLE patients without CVD or healthy controls289.  
They also found higher IgG anti-oxLDL levels in SLE cases compared with SLE 





Another method of assessment for subclinical atherosclerosis employs CT 
scanning to detect coronary artery calcification87. The coronary calcium score is a 
strong predictor for IHD in the general population346.  Asanuma et al. found 
coronary calcification in 31% of SLE patients compared with 9% of controls87.  
 
Endothelial function may be measured by several methods, including Doppler 
ultrasonography of the brachial artery, and coronary angiography.  In response to 
increased arterial blood flow in the brachial artery, normal endothelium produces 
nitric oxide (NO), causing flow-mediated dilatation (FMD)358, 359.  Coronary 
endothelial dysfunction has been shown to be predictive of atherosclerotic 
progression and future CVEs in the general population319, 320.  Patients with SLE 
have impaired endothelium-dependent FMD of the brachial artery, compared 
with controls316, 317, 360.  In one study of women with SLE, endothelial 
dysfunction was positively correlated with increased carotid IMT, providing 
further evidence for accelerated subclinical atherosclerosis in SLE361.  
 
5.4.1   Cardiovascular risk factors 
Several cross-sectional studies in patients with SLE have demonstrated 
independent associations of traditional CV risk factors with carotid ultrasound 
markers of subclinical atherosclerosis (Table 1.5A).  As would be expected, older 
age was the most important factor associated with the presence of carotid plaque 
and increased carotid IMT at baseline, as well as progression over time85, 86, 348-
351, 362, 363.  Hypertension and/or anti-hypertensive therapy and dyslipidaemia were 
other factors with similar vascular associations267, 349, 362, 364.  Smoking, lower 
HDL3 levels and a history of previous CVE were also associated with the 
presence of carotid plaque85, 349, 350, 365, while hyperglycaemia, obesity and 
prevalent IHD were associated with increased carotid IMT349, 350, 362.  
Hyperglycaemia, obesity and dyslipidaemia including low HDL3 levels are 
characteristic features of the metabolic syndrome.  The associations of these 
factors with increased carotid IMT may reflect a state of chronic vascular wall 




adipose tissue pro-inflammatory cytokine production that occurs in type 2 DM366.  
Interestingly, pro-inflammatory HDL (piHDL), homocysteine and leptin (a pro-
inflammatory cytokine secreted by adipose tissue) were also associated with 
carotid plaque and increased IMT in SLE, supporting this hypothesis351, 362, 365, 367.  
Furthermore, lower HDL concentrations may be marker of increased disease 
activity368, itself a predictor for early mortality223, 229.  A recent report noted IMT 
regression with rosuvastatin therapy in SLE patients369, while two studies found 
no effect of atorvastatin on IMT progression370, 371. 
 
5.4.2.  SLE-related and other risk factors  
SLE-related risk factors independently associated with the presence of carotid 
plaque and/or plaque progression include longer disease duration86, higher 
European Consensus Lupus Activity Measurement Index (ECLAM) scores351, 
raised ESR, CRP, white cell, neutrophil and lymphocyte counts and complement 
C3 levels85, 267, 351 (Table 1.5B).  Similarly, predictors of IMT progression 
included factors associated with chronic inflammation such as longer disease 
duration357, elevated creatinine353, elevated white cell count267, CRP267 and C3 or 
C5a levels357.  Doria et al. showed that the presence of antibodies to a component 
of oxLDL, oxidised palmitoyl arachidonoyl phosphocholine (oxPAPC), at the 
time of the follow-up scan, were associated with IMT progression and the 
presence of carotid plaque at follow-up348.   These results provide further support 
for role of chronic inflammatory mechanisms in the pathogenesis of accelerated 
atheromatous plaque formation.  In contrast, other studies found no significant 
associations between disease activity measures and plaque prevalence85, 86, 350, 364.  
It is possible that inflammatory processes involved in accelerated atherosclerosis 
in SLE may differ from those assessed by disease activity outcome measures.  
This may be an explanation for the associations of elevated C3 levels and 
leucocytosis with subclinical atherosclerosis, when hypocomplementaemia and 





Several authors have reported that older age at diagnosis to be associated with 
carotid plaque and/or plaque progression85, 351, 367.  In contrast, Kiani et al. found 
a positive association for older age, but a negative association for older age at 
diagnosis, possibly explained by cohort-related confounding factors267. 
 
Ahmad et al. found an association of previous history of coronary and/or 
cerebrovascular events as well as the presence of aPL and/or LA were 
independent predictors for carotid plaque in Ahmad et al.'s study of 200 women 
with SLE in North-West England85.  However a negative association for aCL was 
found in Roman et al's study86 and no significant associations were reported in 
other studies364, 372.  Jiménez et al. reported a higher prevalence of carotid plaque 
in SLE patients with APS compared with primary APS patients and controls351.  
Furthermore, SLE patients had significantly greater plaque burden, whereas the 
plaque burden was similar in primary APS patients and controls.  This suggests 
that other inflammatory processes apart from thrombosis are involved in 
atherogenesis in patients with SLE and APS.  It is possible that aPL with 
pathogenic effects other than thrombosis may be involved in these atherogenic 
processes. 
 
Higher SLICC DI scores86, 349, 351, 364, baseline immunosuppressant use353, 
increased or cumulative glucocorticoid use348, 362 and azathioprine use85 have also 
been associated with carotid ultrasound measures of subclinical atherosclerosis. 
In contrast, Roman et al. reported a negative association of cyclophosphamide 
use with carotid plaque86.  As immunosuppressant use may act as a marker of 
SLE disease severity and/or activity, it is the most likely explanation for the 
variable associations reported.  Similarly the negative association of anti-Sm 
and/or aCL with the presence of carotid plaque 86 may be due to associations of 







5.5.  Summary  
Patients with SLE have up to a 10-fold increased risk of developing MI or stroke 
and these CVEs tend to occur at an earlier age compared with the general 
population. The prevalence of CV risk factors is increased in patients with SLE. 
Despite this fact, traditional risk factors still do not fully account for the increased 
CV risk in SLE, therefore identification of SLE-related factors that increase CV 
risk will improve patient management.   
 
Table 1.4 presents traditional and SLE-related factors predictive of CVEs, 
including death.   
• Traditional CV risk factors include older age at diagnosis, hypertension, 
dyslipidaemia and smoking.  
• Other important CV factors include male gender, obesity, DM and post-
menopausal status.   
• SLE-related factors that predict future CVEs are usually associated with 
increased disease activity or disease severity, such as longer 
glucocorticoid use, azathioprine use, NP-SLE or vasculitis.  Longer 
disease duration also increases the risk of future CVEs.   
• APL increase thrombotic risk and are also important in predicting future 
CV disease.   
 
The immunopathogenic mechanisms of SLE most likely enhance the complex 
interaction of classic CV risk factors with the inflammatory pathways of 
atherogenesis, thereby accelerating the atherosclerotic process.   
• Atherogenesis is initiated by endothelial dysfunction or damage. This is 
followed by formation of the fatty streak, then the atheromatous plaque 
with a fibrous cap.  The final stage involves plaque destabilisation, 
rupture and thrombosis with vascular occlusion. 





• Activation of TLR4 in SLE is associated with increased disease activity. 
TLR4 is also found in atherosclerotic plaques, supporting the hypothesis 
that SLE inflammatory mechanisms enhance atherogenesis. 
• HDL plays an anti-inflammatory role in the atherosclerotic process. 
 
Subclinical atherosclerosis is common in SLE, with carotid plaque prevalence of 
up to 45%.  Table 1.5A presents CV factors associated with carotid arterial 
plaque and IMT which are similar to those identified in Table 1.4. 
• Older age is the most important factor associated with carotid plaque and 
increased IMT both at baseline and with progression.  Other important 
factors are hypertension and dyslipidaemia.  
• Smoking, lower HDL3 levels and a history of previous CVE are associated 
with carotid plaque 
• Hyperglycaemia, obesity and prevalent IHD are associated with increased 
carotid IMT.   
 
Table 1.5B presents SLE-related factors associated with carotid plaque and IMT. 
• Important factors associated with the presence of carotid plaque and/or 
plaque progression include longer disease duration, increased disease 
activity, increased damage accrual, raised inflammatory markers (such as 
leucocytosis and raised CRP), glucocorticoid and azathioprine use.  
• Markers of IMT thickening or progression also included longer disease 
duration, raised inflammatory markers and glucocorticoid use. 







Table 1.5A.  Cardiovascular-related risk factors for subclinical atherosclerosis 




sample size Study site(s) Carotid plaque Increased carotid IMT 
Multivariate 
analysis 




- 175 women Pittsburgh PA, 
USA 
older age, ↑systolic BP, IHD older age, ↑pulse pressure, 
IHD 
yes 
Roman et al 
(2003)86 
prospective cohort + 
controls, cross-sectional  
- 197 + controls New York NY, 
USA 
older age  yes 




- 214 women Pittsburgh PA, 
USA 
older age, ↑systolic BP, 
↓HDL3  
older age, ↑pulse pressure, 
↑TC, ↑glucose, ↑CRP 
yes 
Jiménez et al 
(2005)351 
prospective cohort + 
controls, cross-sectional  
- 70 SLE, 25 primary 
APS + 40 controls  
Barcelona, Spain older age, ↑apoB  yes 
Maksimowicz-




- 605 Baltimore MD, 
USA 
older age, hypertension  yes 
Ahmad et al 
(2007)85 
prospective cohort + 
controls, cross-sectional  
- 200 + 100 controls NW England smoking, previous CVE  yes 




- 276 Los Angeles, 
CA, USA 
older age, hypertension, 
dyslipidaemia, mixed race, 
piHDL 
older age,  African-
American ethnicity, ↑IMT, 
piHDL,  
yes 
McMahon et al 
(2011)365 
prospective cohort + 
controls, cross-sectional  
- 250 + 122 controls Los Angeles, 
CA, USA 
older age, hypertension, 
smoking, piHDL, ↑leptin 
 yes 
de Leeuw et al 
(2006)363 
prospective cohort + 
controls, cross-sectional  
- 72 + 36 controls Groningen, 
Netherlands 













sample size Study site(s) 
Carotid plaque 
progression Carotid IMT progression 
Multivariate 
analysis 
Doria et al (2003)348 prospective cohort, 
longitudinal  
5 78 Padua, Italy older age older age, hypertension yes 




 158 New York NY, 
USA 
↑homocysteine  yes 




mean 4.2 217 women Pittsburgh PA, 
USA 
older age, ↑TG older age, ↓diastolic BP yes 
de Leeuw et al 
(2009)354 
prospective cohort + 
controls, longitudinal  
> 1.7 74 + 74 controls Groningen & 
Amsterdam, 
Netherlands 
 older age yes 




2 101 Las Palmas, 
Spain 
 older age at diagnosis yes 
Kiani et al (2011)267 prospective cohort, 
longitudinal (Hopkins) 
2 187 Baltimore MD, 
USA 
older age, ↑BP, &/or 
treatment 





Table 1.5B.  SLE-related risk factors for subclinical atherosclerosis 




sample size Study site(s) Carotid plaque Carotid IMT thickening 
Multivariate 
analysis 




- 175 women Pittsburgh PA, USA  ↑SLICC DI yes 
Roman et al 
(2003)86 
prospective cohort + 
controls, cross-sectional  
- 197 + controls New York NY, USA ↑disease duration, ↑SLICC 
DI; negative association - 
cyclophosphamide,  
anti-Sm / aCL 
 yes 
Jiménez et al 
(2005)351 
prospective cohort + 
controls, cross-sectional  
- 70 SLE, 25 primary 
APS + 40 controls  
Barcelona, Spain older age at diagnosis, 
↑disease duration, ↑ESR, 
↑CRP, ↑ECLAM,  
↑SLICC DI, APS 
 yes 
Maksimowicz-





- 605 Baltimore MD, USA ↑SLICC DI  yes 
Ahmad et al 
(2007)85 
prospective cohort + 
controls, cross-sectional 
- 200 + 100 controls NW England older age at diagnosis, 
↑disease duration, 
↑neutrophils, azathioprine 
use, aCL &/or LA 
 yes 




- 276 Los Angeles, CA, 
USA 
 cumulative glucocorticoid 
dose > 20g 
yes 








sample size Study site(s) 
Carotid plaque 
progression Carotid IMT progression 
Multivariate 
analysis 
Doria et al (2003)348 prospective cohort, 
longitudinal 
5 78 Padua, Italy cumulative glucocorticoid 
dose 








 158 New York NY, USA older age at diagnosis, 
↑disease duration 
 yes 




mean 4.2 217 women Pittsburgh PA, USA ↑C3, baseline 
immunosuppressant use 
↑creatinine yes 
de Leeuw et al 
(2009)354 
prospective cohort + 
controls, longitudinal  
> 1.7 74 + 74 controls Groningen & 
Amsterdam, 
Netherlands 
 disease duration > 10 yrs 
 
yes 




2 101 Las Palmas, Spain  ↑C3, ↑C5a yes 
Kiani et al (2011)267 prospective cohort, 
longitudinal (Hopkins) 
2 187 Baltimore MD, USA ↑disease duration, ↑white 
cells ↑lymphocytes, 
↑proteinuria; negative 
association - older age at 
diagnosis 




6.  Lipid profiles in SLE 
The "lupus pattern" of dyslipoproteinaemia is a lipid profile characterised by 
decreased HDL-C and elevated very low density lipoprotein cholesterol (VLDL-
C) and TG368, 373, 374.  This profile is more marked with increased disease activity, 
as measured by SLEDAI or the Systemic Lupus Activity Measure (SLAM), and 
may be accompanied by decreased LDL levels368, 373, 375.  Raised TG and VLDL-
C are positively correlated with increased TNF-α levels376. TNF-α stimulates 
hepatic synthesis of VLDL and also downregulates expression of  lipoprotein 
lipase (LpL), an endothelium-associated enzyme which hydrolyses TGs on 
chylomicrons and VLDL377.  Proteinuria exacerbates hypertriglyceridaemia in 
SLE and is also associated with increased total cholesterol (TC), LDL-C and 
apolipoprotein B (apoB), a component of VLDL and LDL378-380.  In the general 
population, apoB is a stronger predictor for fatal MI than LDL-C381.  In patients 
with SLE, hypercholesterolaemia is associated with an increased risk of 
developing IHD276, 382.  Glucocorticoid therapy causes increases in TC, HDL-C, 
LDL-C and apoB concentrations, thereby potentially increasing CV risk in 
patients with SLE383-385.  Within the general population, TG was found to be an 
independent predictor for IHD in some studies, but not in others386, 387.  This 
discrepancy may be due to TG concentrations representing both TG-rich highly 
atherogenic lipoproteins, such as intermediate density lipoproteins (IDL), as well 
as TG-rich non-atherogenic lipoproteins, such as chylomicrons and large 
VLDLs387.  MacGregor et al. studied lipid profiles of 64 SLE patients and found 
raised TG and apoB concentrations in patients taking prednisolone doses above 
10 mg daily in the previous 6 months.  However, an increase in vascular events 









6.1.  HDL and ApoA-I 
In the Framingham study, reduced HDL-C concentration was the strongest 
independent predictor for IHD in both men and women389.  Numerous studies 
have since confirmed this finding390, 391.  Furthermore, HDL concentrations show 
an inverse relation to CV-related mortality391.  In SLE, low HDL-C levels were 
detected in 79% of patients with active disease and in 29% of patients with 
inactive disease368.  HDL-C is traditionally separated by ultracentrifugation, 
chemical precipitation, or gradient gel electrophoresis into its two major 
lipoprotein subfractions, HDL2-C and HDL3-C390, 392.  In the general population, 
low HDL2-C concentrations are more strongly predictive of IHD risk than low 
HDL3-C concentrations390.  Apolipoprotein A-I (apoA-I) is the predominant 
apolipoprotein of HDL, and has been shown to play a protective role against fatal 
MI in the general population381.  Ettinger et al. compared lipid profiles of SLE 
patients with matched control subjects and found similar levels of HDL-C, 
HDL3-C and apoA-I in both groups, but lower HDL2-C levels in SLE patients383.   
 
HDL plays a critical role in reverse cholesterol transport, which is the primary 
mechanism for delivering excess cholesterol from peripheral tissues to the liver 
for disposal393.  ApoA-I stimulates extracellular efflux of phospholipid and 
cholesterol via ATP-binding membrane cassette transport protein A1 (ABCA1).  
ApoA-I binds to PLs and interacts with cholesterol to form nascent discoidal 
HDL (ndHDL).  Lecithin-cholesterol acyltransferase (LCAT) then esterifies 
cholesterol on the surface of ndHDL.  Cholesteryl esters move to the hydrophobic 
core of HDL, producing a steady gradient for free cholesterol to move out of cells 
towards HDL.  As the amount of esterified cholesterol within the HDL particle 
increases, it becomes progressively rounder and larger, resulting in the formation 
of mature HDL.  Exchange of cholesteryl esters on HDL for TGs on lipoprotein 
remnant particles (VLDL or IDL) is mediated by cholesteryl ester transfer protein 
(CETP).  These lipoprotein remnant particles are subsequently cleared by the 
liver.  At the same time, TGs and PLs on HDL undergo hydrolysis by hepatic 
lipase (HL), a process which converts larger and more buoyant HDL2 to smaller 





In addition to its role in reverse cholesterol transport, HDL has a variety of other 
anti-inflammatory, anti-oxidant and anti-thrombotic functions which contribute to 
its protective effect on atherosclerosis.  HDL actions on endothelium include 
stimulation of NO and prostacyclin production, inhibition of adhesion molecule 
expression, and prevention of endothelial apoptosis.  HDL's antioxidant effects 
are due to reduction of lipid peroxides in LDL by apoA-I and activity of several 
of its anti-oxidant enzymes, including paraoxonase 1 (PON1), which hydrolyses 
LDL-associated lipid peroxides and prevents generation of oxLDL394, 395.  
However, during chronic inflammation, the oxidative environment promotes 
oxidative and enzymatic modification of lipids and proteins within HDL, hence 
impairing its anti-atherogenic effects.  This form of HDL, termed pro-
inflammatory HDL (piHDL), has a reduced ability to promote cholesterol efflux, 
and is associated with IHD396.  McMahon et al. found pro-inflammatory effects 
of HDL in 45% of SLE patients compared with 4% of controls397.  Furthermore, 
piHDL was associated with plaque and increased carotid IMT in SLE patients362. 
However, there were no associations between PON1 activity and apoA-I levels 
with piHDL or plaque, suggesting that the pro-atherogenic actions for piHDL are 
independent of PON1 and apoA-I activity.  In SLE, conversion of normal HDL to 
piHDL may result from inhibition of its anti-oxidant enzyme and apolipoprotein 
activities by antibodies such as aPL directed against HDL epitopes.  IgG anti-
HDL and anti-apoA-I are associated with reduced PON1 activity374, 398.  One 
study found that antibodies from SLE sera directed against HDL and apoA-I also 
exhibited cross-reactivity with cardiolipin399.  Lower TC, HDL-C and apoA-I 
levels were found in aCL GPL positive patients with SLE, compared with aCL 
GPL negative patients400.  The prevalence of IgG anti-apoA-I was reported to be 
32.5% in SLE patients and was associated with anti-β2GPI GPL401.  The 
association of anti-apoA-I with aCL and anti-β2GPI antibodies may be explained 
by the presence of cardiolipin within HDL, possibly bound to β2GPI72.  An 
increased prevalence of IgG anti-apoA-I has also been found in patients with 
acute coronary syndromes402.  There is evidence to support pro-inflammatory 




apoA-I titres are associated with increased disease activity and damage, as 
measured by BILAG and SLICC DI respectively in patients with SLE, and 
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ABC1 = ATP-binding cassette protein 1; A-I = apolipoprotein A-I; CE = 
cholesteryl ester; FC = free cholesterol; LCAT = lecithin:cholesterol 
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Figure 1.3. 
Reverse cholesterol transport is the primary mechanism for delivering excess cholesterol 
from peripheral tissues to the liver for disposal.  A-I stimulates extracellular efflux of 
phospholipid and cholesterol via ABC1.  A-I binds to PLs and interacts with cholesterol to 
form nascent discoidal HDL.  LCAT then esterifies cholesterol on the surface of nascent 
HDL.  Cholesteryl esters move to the hydrophobic core of HDL, producing a steady 
gradient for free cholesterol to move out of cells towards HDL.  As the amount of 
esterified cholesterol within the HDL particle increases, it becomes progressively rounder 
and larger, resulting in the formation of mature HDL.  HDL is then taken up by the liver 
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Figure 1.4. 
LPL is bound to endothelium in muscle and adipose tissue and hydrolyses lipoprotein-
associated TG into free fatty acids.  CMs carrying dietary TG absorbed from the intestine 
compete with VLDL for LPL hydrolysis of TGs.  Resultant CMRs are removed from the 
circulation by the liver.  Removal of TG from VLDL results in VLDL remnant particles 
such as IDL, which are later converted to LDL and subsequently cleared by the liver.  
Exchange of cholesteryl esters (CE) on HDL for TGs on lipoprotein remnant particles 
(VLDL or IDL) is mediated by CETP.  At the same time, TGs and PLs on HDL undergo 
hydrolysis by HL, a process which converts larger and more buoyant HDL2 to smaller 




6.2.  Lipoprotein lipase  
Inhibition of LpL activity may be one of the factors contributing to the elevated 
TG and VLDL concentrations observed in patients with active SLE404.  LpL is 
bound to endothelium in muscle and adipose tissue and hydrolyses lipoprotein-
associated TG into free fatty acids.  Chylomicrons are lipoproteins carrying 
dietary TG absorbed from the intestine, which compete with VLDL for LpL 
hydrolysis of TGs405. Resultant chylomicron remnants are removed from the 
circulation by the liver, using apolipoprotein E (apoE) as a ligand406.  Removal of 
TG from VLDL results in VLDL remnant particles such as IDL, which are later 
converted to LDL405.  HDL levels are also influenced by LpL activity.  Reduced 
LpL activity results in increased transfer of TGs from VLDL to HDL. TG-rich 
HDL then acts as a substrate for HL, resulting in smaller, lipid-poor apoA-I, 
which is then rapidly cleared, thereby accounting for the association of reduced 
LpL activity with low HDL levels406 (Figure 1.4).  LpL activity is reduced by 
approximately 50% in patients with SLE compared with healthy individuals404 
and may be a result of inhibition by anti-LpL antibodies. Reichlin et al. detected 
anti-LpL in 47% of SLE patients407.  Anti-LpL levels have been positively 
correlated with TG, apoB and apoE concentrations, providing further evidence 
for anti-LpL activity407.  Anti-LpL is also associated with aCL GPL and increased 
disease activity in SLE408. 
 
6.3.  Lipoprotein(a) 
Lipoprotein(a) [Lp(a)] is a LDL-like lipoprotein consisting of apoB100 
covalently-linked to a plasminogen-like glycoprotein, apolipoprotein(a) [apo(a)].  
Apo(a) interferes with fibrinolysis and promotes thrombosis by inhibiting the 
function of tissue factor pathway inhibitor (TFPI),  a major regulator of TF-
mediated coagulation409, 410.  Lp(a) also promotes monocyte adhesion to 
endothelium409, and mediates plaque inflammation and rupture411, 412.  Lp(a) 
binds pro-inflammatory oxPLs291, with apoB100 as the preferential carrier of 




pathogenesis of atherosclerosis within the general population, and higher levels 
correlate with ultrasound measures of carotid and femoral atherosclerosis289, 413.  
Elevated Lp(a) independently predicts for IHD, ischaemic stroke and coronary 
mortality, although the effect is relatively weak (adjusted RR 1.1 for all 
outcomes)409. Elevated levels of Lp(a) have also been detected in patients with 
SLE414-416.  One study reported serum Lp(a) concentrations were elevated in SLE 
patients with renal disease and hypoalbuminaemia, and were reduced by 
treatment with glucocorticoids416.  Furthermore, SLE patients with elevated Lp(a) 
concentrations (> 300 mg/L) have higher levels of ICs containing IgM anti-
oxLDL, implying involvement of Lp(a) in autoimmune pathways in SLE417.  In 
contrast, another group reported that Lp(a) levels were not influenced by 
glucocorticoids, disease activity or aCL415.   
 
6.4.  Lipoprotein and apolipoprotein ratios 
The TC : HDL-C ratio has been used to predict future IHD risk in the general 
population, with higher ratios predicting increased risk418.  Recent studies have 
demonstrated that the apoB : apoA-I ratio may be a more reliable predictor of 
IHD risk than the TC : HDL ratio419, 420.  ApoB is considered to be representative 
of atherogenic lipoproteins, whereas apoA-I represents anti-atherogenic HDL 
particles419.  Lipoprotein or apolipoprotein ratios may be more reliable CV risk 
predictors in the setting of SLE, where lipid profiles may vary according to 
disease activity. 
 
6.5.  Summary 
• The "lupus pattern" of dyslipoproteinaemia is characterised by low HDL-
C, and elevated VLDL-C and TG and is more marked with increased 
disease activity.  





• HDL plays a critical role in reverse cholesterol transport, but also has 
anti-oxidant effects via PON1 activity. 
• Reduced HDL-C is a strong predictor of IHD. 
• ApoA-I is the predominant apolipoprotein of HDL. 
• SLE patients who are ACL GPL+ve  have been shown to have lower TC, 
HDL-C and apoA-I levels. 
• Low HDL levels are associated with lower LpL activity. LpL activity may 
in turn be inhibited by anti-LpL in SLE. 
• Lp(a) is a predictor of IHD and elevated Lp(a) levels have been found in 
patients with  SLE. 
• The TC : HDL-C ratio and apoB : ApoA-I ratios are predictors of 
increased CV risk in the general population and may be useful in 
assessing CV risk in SLE. 
 
Conclusions 
Due to the complex pathogenesis of SLE and the wide spectrum of disease 
manifestations and clinical outcomes discussed in this review, it is clear that a 
range of biomarkers would be required to assist clinicians in the management of 
their lupus patients.   
 
Autoantibodies may be associated with distinct clinical subsets of SLE disease 
manifestations. These results support the hypothesis that auto-immune 
inflammatory pathways leading to specific SLE disease manifestations are shared 
with other auto-immune diseases with similar disease manifestations.  Studying 
biomarkers of other diseases may therefore yield useful biomarkers for clinical 
subsets of SLE. For example, ACPA may be a useful marker for an erosive 
subset of lupus arthritis.   
 
Recently discovered genetic markers have provided new insights into SLE 




pathways and autoimmune mechanisms in the pathogenesis of SLE.  While the 
majority of these genetic markers are also markers of SLE disease susceptibility, 
their specific autoantibody and clinical disease associations may provide further 
prognostic information for patients with established SLE. 
 
Despite recent advances in the medical treatment of SLE, patients still have 
poorer clinical outcomes and higher mortality rates compared with the general 
population.  Important non-SLE related factors include older age at disease onset, 
male gender and low socio-economic status. Major SLE-related factors include 
higher disease activity, organ damage accrual, more severe disease manifestations 
(e.g. renal and neuropsychiatric involvement), and APS. However, there is very 
little data published on the associations of autoantibodies with mortality. This 
may reflect the highly complex nature of autoimmune inflammatory processes, so 
a single isolated factor such as an autoantibody may not be able to directly 
predict a future clinical outcome. Nonetheless, research for autoantibodies as 
markers of future mortality is still warranted, because testing for an autoantibody 
with predictive value would provide added prognostic accuracy when other 
predictive factors are taken into account. 
 
This chapter described the multifactorial pathogenesis of premature CVD in SLE, 
which most likely involves complex interactions of vascular inflammation, lipid 
oxidation, lipoprotein metabolism, endothelial dysfunction, adverse 
glucocorticoid effects, hypertension, and aPL-related vascular and thrombotic 
effects.   
 
As traditional risk factors do not fully account for the increased CV risk in SLE, 
identification of SLE-related factors that increase CV risk will improve patient 
management.  Traditional CV risk factors include older age at diagnosis, 
hypertension, dyslipidaemia and smoking. Other important CV factors include 
male gender, obesity, DM and post-menopausal status.  Of note, SLE-related 
factors that predict future CVEs are usually associated with increased disease 




NP-SLE or vasculitis.  Longer disease duration also increases the risk of future 
CVEs.  APL increase thrombotic risk and are also important in predicting future 
CV disease.   
 
Lower HDL concentrations are associated with subclinical atherosclerosis and 
may be a marker of increased disease activity, itself a predictor for mortality.  
SLE-related factors associated with carotid plaque and increased IMT thickness 
and/or progression are similar to the predictors for CVEs, such as longer disease 
duration, increased damage accrual, increased disease activity, raised 
inflammatory markers, glucocorticoid and azathioprine use. However, there are 
conflicting results for aPL.  
 
The factors above that are associated with CVEs and subclinical atherosclerosis 
highlight the importance of good control of SLE disease activity for the 
prevention of long-term CV complications.  Moreover, vigilance in identifying 
and actively treating traditional CV risk factors is an essential component of 
long-term management of patients with SLE.   
 
The following thesis chapters present the research conducted to identify 
serological biomarkers for certain clinical aspects of SLE. Markers studied 
include auto-antibodies and genetic markers of erosive arthritis, markers for the 






Associations of erosive arthritis with anti-cyclic 
citrullinated antibodies and MHC class II alleles in SLE 
 
Background 
Joint involvement is a common feature of SLE, occurring in up to 91% of 
patients25, 183.  Clinical manifestations range from recurrent, transient 
polyarthralgia to deforming, rheumatoid-like arthritis, with synovitis affecting 
MCP or proximal PIP joints.  Jaccoud's arthropathy is an uncommon type of 
correctable, deforming NEA that occurs in 3% to 13% of SLE patients184-187.  
Typical RA-like erosions are absent on radiographs, although "hook-like" 
erosions of the metacarpal heads may develop in late disease.  Erosive arthritis 
(EA) is also uncommon in SLE, and has been reported to affect 5% of patients187-
189.  A further clinical subset, termed "rhupus" describes patients with 
radiological RA-like joint erosions, who fulfil both clinical features of RA and 
SLE.  As EA is associated with worse functional outcome and disability, 
determining a biomarker to identify the subset of patients at risk of developing 
EA would enable clinicians to make informed decisions about initiating 
aggressive disease-modifying therapy for arthritis.   
 
The presence of RF is one of the ACR/ EULAR classification criteria for RA192-
194 (see Appendix), however, RF is relatively insensitive as a predictor for RA, as 
only 75% of patients with RA are RF-positive195.  Moreover, RF is not specific 
for RA and has been detected in other autoimmune diseases, including SLE195.  
Mediwake et al. found that RF was unhelpful in distinguishing RA patients from 
SLE patients with EA187.  ACPA has been reported to be much a more specific 




other autoimmune diseases, including SLE129, 187, 421.  In both RA and PsA, 
ACPA is associated with EA and radiographic disease progression200, 202.   
 
Antibody production and clinical subsets of SLE are influenced by genetic 
factors.  Several studies have confirmed the association of HLA-DR3 with the 
production of both anti-Ro/SSA and anti-La/SSB147, 148.  Anti-Ro/SSA and anti-
La/SSB positive patients with the HLA-DR3 haplotype are more likely to be older 
at disease onset, with sicca symptoms and less renal involvement151.  In RA, 
disease susceptibility and severity are associated with several MHC Class II 
alleles encoding protein products collectively termed the shared epitope (SE)207, 
422.  HLA-DQB1*0302 is inherited in linkage disequilibrium with HLA-DRB1 SE 
alleles and is associated with RA disease severity and ACPA production209.  
However, recent evidence suggests that the SE may not be a specific marker for 
RA, but instead may be a marker for ACPAs involved in the pathogenesis of 
progressive, erosive joint destruction208.  In view of the frequent clinical 
manifestation of arthritis in SLE and the joint damage and functional limitation 
that is a consequence of EA, ACPA may serve a useful clinical role as a predictor 
of EA in SLE.  This chapter describes in detail our research on the association of 
ACPA with EA in SLE, a finding which has been confirmed by others129-131, 187, 
203, 423.   
 
Aim 
To determine the associations of erosive arthritis with ACPA and MHC class II 










Personal contribution by the candidate  
This study was designed as a retrospective cohort study by the candidate, under 
the supervision of Prof Neil McHugh.  MHC class II genetic data and serological 
data were available from a database of SLE patients who were participating in an 
ongoing serological and genetic study and who had been consecutively recruited 
from the RNHRD CTD Clinic. Genetic and serological data was also available 
from a group of local healthy blood donors who were consecutively recruited for 
a previous study.  The SLE patients attended the Connective Tissue Diseases 
(CTD) Clinic at the Royal National Hospital for Rheumatic Diseases (RNHRD).  
Radiological reports and clinical data were collected by the candidate for this 
study.  The candidate designed the SLE questionnaire (see Appendix), with 
advice from Prof McHugh and Dr Eleanor Korendowych.  Mrs Charlotte Cavill, 
the CTD database manager at the Bath Institute for Rheumatic Diseases (BIRD), 
was responsible for mailing of questionnaires, collation of questionnaire results 
and tracing of patients who were lost to follow-up.  Mrs Juliet Dunphy and Mrs 
Patricia Owen at BIRD provided training and supervision for the candidate's 
work on all RF and several ELISAs.  The remainder of the ACPA ELISAs were 
performed by Mrs Dunphy and Owen. 
 
Sample size  
Prior to commencement of this study, there was only one published report on the 
association of ACPA with EA in SLE187.  In this study, Mediwake et al. utilised 
the earliest version of the ACPA ELISA, which had a sensitivity of 68%424, 
compared with the manufacturer's reported sensitivity of 76%  for its later version 
ACPA-2 ELISA (INOVA Diagnostics, San Diego, CA, USA) that was used in 
our study. Although a sample size calculation was not performed prior to the 
study, we expected that a study sample of at least 66 SLE patients (the number of 




detect a difference in ACPA positivity between SLE patients with EA and those 
without EA.  Hence we aimed to recruit at least 100 patients for this study.   
 
Patients and controls 
We studied 104 subjects with SLE (91 females and 13 males) from a research 
database of patients attending the RNHRD CTD Clinic, a tertiary rheumatology 
centre in the UK. All patients fulfilled the updated ACR classification criteria 
(1997) for SLE8, 425.  Ethical approval for the study was given by the Bath Local 
Research Ethics Committee and written informed consent was given by all 
participants. Clinical data collected for each patient included the documentation 
of the presence of joint synovitis at any time in the course of the disease. Patients 
who experienced joint symptoms had radiographs of hands and feet taken during 
their routine clinic visits, with radiographs repeated at a minimum of yearly 
intervals (up to 9 year intervals), according to the treating clinician’s decision. 
Available radiographs were reviewed to determine the presence of joint erosions.  
Patients with synovitis were designated as having erosive arthritis (EA) 
attributable to an inflammatory arthropathy, or nonerosive arthritis (NEA), 
according to the presence or absence of joint erosions on radiographs.  Each 
patient with EA was then assigned as having major or minor erosions according 
to the size and extent of the erosions.  Patients with EA were also assessed for 
RA according to ACR criteria193. All remaining patients without joint synovitis 
were designated as "no arthritis" (NA).  Blood samples were collected from all 
patients for genetic studies and serological tests.  
 
Serum samples from 130 age- and sex-matched healthy local blood donors were 
selected as serum controls. Seventy-six blood samples from the 130 serum 
controls were also genotyped and a further 41 samples from sex-matched local 
blood donors were selected as genetic controls (total n = 117). All serum and 







Serum ACPA and RF autoantibodies from patients and serological controls were 
measured using commercial ACPA-2 and IgM RF ELISA kits (INOVA 
Diagnostics).  ANA titres were determined by indirect immunofluorescence on 
HEp-2 cells.  Anti-dsDNA antibodies were determined using commercial ELISA 
kits (Cambridge Life Sciences, Ely, UK). Antibodies to extractable nuclear 
antigens (including U1RNP, Sm, Ro/SSA, and La/SSB,) were measured by 
Ouchterlony double diffusion.  Patients with anti-U1RNP, anti-Sm, or anti-
La/SSB antibodies had these autoantibodies confirmed by western blotting on at 
least one sample.  For ELISAs, all serum samples were tested in duplicate and 
absorbances were determined using a commercial microplate photometer 
(Multiskan Ascent, Labsystems, Helsinki, Finland). The intra- and inter-assay 
coefficients of variation (%CV) for ACPA were 9.0% and 11.3% respectively 
and intra- and inter-assay %CVs for RF were 8.9% and 20.2% respectively.  Cut-
off values of > 25 Units (U) for ACPA and > 6 U for RF were used to indicate a 
positive result, which were above the 98th and 95th percentiles of control sample 
results respectively. 
 
HLA-DRB1 and HLA-DQB1 genotyping 
All 104 SLE and 117 genetic control whole blood samples were collected into 
ethylenediamine tetra-acetate (EDTA) tubes and genomic DNA was extracted 
using a standard salting out procedure. Twenty-six HLA-DRB1 and 13 HLA-
DQB1 alleles were identified from extracted DNA, using a polymerase chain 
reaction-based method with sequence specific primers (PCR-SSP), as previously 
described by McHugh et al.145  Carriage of an SE allele was documented 
according to the presence of HLA-DRB1*0101, *0102, *0401, *0405, *0408 or 
*1001422.  The presence of the SE-associated allele HLA-DQB1*0302 was also 







Statistical analysis was performed using the SPSS Statistics 17.0 software 
package (IBM Corporation, Armonk, NY, USA).  Comparisons were made for 
nominal data using the chi-square test with 2 x 2 contingency tables, and odds 
ratios (OR) and 95% CI were calculated. Where expected numbers for the 
contingency tables were less than 5, the Fisher’s exact test was used. The 
Student's t-test was used to compare normally distributed data, with means and 
standard deviations (SD) quoted. For nonparametric comparisons, Mann-Whitney 
U and Kruskal-Wallis tests were used, with medians and interquartile ranges 
(IQR) quoted. Logistic regression was used for comparisons of continuous data to 
determine ORs.  A p value of < 0.05 was considered to represent a significant 
difference between groups and where appropriate, Bonferroni corrections were 
made for the number of alleles observed. 
 
Results 
Clinical features of SLE patients 
We found that 71 of 104 (68%) SLE patients had experienced synovitis during 
the course of their disease, of whom 12 (11%) patients had EA and 59 (57%) had 
NEA. The remaining 33 (32%) patients had NA.  Patients were followed for a 
median (IQR) of 13 (13) years.  Table 2.1 shows the clinical features of the 3 
patient groups. There were no significant differences in age among the groups.  
Patients from the EA group had a longer median (IQR) disease duration of 14 
(10) years, compared with median (IQR) disease durations of 9 (6) and 7 (5.5) 
years in the NEA and NA groups respectively, although this was not significant 
(pcorrected = 0.2 for EA vs NEA and pcorrected = 0.2 for EA vs NA).  There were no 
significant differences in ethnicity among the groups, as the majority (n = 102, 
98%) were of British Caucasian origin. There were two patients of Afro-
Caribbean origin who both had NEA. All patients with EA were female, 




no significant differences between groups for SLE-related clinical features, 
although none of the EA patients had a history of discoid rash or NP-SLE.  
 
Serology results of SLE patients  
All 104 SLE patients were ANA positive. Eight (8%) patients were ACPA 
positive, compared with 2 (1.5%) of 130 ACPA+ serum controls (OR 5.3, 95% 
CI 1.1, 25.7, p = 0.02).  Eighteen (17%) of SLE patients were RF positive, 
compared with 4 (3%) of RF+ serum controls (OR 6.6, 95% CI 2.2, 20.2, p < 
0.0001).  ACPA was significantly associated with RF (OR 5.9, 95% CI 1.3, 26.2, 
p = 0.03). Table 2.2 shows the serology results of the 3 SLE patient groups. 
Among the 71 patients with a history of synovitis (comprising 12 EA and 59 
NEA patients), 6 (11%) were ACPA+ and 5 (15%) were RF+. Compared with 
other SLE patients, patients with EA were more likely to be ACPA+ [6/12 (50%) 
in EA vs 2/92 (2%) in other SLE patients, OR 45.0, 95% CI 7.4, 272.5, p < 
0.0001]. Similarly, ACPA was more likely to be present in EA patients compared 
with NEA patients (OR 28.5, pcorrected = 0.01). When corrected for multiple 
comparisons, the association of RF with EA was no longer significant (p = 0.02, 
pcorrected = 0.3).  None of the patients with EA had anti-Ro/SSA or anti-La/SSB 
antibodies.  Although more EA patients were anti-U1RNP positive (58% vs 36% 
of NEA and 33% of NA patients), this was not statistically significant. 
 
Characteristics of SLE patients with EA  
Table 2.3 shows the characteristics of the 12 patients with EA, subdivided into 2 
groups with major erosions or minor erosions.  Six (50%) patients had major 
erosions on radiographs.  The earliest erosions occurred after a mean (SD) of 11.3 
(6.8) years for all EA patients, with no differences between those with major or 
minor erosions.  Four of the 6 patients with major erosions (66.7%) were ACPA+ 
and 3 (50%) were RF+.  There were no differences in median ACPA or RF levels 




erosions also fulfilled the ACR criteria for RA, compared with only 1 patient 
with minor erosions (p = 0.01). 
 
Characteristics of ACPA positive SLE patients and controls  
Table 2.4 shows the characteristics of the 8 ACPA+ SLE patients and 2 ACPA+ 
serum controls. Both serum controls were also genotyped. Six patients (75%) 
developed EA, of whom 4 (50%) had major erosions.  All 5 HLA-DQB1*0302 
carriers had EA, 4 of whom developed major erosions.  Patients 5 and 6 were 
anti-U1RNP and anti-Sm positive and had LN (patient 5 - class IV diffuse 
proliferative glomerulonephritis, patient 6 - class II mesangioproliferative 
glomerulonephritis).  Both of these patients had Jaccoud’s arthropathy, with one 
patient developing minor erosions.  This patient also met the ACR criteria for 
RA.  Both were carriers of DRB1*1303, but neither carried the SE nor 
DQB1*0302.  Three patients carried 2 SE alleles and 2 patients were 
heterozygotes for the SE and the SLE-associated allele DRB1*1501.  Both 
ACPA+ controls were carriers of the SE allele DRB1*0401.  
 
Frequencies of MHC class II alleles in SLE patients and genetic 
controls 
HLA-DRB1*0301 was significantly associated with SLE [39/104 (37%) SLE 
patients vs 24/117 (20%) genetic controls, OR 2.3, 95% CI 1.3, 4.2, p = 0.005, 
pcorrected=0.05]. There was a similar trend for DQB1*0201 [49/104 (47%) SLE vs 
41/117 (35%) controls, OR 1.6, 95% CI 1.0, 2.8, p = 0.08].  Almost all SLE 
patients and all genetic controls were British Caucasian individuals and as 
expected, the most common SE allele present was DRB1*0401 [25/104 (24%) 
SLE vs 21/117 (18%) controls]. There were no differences between patients and 






Associations of arthritis with MHC class II alleles 
Table 2.5 shows the associations of arthritis with MHC class II alleles. When 
corrected for multiple comparisons, DQB1*0302 was the only SE-related allele 
significantly associated with EA (OR 8.2, 95% CI 2.2, 30.4, pcorrected = 0.01).  
Furthermore, all 6 patients with major erosions were DQB1*0302 carriers [6/6 
(100%) vs 20/98 (20%) all other SLE, p < 0.0001, pcorrected = 0.001]. There was a 
similar but non-significant association of EA with 2 copies of the SE (OR 8.0, 
95% CI 1.8, 36.1, p = 0.01, pcorrected = 0.1).  
 
Associations of MHC class II alleles with ACPA and RF 
We also looked for associations of MHC class II alleles with ACPA production.  
There were trends for HLA-DQB1*0302 (OR 6.0, 95% CI 1.3, 27.0, p = 0.02, 
pcorrected = 0.3), HLA-DRB1*1303 (OR 15.7, 95% CI 1.9, 131.4, p = 0.03, pcorrected 
= 0.4) and for 2 SE copies (OR 5.2, 95% CI 1.07, 24.9, p = 0.06), but no 
association for DRB1*0401 (OR 2.0, 95% CI 0.4, 9.1, p = 0.4). There was a trend 
towards a negative association for DRB1*0301 with ACPA production [0/39 
(0%) vs 8/65 (12%), p = 0.02, pcorrected = 0.3).  There were no genetic associations 




Table 2.1.  Clinical features of patients with SLE (n=104) 
 












Mean (SD) age (years) 45.5 (12.0) 50.2 (14.0) 48.9 (12.9) 0.5 
Median (IQR) disease duration  
(years) 
14 (10)a,b 9 (6)c 7 (5.5) 0.01 (0.1) 
Race: British Caucasian 12 (100) 57 (97)† 33 (100) 0.3 
Female gender 12 (100) 52 (88.1) 27 (81.8) 0.1 
Malar rash 8 (66.67) 29 (49.2) 21 (63.6) 0.3 
Discoid rash 0 7 (11.9) 4 (12.1) 0.2 
Serositis 6 (50) 22 (37.3) 12 (36.4) 0.7 
NP-SLE 0 (0) 9 (15.3) 8 (24.2) 0.06 
Renal disease 1 (8) 8 (13.6) 9 (27.3) 0.2 
Haematological disorder 11 (91.7) 45 (76.3) 27 (81.8) 0.4 
Median (IQR) no. of SLE criteria 5 (2.75) 6 (2) 6 (1) 0.1 
 
* variables presented as n (%) unless indicated otherwise 
‡ Comparisons made among all 3 groups 
† 2 patients (3%) were of Afro-Caribbean descent 
 
a Erosive arthritis vs nonerosive arthritis: p = 0.03 (pcorrected = 0.2) 
b Erosive arthritis vs no arthritis: p = 0.005 (pcorrected = 0.2) 






   
Table 2.2.  Antibody profiles of patients with SLE (n=104) 
 
Synovitis, n = 71 
     
Antibody 
Erosive arthritis                            
n = 12, n (%) 
Nonerosive arthritis                   
n = 59, n (%) OR (95% CI)* p (corrected) 
No arthritis               
n = 33, n (%) OR (95% CI)† p (corrected) 
ACPA + 6 (50) 2 (3) 28.5 (4.7, 173.8) <0.0001 (0.001) 0 (0) - <0.001 (0.001) 
RF + 5 (42) 6 (10) 6.3 (1.5, 26.2) 0.02 (0.3) 7 (21) 2.7 (0.6, 11.0) 0.3 
Anti-dsDNA + 10 (83) 48 (81) 1.1 (0.2, 6.0) 1.0 26 (79) 1.3 (0.2, 7.6) 1.0 
Anti-U1RNP + 7 (58) 21(36) 2.5 (0.7, 9.0) 0.2 11 (33) 2.8 (0.7, 10.9) 0.2 
Anti-Sm + 1 (8) 9 (15) 0.5 (0.1, 4.4) 1.0 6 (18) 0.4 (0.1, 3.8) 0.7 
Anti-Ro/SSA + 0 (0) 16 (27) - 0.06 (0.8) 11 (33) - 0.02 (0.3) 
Anti-La/SSB + 0 (0) 7 (12) - 0.6 7 (21) - 0.2 
 
* Erosive arthritis vs nonerosive arthritis   





   
Table 2.3.  Characteristics of SLE patients with erosive arthritis (n=12) 
Clinical feature 
Erosive arthritis               
n = 12, n (%) 
Major erosions                    
n = 6, n (%) 
Minor erosions                             
n = 6, n (%) OR (95% CI)* p 
ACPA + 6 (50.0) 4 (66.7) 2 (33.3) 4.0 (0.4, 44.1) 0.6 
Median (IQR) ACPA (U) 13 (44) 28 (98) 0 (42) 1.0 (0.99, 1.01) 0.4 
RF + 5 (42) 3 (50.0) 2 (33.3) 2.0 (0.2, 20.6) 1.0 
Median (IQR) RF (U) 0 (19) 3.6 (24) 18 (32) 0.99 (0.9, 1.03) 0.6 
Mean (SD) time to  earliest erosion (years) 11.3 (6.8) 12.2 (8.5) 10.5 (5.2) 1.04 (0.9, 1.2) 0.7 
Mean (SD) no. of ACR SLE criteria 5.5 (1.6) 5.2 (1.2) 5.8 (1.9) 0.7 (0.3, 1.7) 0.5 
Fulfils ACR RA criteria 7 (58.3) 6 (100) 1 (16.7) - 0.01 
 





   

















No. of SE 
alleles Type of arthritis 
Other clinical 





1 17 > 250 29 ANA, DNA, 
U1RNP 
0401, 1001 0302, 0501 2 erosive 
(major erosions) 
haem, skin (5) yes 
2 20 68 > 100 ANA, DNA, 
U1RNP 
0101, 1501 0501, 0602 1 erosive 
(minor erosions) 
skin (4) no 
3 12 65 > 100 ANA, DNA, Ro 0405, 1501 0302, 0602 1 nonerosive 
(nondeforming) 
skin (4) yes 
4 22 47 22 ANA, DNA 0401H 0301, 0302 2 erosive 
(major erosions) 
skin, haem (5) yes 
5 14 42 0 ANA, DNA, 
U1RNP, Sm, Ro 
0302, 1303 0402, 0301 0 nonerosive, deforming serositis, renal (5) no 
6 35 33 0 ANA, U1RNP, 
Sm 
0901, 1303 0303, 0301 0 erosive, deforming 
(minor erosions) 




7 18 30 7 ANA 0101, 0401 0301, 0302 2 erosive 
(major erosions) 
skin, haem (4) yes 
8 12 26 0 ANA, DNA, 
U1RNP 
0403, 1501 0302, 0602 0 erosive 
(major erosions) 
skin, haem (5) yes 
Control 1 ND 196 13 ND 0401, 1401 0301, 0503 1 ND ND ND 
Control 2 ND 56 9 ND 0401H 0302H 2 ND ND ND 
 





   




n = 12, n (%) 
Major erosions 
n = 6, n (%) 
Nonerosive 
arthritis 
n = 59, n (%) 
No arthritis 
n = 33, n (%) OR (95% CI)* p (corrected) 
DRB1*0301 + 2 (17) 1 (17) 24 (41) 13 (39) 0.3 (0.1, 1.4) 0.2 
DRB1*0401 + 6 (50) 4 (67) 13 (22) 6 (18) 3.8 (1.1, 13.3) 0.04 (0.5) 
DQB1*0201 + 4 (33) 2 (33) 28 (48) 17 (52) 0.5 (0.1, 1.9) 0.4 
DQB1*0302 + 8 (67) 6 (100) 11 (19) 7 (21) 8.2 (2.2, 30.4) 0.001 (0.01) 
SE + 8 (67) 5 (83) 28 (47) 13 (39) 2.5 (0.7, 8.8) 0.2 
SE, 1 copy 3 (25) 1 (17) 21 (36) 12 (37) 1.2 (0.2, 5.5)‡ 1.0 
SE, 2 copies 5 (42) 4 (66) 7 (11) 1 (5) 8.0 (1.8, 36.1)‡ 0.01 (0.1) 
 
* Comparing erosive arthritis with other groups 




The proportion of patients with EA in our SLE cohort was 11%, which was 
higher than the prevalence of 4 to 6% reported in other studies130, 131, 187, 426.  This 
may reflect differences in the clinical characteristics of our patient population 
compared with other SLE patient populations.  Almost all of our patients were 
British Caucasian (Table 2.1), whereas in a previous series, 35% were Afro-
Caribbean, Asian, or other races187. As the mean time from SLE diagnosis to the 
development of erosions was 11.3 years and our patients were followed up for a 
long time (median 13 years), our study may have identified more patients in the 
later stages of arthritis, when erosions are more likely to occur.  All patients with 
EA were women and the 1987 ACR criteria for RA were met for 7 of these 
patients. Most of the patients with EA (91.7%) had a haematological disorder and 
over half had skin involvement, serositis and were anti-dsDNA+ and anti-
U1RNP+, however, none had NP-SLE.  Only one patient with EA had renal 
involvement, which is consistent with a previous report showing that SLE 
patients with  persistent rheumatoid-like arthritis were less likely to develop 
LN427.  As our study was retrospective in nature, it is possible that patient self-
selection bias may have influenced the clinical characteristics of our patient 
cohort. Patients participating in our long-term follow-up study may represent 
those with less severe major organ disease and more arthritis and skin 
involvement.   
 
The frequencies of ACPA and RF were low in our SLE cohort (8% and 17% 
respectively), but higher within the subgroup of patients presenting with synovitis 
(11% and 25% respectively). As expected, ACPA was significantly associated 
with RF.  Mediwake et al. previously found that 3 of 231 SLE patients (1%) were 
ACPA+ and that 2 of these patients had EA187. These results were based on 
determinations by ACPA-1 ELISA, which most likely had a lower sensitivity for 
the detection of ACPAs than the ACPA-2 ELISA used in our study. In support of 
this explanation is the report from a recent study testing ACPA-2 in 201 SLE 
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patients, which showed a prevalence of 5.5% for ACPA421, 428, a result 
comparable with ours.  A more recent study of 267 Chinese patients found a 
prevalence of 27.3%, however, the cut-off value for ACPA positivity was low 
(5U)130. 
 
ACPA antibodies were previously reported to be highly specific for RA198, 199, 209. 
However, ACPA is associated with erosive disease not only in RA, but also in 
PsA200, 202.  We found that ACPA was significantly associated with EA in our 
SLE cohort, as 6 of 12 (50%) EA patients were ACPA+ (pcorrected = 0.001, Table 
2.2). Moreover, 4 of the 8 ACPA+ patients (50%) had major erosions (Table 2.4). 
Although 42% of patients with EA were RF+, RF was also found in 21% of 
patients without arthritis (Table 2.2).  Two previous studies found an association 
of RF with EA in SLE187, 426, however one of these studies reported that RF was 
unhelpful in distinguishing RA patients from SLE patients with EA187.  Similarly, 
our findings suggest that RF is less useful than ACPA as a marker of EA in SLE. 
There were no significant differences in median ACPA or RF levels between 
patients with major or minor erosions in our study, however, our patient numbers 
were small.  Qing et al. reported that higher ACPA levels may be more useful in 
predicting EA development130, however, 2 of our patients with major erosions 
had relatively low ACPA levels (26U and 30U, Table 2.4).   
  
Five of the 8 ACPA+ patients (62.5%) were anti-U1RNP+ (Table 2.4) and anti-
U1RNP was present more frequently in patients with EA (7/12, 58%).  As the 
numbers of patients were small, it is difficult to certain about the significance of 
this observation.  Anti-U1RNP is the serological hallmark of mixed connective 
tissue disease (MCTD). Several different patterns of arthritis have been found in 
MCTD, ranging from NEA to arthritis mutilans429. Piirainen reported that anti-
U1RNP was associated with progression to EA in patients with MCTD430.  
However, 35% of MCTD patients in his study also fulfilled criteria for RA. It is 
noteworthy that all 6 of our SLE patients with major erosions also fulfilled 
criteria for RA.  Four of these patients were ACPA+, with higher median ACPA 
levels (Table 2.3).  All 3 ACPA+ patients who carried 2 copies of the SE had 
 112 
major erosions.  Of the 2 ACPA+ patients who were compound heterozygotes for 
the SE and the SLE-associated allele DRB1*1501, one had minor erosions and 
the other had non-erosive disease.  Patients with overlapping features of both 
SLE and RA may be defined as belonging to a "rhupus" subset of SLE.  Apart 
from polyarthritis, clinical features that occur more frequently in rhupus patients 
include malar rash, DLE, photosensitivity, LN, anaemia, leucopenia, and 
thrombocytopenia191.  Most of these features were also present in our EA 
patients.  ACPA therefore appears to be a useful marker for the rhupus subset in 
SLE.  Further support for this was provided by Damián-Abrego et al., who found 
that all 9 rhupus patients in their study were positive for ACPA423. Moreover, 2 
other studies have reported the presence of ACPA in their rhupus patients421, 431.   
 
Two ACPA+ patients with Jaccoud's arthropathy had LN and both were carriers 
of HLA-DRB1*1303, an allele associated with LN126.  One patient with low 
ACPA levels (26U) had major erosions and was negative for the SE.  Recent 
genetic studies have demonstrated that several SNPs at the IRF5, STAT4, BLK 
and TNFAIP3 loci are shared by SLE and RA171, 210, 211.  In mice, interference 
with the function of the TNFAIP3 protein product A20 resulted in a destructive, 
erosive polyarthritis212.  The IRF5 locus was also found to be shared by patients 
with SLE and the RF-negative polyarthritis subtype of JIA213.  These studies 
suggest that the pathogenesis of arthritis in SLE involves at least several complex 
immunological pathways and low level ACPA does not preclude the possibility 
of developing EA.  The shared genetic loci of SLE and RA also suggest that 
future RA markers may also have potential utility as markers for lupus arthritis. 
 
As we found previously, the most common SLE-associated MHC class II alleles 
were HLA-DRB1*0301 and HLA-DQB1*0201145, which are in linkage 
disequilibrium. As 67% of our patients with EA were SE carriers, it is not 
surprising that they were seronegative for anti-Ro/SSA and anti-La/SSB (Table 
2.2), auto-antibodies known to be associated with HLA-DRB1*03147, 148. The 
most common SE allele was HLA-DRB1*0401, which was expected in our 
mainly British Caucasian cohort432.  HLA-DQB1*0302 had the strongest genetic 
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association with EA in our cohort (OR 8.2, pcorrected = 0.01, Table 2.5) and all 6 
patients with major erosions carried DQB1*0302.  There were similar trends for 
associations of HLA-DRB1*0401 and 2 copies of the SE with major erosions 
(Table 2.5). These associations were similar to well-known associations of 
specific MHC Class II alleles with progression of erosions in RA, including the 
SE and HLA-DQB1*0302433-435.  These results provide further information for the 
subset of SLE with specific genetic and antibody features, the "rhupus" subset. 
 
A dose effect of the SE on ACPA production is seen in RA populations and the 
association of the SE with radiographic disease progression is thought to be an 
indirect effect mediated by antibodies against citrullinated peptides204, 205. 
Citrullination of arginine-containing residues greatly increases the affinity of the 
MHC class II peptide binding groove for the SE, thereby facilitating antigen 
presentation and generation of antibodies to citrullinated antigens206.  This theory 
is supported by our finding that both ACPA+ controls were carriers of the SE 
allele DRB1*0401. 
 
HLA-DQB1*0302 is associated with ACPA production in RA209 and its 
association with erosive arthritis in SLE may be via similar immunopathogenic 
mechanisms.  We also observed positive associations of ACPA with DQB1*0302 
and 2 SE copies and a negative association of DRB1*0301 with ACPA, however, 
because of the small numbers of ACPA+ patients in our study, these findings did 
not reach statistical significance. Larger studies may be able to confirm this 
effect. HLA-DR3 is associated with ACPA-negative RA, which runs a less severe 
course436. The presence of DRB1*0301 in SLE populations may therefore 
account for the infrequent development of EA, despite the common clinical 







Synovitis is a common clinical feature of SLE. Our findings suggest that the 
incidence of EA in SLE may be higher than previously reported. ACPA may be a 
useful serological marker for EA, particularly among patients with synovitis. 
Furthermore, ACPA may also be a marker for the rhupus subset of SLE.  Future 
studies of patients with early SLE may show a predictive role for ACPA in the 
future development of EA. Future studies may also further elucidate the 
mechanisms by which MHC Class II alleles influence production and the 
development of a severe arthritis phenotype that is common to several 
autoimmune diseases.  
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CHAPTER 3 
Associations of anticardiolipin antibodies with 
cardiovascular events and mortality 
 
Background 
Anticardiolipin antibodies (aCL) are associated with arterial thrombosis 
(including stroke and MI) and venous thrombosis, which are clinical 
manifestations of the APS. The prevalence of aCL has been reported in up to 
44% of patients with SLE42, and the prevalence of APS in SLE cohorts of 23% to 
42%41-43.  We previously found a prevalence of 23% for aCL GPL and 5% for 
aCL MPL in our RNHRD SLE cohort437.  Within the general population, aCL has 
been associated with thrombotic stroke and MI in some studies, but not in 
others56, 79.  Edwards et al. previously measured aCL in patients with acute MI or 
unstable angina and found no associations78.  In SLE, aPL have been reported to 
be predictors for CV events83, 84.  However, in contrast, Petri et al. found that aCL 
was a predictor for thrombotic stroke, but not for MI49, 61. There is little data 
published on the influence of aCL on survival in SLE, particularly persistent aCL 
as predictors. One study demonstrated an adverse effect of aCL MPL on 
survival271 and another found reduced survival rates in SLE patients with aCL270. 
 
Aim 
To determine the associations of persistently raised ACL GPL and MPL with 






Ethical approval for the study was given by the Bath Regional Ethics Committee 
and informed written consent was given by all study participants.  All study 
subjects were patients with SLE seen at the RNHRD CTD clinic between 1992 
and 2006.   
 
Personal contribution by the candidate  
This study was designed as a retrospective case-control pilot study by the 
candidate, under the supervision of Prof Neil McHugh.  Serological data was 
available from a database of SLE patients who were participating in an ongoing 
serological and genetic study and previously consecutively recruited from the 
RNHRD CTD Clinic.  Patient clinical data was collected by the candidate for this 
study from review of medical records and SLE questionnaire responses.  The 
candidate designed the SLE questionnaire (see Appendix), with advice from Prof 
McHugh and Dr Eleanor Korendowych.  Mrs Charlotte Cavill, BIRD CTD 
database manager, was responsible for mailing of questionnaires, collation of 
questionnaire results, tracing of patients who were lost to follow-up, data 
extraction from the Office for National Statistics (ONS) annual UK population 
mortality rates and obtaining patient mortality data from the UK National Health 
Service primary care mortality database.  Advice and assistance on statistical 




Prior to commencement of this study, there were only two previous published 
reports on the associations of aCL with mortality in SLE. Both used definitions 
for predictive factors which differed from our study, hence it was not possible to 
perform an accurate sample size calculation.  In Gómez et al.'s cohort study of 
363 SLE patients270, 28.1% of patients were aCL+, however it was not stated in 
this study whether the test was positive on least 2 occasions, which was one of 
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the inclusion criteria for our study. In Gulko et al.'s cohort study of 139 
patients271, all patients were tested at least once for aCL and 72 patients were 
tested twice for aCL, however mortality associations were published for the total 
group.  Although a sample size calculation was not performed prior to our pilot 
study, we estimated that a study sample of 130 to 140 SLE patients (as in Gulko 
et al.'s study) would have sufficient power to detect a difference in survival 
between aCL+ and aCL- patients.   
  
Autoantibody measurement 
Antinuclear antibodies (ANA) were measured by indirect immunofluorescence 
on HEp-2 cells.  Serial serum samples were available on patients over a span of 
up to 10 years (median three samples; range 1 to 11 samples)145.  Antibodies to 
extractable nuclear antigens (including U1RNP, Sm, Ro/SSA, and La/SSB,) were 
measured by Ouchterlony double diffusion.  All patients with anti-U1RNP, anti-
Sm, or anti-La/SSB antibodies had these autoantibodies confirmed by western 
blotting on at least one sample.  Anti-dsDNA and aCL were measured by 
commercial ELISAs (Cambridge Life Sciences, Ely, UK).  ACL was defined as 
positive if GPL was > 14U/mL or MPL was > 10U/mL, according to the 
manufacturer's instructions.   
 
Study subjects 
SLE patients with 2 or more positive aCL results, at least 6 weeks apart, were 
identified from a database of serology results at BIRD and matched for age and 
sex with other SLE patients who were aCL negative from the database of patients 
attending the CTD clinic.  Disease duration was defined as the interval from the 
date of SLE diagnosis to the date of the first positive aCL result for aCL+ patients 
and their matched aCL- counterparts.  Clinical information was obtained from 
RNHRD medical records and cause of death data from the UK National Health 
Service primary care mortality database.  Patients' medical records were reviewed 
for SLE disease features, CV risk factors, previous histories of IHD (defined as 
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MI and/or angina) or cerebrovascular events (defined as stroke and/or transient 
ischaemic attacks [TIAs]), as well as subsequent CV events.  Additional clinical 
information was obtained from questionnaires posted to surviving patients in 
2006, which included CV risk factors and any history of IHD or cerebrovascular 
disease (see Appendix). Initial non-responders were posted another copy of the 
questionnaire after 2 months. Survival of the patients was determined from the 
date of the second positive aCL for aCL+ patients and for matched aCL- patients.  
Five and 10-year survival rates were compared with mean age and sex-matched 
population cohort survival data from the ONS annual UK population mortality 
rates (online). (Available from: http://www.ons.gov.uk/ons/datasets-and-tables 
[Accessed 3 March 2012]). 
 
Statistical analysis 
Statistical tests employed included chi-square tests, with Fisher's exact test used 
where expected numbers for contingency tables were less than 5. For 
nonparametric comparisons, the Mann-Whitney U test was used, with medians 
and interquartile ranges (IQR) quoted.  Due to the limited numbers of patients 
available for this study (total n = 135), with incomplete data from medical 
records and SLE questionnaires with respect to dates of onset of CV and SLE-
related predictor factors and CVEs, the decision was made by the candidate to 
utilise unconditional binary logistic regression to compare predictor factors with 
outcome variables of CVEs and survival.  For the same reasons, the χ2 Goodness-
of-fit test was employed to compare survival of SLE subgroups with age- and 
sex-matched UK population survival data.  Backward, stepwise binary logistic 
regression models were used for multivariate analyses.  Variables found to be 
significant at p < 0.2 in the univariate analyses, as well as known predictor 
variables, were included in the multivariate regression models.  The predicted 
probability of each model was used to generate a receiver operator characteristic 
(ROC) curve.  The areas under the ROC curves (AUC ROC) were then used to 




This was a retrospective study of 135 patients (18 males and 117 females), of 
whom 132 met at least 4 of the updated 1997 ACR classification criteria for SLE.  
All patients were ANA positive.  There was missing ACR criteria information for 
3 subjects, who had previously been given definite diagnoses of SLE.  The group 
comprised 132 (97.8%) patients of British Caucasian descent, 1 African, 1 Afro-
Caribbean and 1 Indian patient. Median (IQR) follow-up time from the time of 
the second positive aCL for the whole group was 8 (7) years.  Ten (7.4%) patients 
died during the follow-up period.  Disease duration was unknown for one of these 
patients, who died at the age of 83.   
 
Comparisons of aCL positive and aCL negative patients 
Seventy (51.9%) patients had persistent aCL antibodies.  Of these 70 patients, 53 
(75.7%) were GPL+ and 34 (48.6%) were MPL+. The median (IQR) GPL value 
was 26.5 U (28.7) and median (IQR) MPL value was 14.8 U (28.8) in the aCL+ 
group.  Nineteen (27.1%) patients were positive for both GPL and MPL. Of the 
aCL positive patients, 12 (17.1%) had a diagnosis of APS at the time of the 2nd 
positive aCL.  Over the total follow-up period, the number of patients with APS 
increased to 19 (27.1%).  Table 3.1 shows characteristics of aCL+ patients 
compared with the aCL- patients.  There were no differences between both 
groups in terms of age at SLE diagnosis or disease duration. The aCL+ group met 
more ACR SLE criteria than the aCL- group (median number 6 vs 5 
respectively), with trends for aCL+ patients to have more frequent manifestations 
of discoid rash, serositis, renal disease and NP-SLE.  More aCL+ patients had a 
history of cerebrovascular disease at the time of the second positive aCL, with a 
similar trend for deep venous thrombosis (DVT) in these patients.  
 
Questionnaire survey results 
The overall response rate from the questionnaire survey in surviving patients was 
79/126 (62.7%), with no differences between aCL+ and aCL- patients [39/64 
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(60.9%) responded in the aCL+ group, vs 40/62 (64.5%) in the aCL- group, OR 
0.86, 95% CI 0.42, 1.77, p = 0.7].  Table 3.2 shows comparisons of CV risk 
factors between aCL+ and aCL- patients who responded to the questionnaire.  
There was a trend for more aCL- patients to be hypertensive and overweight (p = 
0.1). 
 
Associations of aCL with CV events 
Table 3.3 shows comparisons of aCL+, aCL GPL+, and aCL MPL+ patients with 
aCL- patients for the outcomes of all CV events, subsequent CV events and 
death. There were no associations between the presence of aCL with IHD or 
mortality.  Increasing age was associated with IHD in the whole group (OR 1.07, 
95% CI 1.02, 1.11, p = 0.003).  This association was also found in the aCL- 
group (OR 1.09, 95% CI 1.03, 1.16, p = 0.005), but not in the aCL+ group (OR 
1.04, 95% CI 0.97, 1.10, p = 0.3).  The presence of aCL GPL or aCL MPL was 
significantly associated with all cerebrovascular events.  ACL MPL was also 
associated with subsequent cerebrovascular events, with a similar trend for aCL 
GPL.  There was no association of age with cerebrovascular events (OR 1.00, 
95% CI 0.97, 1.04, p = 1.0).   
 
Survival data 
Table 3.4 shows the 5- and 10-year survivals for aCL+, aCL GPL+, aCL MPL+ 
and aCL- groups, compared with expected survivals for age- and sex-matched 
population cohorts in the UK.  The proportions quoted are based on the numbers 
of patients in each subgroup who were followed up for at least 5 or 10 years.  
Overall, the SLE group's 5-year survival was not significantly lower than 
expected (98.2% vs 99.2%, p = 0.2).  However, at 10 years, survival was 
significantly lower than expected (91.7% vs 98.7%, p < 0.0001).  This was due to 
the presence of aCL, (p < 0.0001) with 10-year survival of 85.2% compared with 
expected survival of 98.7%. There were similar survivals in the aCL GPL+ and 
aCL MPL+ patients (84.6% and 85.7% respectively). 
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Associations of CV events and aCL with mortality 
The influence of CV events and APS on mortality was also determined. Table 3.5 
shows comparisons of CV events and aCL with mortality.  Patients with IHD 
and/or cerebrovascular events were at significantly increased risk of mortality (p 
< 0.0001).  However, there was no association of mortality with cerebrovascular 
events or with APS.  Mortality was significantly associated with IHD (p < 
0.0001).  There were no associations of mortality with aCL.  Similarly, IHD was 
significantly associated with mortality in both aCL+ and aCL- groups.  In the 
aCL+ group, 4 of 7 deceased patients (57.1%) had IHD, compared with none of 
63 living patients (p < 0.0001).  In the aCL- group, 2 of 3 deceased patients 
(66.7%) had IHD, compared 6 of 62 living patients (9.7%, OR 18.67, 95% CI 
1.47, 237.59, p = 0.04).  Of the 10 deceased patients, 5 died from IHD-related 
causes and one from a presumed IHD-related cause at the age of 84.  Disease 
duration was unknown for one patient.  The other 5 patients who died of IHD-
related causes had disease durations of at least 11 years (up to 36 years).  Two 
patients died from malignancies (metastatic epithelioid tumour and metastatic 
rhabdomyosarcoma), one patient from pneumonia and one patient from end-stage 
pulmonary fibrosis.  The final age- and sex-adjusted multivariate regression 
model retained IHD as the independent risk factor for mortality (p < 0.0001), 
with the presence of aCL GPL retained as a contributory factor (p = 0.06).  The 
area under the ROC curve for this final model was 0.86. 
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(n=70), n (%) 
aCL negative  
(n=65), n (%) p - value 
Female 61 (87.7) 56 (86.2) 0.9 
Median (IQR) age at time of 1st aCL 
(years) 
39.0 (21.5) 41.0 (22.0) 0.7 
Median (IQR) age at SLE diagnosis 
(years) 
32.3 (19.7) 30.9 (8.9) 0.5 
Median (IQR) SLE disease duration at 
time of 1st aCL (years) 
4.0 (6.0) 4.0 (9.0) 0.4 
Median (IQR) no. of ACR criteria 6 (2) 5 (2) 0.02 
Malar rash 34 (49.3) 31 (49.2) 1.0 
Discoid rash 11 (15.9) 4 (6.3) 0.08 
Arthritis 39 (56.5) 36 (55.4) 0.9 
Serositis 25 (36.2) 15 (23.8) 0.1 
Renal disease 18 (26.1) 10 (15.9) 0.1 
NP-SLE 14 (20.3) 7 (11.1) 0.1 
Haematological disorder 57 (82.6) 49 (77.8) 0.5 
Anti-dsDNA + 58 (82.9) 50 (76.9) 0.4 
Anti-U1RNP + 14 (20.0) 19 (29.2) 0.2 
Anti-Sm + 7 (10.0) 8 (12.3) 0.7 
Anti-Ro/SSA + 21 (30.0) 14 (21.5) 0.3 
Anti-La/SSB + 10 (14.3) 5 (7.7) 0.2 
Median (IQR) GPL value (U) 26.5 (28.7) 2.0 (7.5) < 0.0001 
Median (IQR) MPL value (U) 14.8 (28.8) 0 (4.0) < 0.0001 
Previous cerebrovascular disease at 
time of 2nd aCL 
10 (14.3) 2 (3.1) 0.02 
Previous IHD at time of 2nd aCL 1 (1.4) 5 (7.7) 0.1 
Previous DVT at time of 2nd aCL 8 (11.4) 3 (4.6) 0.1 
 
* variables presented as n (%) unless indicated otherwise 
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Table 3.2.  Comparisons of cardiovascular risk factors in aCL+ and aCL- patients who 
completed questionnaires  
CV risk factor 
aCL positive 
(n=39), n (%) 
aCL negative 
(n=40), n (%) OR (95% CI) p - value 
Smoker ever 19 (48.7) 16 (40.0) 1.43 (0.58, 3.48) 0.4 
Hypertension 15 (38.5) 22 (55.0) 0.51 (0.21, 1.25) 0.1 
Hypercholesterolaemia 10 (25.6) 8 (20.0) 1.38 (0.48, 3.97) 0.6 
Diabetes mellitus 2 (5.1) 2 (5.1) 1.00 (0.13, 7.48) 1.0 
Overweight (BMI > 25 kg/m2) 13 (34.2) 20 (51.3) 0.49 (0.20, 1.24) 0.1 
Glucocorticoid use ever 34 (87.2) 33 (82.5) 1.44 (0.42, 5.00) 0.6 
Oral contraceptive use ever 23 (59.0) 24 (60.0) 0.96 (0.39, 2.35) 0.9 
Hormone replacement therapy 
ever 




































All IHD / cerebrovascular 
events† (n = 24) 
9 (13.8) 15 (21.4) 1.70 
(0.69, 4.20) 
0.2 13 (24.5) 2.02 
(0.79, 5.19) 
0.1 10 (29.4) 2.59 
(0.94, 7.19) 
0.07 
All cerebrovascular events‡ 
(n = 16) 
4 (6.2) 12 (17.1) 3.16 
(0.97, 10.34) 
0.06 10 (18.9) 3.55 
(1.04, 12.05) 
0.03 9 (26.5) 5.49 
(1.55, 19.48) 
0.009 
All IHD¶ (n = 12) 8 (12.3) 4 (5.7) 0.43 
(0.12, 1.51) 
0.2 4 (7.5) 0.58 
(0.16, 2.05) 
0.4 2 (5.9) 0.45 
(0.09, 2.23) 
0.5 
Subsequent IHD / 
cerebrovascular events  
(n = 17) 
7 (10.8) 10 (14.3) 1.38 
(0.49, 3.87) 
0.5 8 (15.1) 1.47 
(0.50, 4.37) 




events (n = 9) 
2 (3.1) 7 (10.0) 3.50 
(0.70, 17.51) 
0.2 5 (9.4) 3.28 
(0.61, 17.65) 
0.2 6 (17.6) 6.75 
(1.28, 35.54) 
0.02 
Subsequent IHD (n = 10) 7 (10.8) 3 (4.3) 3.71 
(0.09, 1.50) 
0.2 3 (5.7) 0.50 
(0.12, 2.03) 
0.3 1 (2.9) 0.25 
(0.03, 2.13) 
0.3 
Death (n = 10) 3 (4.6) 7 (10.0) 2.30 
(0.57, 9.29) 
0.3 6 (11.3) 2.64 
(0.63, 11.1) 




† All previous and subsequent cardiovascular events (MI, angina, stroke and TIA)  
‡ All previous and subsequent cerebrovascular events (Stroke and TIA)  
¶ All previous and subsequent IHD events (MI and angina)  



















n (%) p-value 
Total SLE group (n = 110 at 5 yrs, n = 60 at 10 yrs) 108 (98.2) 109.1 (99.2) 0.2 55 (91.7) 59.2 (98.7) < 0.0001 
ACL + (n = 56 at 5yrs, n = 27 at 10 yrs) 55 (98.2) 55.6 (99.3) 0.3 23 (85.2) 26.6 (98.7) < 0.0001 
ACL GPL + (n = 44 at 5 yrs, n = 26 at 10 yrs) 43 (97.7) 43.8 (99.5) 0.07 22 (84.6) 25.8 (99.2) < 0.0001 
ACL MPL + (n = 27 at 5 yrs, n = 7 at 10 yrs) 27 (100) 26.7 (99.0) - 6 (85.7) 6.8 (97.4) 0.07 
ACL - (n = 54 at 5 yrs, n = 33 at 10 yrs) 53 (98.1) 53.5 (99.1) 0.5 32 (97.0) 32.6 (98.8) 0.3 
 




Table 3.5.  Comparisons of clinical factors with mortality 
Factor 
Deceased (n = 10) 
n (%) 
Alive (n = 125) 
n (%) OR (95% CI) p - value 
Median (IQR) age (years) 59 (46.5) 40 (20.5) 1.05 (0.09) 0.02 
Antiphospholipid syndrome (n = 19) 2 (20.0) 17 (13.6) 1.58 (0.31, 8.12) 0.6 
All IHD / cerebrovascular events (n = 24)  7 (70.0) 17 (13.6) 14.82 (3.49, 62.94) < 0.0001 
All cerebrovascular events (n = 16) 2 (20.0) 14 (11.2) 1.98 (0.38, 10.28) 0.6 
Ischaemic heart disease (n = 12) 6 (60.0) 6 (4.8) 29.75 (6.59, 134.36) < 0.0001 
ACL + (n = 70) 7 (70.0) 63 (50.4) 2.30 (0.57, 9.29) 0.3 
ACL GPL + (n = 53) 6 (60.0) 47 (37.6) 2.49 (0.67, 9.28) 0.2 




Table 3.6.  Final age- and sex-adjusted model comparing SLE factors and CV events 
with mortality 
Variable β-coefficient (SE) Odds Ratio (95% CI) p - value 
Age at 2nd positive aCL 0.036 (0.027) 1.04 (0.98, 1.09) 0.2 
Female sex 0.753 (1.075) 2.12 (0.26, 17.45) 0.5 
Ischaemic heart disease 3.750 (1.008) 42.52 (5.90, 306.56) < 0.0001 





Figure 3.1.   ROC curve for the final age- and sex-adjusted model comparing SLE 
factors and CV events with mortality 
         
 




This study showed that 27.1% of aCL+ patients had thrombosis and a diagnosis 
of APS. As expected, the prevalence of pre-existent cerebrovascular disease at 
baseline was significantly higher in the aCL+ group than in the aCL- group 
(14.3% vs 3.1%, p = 0.02).  These findings are consistent with Pérez-Vázquez et 
al.'s prevalence of APS in patients with SLE of 23% after 15 -18 years of follow-
up41.  In Love and Santoro's systematic review, 40% of aCL+ SLE patients 
developed thrombotic complications42.  McNeil et al. reported a risk of 42% for 
developing thrombotic complications in aPL-positive SLE patients43.  The higher 
frequency of thrombotic complications in previous series compared with our 
group may be explained by differences in selection of patient cohorts and length 
of follow-up.  The aCL+ group met more ACR SLE criteria than the aCL- group 
(median number 6 vs 5 respectively), with trends for aCL+ patients to have more 
frequent manifestations of discoid rash, serositis, renal disease and NP-SLE.  
These observations are consistent with those of McClain et al., who reported that 
the presence of aCL in early SLE predicted a more severe clinical course438. As 
measurement of aCL was according to clinical decisions, this may have resulted 
in a lower detection rate for aCL in this group compared with previous reports. 
 
The questionnaire response rates for the surviving SLE patients in 2006 were 
similar for both aCL+ and aCL- groups (60.9% vs 64.5%, p = 0.7).  There is a 
possibility of non-responder bias in patients' questionnaire responses, which may 
have resulted to an underestimation of the overall true prevalence of CV risk 
factors and CV events in this population.  However, the similar response rates 
suggest that the risk of non-responder bias would be similar between both groups.  
Although there were trends for more hypertension and obesity in the aCL- group, 
the prevalence of CV risk factors was similar for both groups, suggesting that 




There were no differences between aCL+ and aCL- groups for the combined 
outcome of IHD and cerebrovascular events.  ACL GPL and MPL were both 
significantly associated with cerebrovascular events (p = 0.03 and 0.009 
respectively), however, there were no associations with IHD.  The positive 
association of aCL with cerebrovascular events confirms previous studies of aPL 
as predictors of CV events83, 84.    The lack of any association of aCL with MI 
also confirms Petri et al.'s results in the Hopkins Lupus Cohort, which showed 
significant associations of aCL with stroke and TIA, but no association with MI49, 
61.  The differences in associations of aCL between cerebrovascular disease and 
ischaemic heart disease in our cohort may be due to the increased frequency of 
IHD in the aCL- cohort (12.3% vs 5.7%, p = 0.2), which may reflect the 
association of age with IHD but not with cerebrovascular events.  The small 
numbers of CV events in our study may also have affected our results.  
Furthermore, as not all aCL are pro-thrombotic, LA may better identify patients 
with both unstable atherosclerotic plaque and a pro-coagulant state, as 
demonstrated in the Hopkins Lupus Cohort49, 61. 
 
The 5-year survival in our SLE cohort was similar to the expected survival for 
age- and sex- matched cohorts in the general UK population.  However, survival 
of SLE patients was significantly reduced at 10 years. The 5- and 10-year 
survival results for our cohort (98.2% and 91.7% respectively) are comparable to 
the survival rates of recent SLE cohorts of 95% - 97% at 5 years and 93% at 10 
years222-224.  Overall, the survival for our cohort was significantly lower 
compared with the general population, providing confirmation of previous 
evidence showing that patients with SLE have an increased mortality risk 
compared with the general population50, 225-228.  Interestingly, reduced 10-year 
survival occurred in the aCL+ and aCL GPL+ groups, with a similar trend for 
aCL MPL.  In contrast, survival was not reduced in the aCL- group. This suggests 
that aCL may have a weak or indirect effect on mortality and this was confirmed 
in the final multivariate model, where aCL GPL was retained in the model as a 
contributory factor (p = 0.06).  Gomez et al. showed that the presence of aCL was 
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associated with increased mortality270, while Gulko et al. found that only aCL 
MPL was associated with increased mortality271.  
 
Table 3.5 shows that older age and IHD were predictors of mortality.  In the 
multivariate analysis, IHD was shown to be an independent predictor for 
mortality (p < 0.0001), with age no longer a significant factor (p =0.2).  Mortality 
of our SLE patients with APS was not increased, which contrasts with Drenkard 
et al.'s study showing APS as an independent predictor of mortality259. The 
difference is most likely due to our small study numbers and possible ethnic 
differences in our study of mainly British Caucasian subjects, compared with 
Drenkard et al.'s study of 667 Mexican SLE patients.  Five of the 10 deceased 
patients died from IHD-related causes and one from a presumed IHD cause.  This 
confirms the importance of atherosclerosis as a major cause of death in SLE227, 
229, 236.  Furthermore, 5 of the 10 deceased patients (50%) had disease durations of 
at least 11 years at the time of death, confirming Urowitz et al.'s "bimodal 
mortality pattern" of late deaths from CV-related causes231. 
 
There were no statistically significant associations of aCL with mortality in this 
study. This may be due to the small numbers in our study, or to a possible 
selection bias in our study group, where more healthy patients were able to 
continue in long-term participation (median 8 years) of our study.  As this was a 
retrospective study, there was limited data available for other possible 
confounding risk factors, such as CV risk factors and medications.  However, the 
clinical information obtained from the combined sources of patient medical 
records, questionnaires and mortality data was sufficient to generate a final 
multivariate model with an AUC ROC curve of 0.86, which demonstrated good 









This study confirms previous reports of the associations of aCL GPL and aCL 
MPL with cerebrovascular events, including subsequent cerebrovascular events. 
The 10-year survival in this cohort was significantly reduced at 10 years, 
compared with expected 10-year survival figures for the general UK population, 
also confirming other studies' reports of increased mortality risk in patients with 
SLE.  However, although IHD was the major independent predictor of mortality 
in this study group, aCL GPL was a contributory factor for mortality in the final 
multivariate model.  Moreover, 10-year survival was reduced in aCL+ patients, 
but not in aCL- patients. These results together suggest that aCL have an indirect 
influence on mortality, possibly through pathogenic and inflammatory effects on 
atherosclerosis. In addition, these results provide further evidence of the 
complexity of the pathogenesis of atherothrombosis in SLE, where multiple 




Extended lipoprotein profiles and anticardiolipin 




Patients with SLE have an increased risk of developing accelerated 
atherosclerosis and an increased mortality risk compared with the general 
population.  Moreover, a characteristic pro-atherogenic lipoprotein profile, the 
"lupus pattern" has been described and comprises reduced HDL-C and elevated 
VLDL-C and TG concentrations.  This pattern is enhanced by active disease368, 
373, 374.  Reduced LpL activity has been demonstrated in patients with SLE404.  
Suppression of LpL activity is associated with increased TG and reduced HDL-C 
concentrations.  ACL from SLE sera have been shown to cross-react with HDL-C 
and apoA-I399, and are associated with lower TC, HDL-C and apoA-I 
concentrations400.  Lp(a) is an independent predictor of future CVEs409 and may 
be a useful marker of CV risk in SLE.  Studying extended lipoprotein profiles 
may yield novel predictors of future CVEs and mortality in SLE. 
 
Aims 
1. To compare extended lipoprotein profiles in SLE patients with local healthy 
controls. 
2. To determine the associations of baseline lipoprotein profiles and antibodies 




Personal contribution by the candidate  
This study was designed by the candidate as a follow-up study to an earlier case-
control pilot study carried out from 1992 to 1993 by Dr Keng Hong Leong, under 
the supervision of Prof Neil McHugh.  During the initial study, SLE patients were 
consecutively recruited by Drs Leong and McHugh from the RNHRD CTD 
Clinic, with baseline clinical data collected by Dr Leong.  Baseline patient 
serological assays, including aCL GPL, were performed at BIRD and baseline 
extended lipoprotein profiles were determined by Ms Chris Stirling at the 
Wolfsen Centre Clinical Research Unit for Diabetes, Lipid and Endocrinology 
Research, Royal United Hospital, Bath.  A group of healthy volunteers from the 
surrounding districts of Bath had their lipoprotein profiles determined at the 
Wolfsen Centre between 1992 and 1993.  Age and sex-matched profiles from this 
cohort were used as controls for the study.  Subsequent patient clinical data was 
collected by the candidate for this study from review of medical records and SLE 
questionnaire responses.  The candidate designed the SLE questionnaire (see 
Appendix), with advice from Prof McHugh and Dr Eleanor Korendowych.  Mrs 
Charlotte Cavill, BIRD CTD database manager, was responsible for mailing of 
questionnaires, collation of questionnaire results, tracing of patients who were 
lost to follow-up, data extraction from the ONS annual UK population mortality 
rates and obtaining patient mortality data from the UK National Health Service 
primary care mortality database.  Advice and assistance on statistical analysis 
was provided by Prof Satvinder Dhaliwal (Curtin University). 
 
Sample size 
No power calculations were performed prior to commencement of this study.  As 
the original investigators designed this study as a pilot study, they estimated that 
a case-control sample size of 50 patients and 50 controls would have adequate 
power to detect a difference in lipoprotein profiles between patients and controls.   
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Patients and controls 
This study was approved by the Bath District Research Ethics Committee. 
Subjects with SLE were recruited between 1992 and 1993 from a cohort of 
patients attending the Royal National Hospital for Rheumatic Diseases (RNHRD) 
Connective Tissue Diseases Clinic.  Subjects with SLE were followed until 2006.  
Patients' auto-antibodies and lipoprotein profiles were measured and their clinical 
information collected from review of their medical records.  Additional clinical 
information was obtained from results of questionnaires sent to the surviving 
patients in 2006, which included information about CV risk factors and history of 
MI and strokes (see Appendix).  Lipoprotein profiles from age and sex-matched 
controls were obtained from a concurrent local population survey.  Abnormal 
lipoprotein concentrations were defined according the Joint British Societies' 
2005 guidelines (JBS 2) on prevention of CVD418.  A subsequent CVE was 
defined as the development of MI, angina, stroke, transient ischaemic attack 
(TIA), or peripheral vascular disease (PVD).  Patients' mortality data was 
obtained from the UK National Health Service primary care mortality database.  
Life expectancy data was derived from the Office for National Statistics annual 
UK population mortality rates and 2006 period life expectancy tables (online). 




ACL GPL and anti-dsDNA were determined by ELISA (Cambridge Life 
Sciences, Ely, UK). ANA was measured by indirect immunofluorescence on 
HEp-2 cells (The Binding Site, Birmingham, UK). Antibodies to extractable 
nuclear antigens (U1-RNP, Sm, Ro/SSA and La/SSB) were measured by 





Measurement of lipoproteins  
Lipoprotein profiles were determined at the Wolfson Centre for Diabetes, Lipid 
and Endocrinology Research in Bath.  Following an overnight fast of 12 hours, 
blood samples were obtained from all study subjects and centrifuged within 2 
hours of collection.  Aliquots of the supernatant were then stored at -20ºC and 
subsequently analysed in batches.  Automated measurements were made using 
the Abbott VP Super System Autoanalyzer (Abbott, Maidenhead, UK). VLDL, 
HDL and HDL3 were prepared by standard precipitation techniques, as 
previously described by Gidez et al.439  HDL2 was calculated by subtraction of 
HDL3 from total HDL. TC was measured by cholesterol oxidase - p-amino-
antipyrine (CHOD-PAP) and total TG by glycerol phosphate oxidase - p-amino-
antipyrine (GPO-PAP) enzymatic colorimetric methods (Boehringer, Mannheim, 
Germany). Inter-assay coefficients of variation (%CV) were 4% and 5%, and 
intra-assay %CVs were 3% and 2% respectively. LDL-C and LDL-TG fractions 
were calculated by subtraction of HDL and VLDL from TC and total TG. ApoA-
I and apoB were measured by agarose gel electrophoresis (Sebia, Issy-les-
Moulineaux, France). Lp(a) was measured by ELISA (Biopool, Umea, Sweden). 
Post-heparin LpL and HL lipolytic activities were determined in the following 
steps: following a single IV heparin injection, blood samples were collected, 
centrifuged, and incubated with a triolein emulsion.  To make the assay specific 
for HL, LpL was inactivated by incorporating 1 mol NaCl to the mixture. Lipase-
mediated free fatty acid release was then measured by the acyl-CoA synthetase - 
acyl-CoA oxidase - 3-methyl-N-ethyl-N-(β-hydroxyethyl)-aniline (ACS-ACOD-
MEHA) enzymatic colorimetric assay (Wako, Neuss, Germany). 
 
Statistical analysis 
Data was entered into an electronic Access database and statistical analysis 
carried out using the SPSS Statistics 17.0 software package (IBM Corporation, 
Armonk, NY, USA).  The chi-square test was employed for comparisons of 
categorical data. For normally distributed data, the t-test was used and the Mann-
Whitney U test for non-parametric data.  Pearson's and Spearman's rho 
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correlations were used for comparisons of parametric and non-parametric 
continuous data respectively.  Statistical significance was set at a p-value of 
<0.05.   Due to the limited numbers of patients available for this study (total n = 
105), with incomplete data from medical records and SLE questionnaires with 
respect to dates of onset of CV and SLE-related predictor factors and CVEs, the 
decision was made by the candidate to utilise unconditional binary logistic 
regression to compare predictor factors with outcome variables of CVEs and 
mortality.  For the same reasons, the χ2 Goodness-of-fit test was employed to 
compare survival of SLE subgroups with age- and sex-matched UK population 
survival data.  Backward stepwise binary logistic regression analysis was carried 
out for associations of aCL and other predictor variables with survival and an 




This was a retrospective study of 54 SLE patients and 51 controls.  The patients' 
mean (SD) age was 45.5 (15.4) years and the controls' mean (SD) age was 47.9 
(13.3) years (OR 1.0, 95% CI 0.96, 1.01, p = 0.4). There were 8 males and 46 
females in the patient group and 8 males and 43 females in the control group (OR 
1.0, 95% CI 0.4, 3.1, p = 0.9).  Fourteen (25.9%) SLE patients died during the 
follow-up period. The response rate from the questionnaires was 24/40 (60%). 
 
Table 4.1 shows the baseline lipoprotein profiles of patients and controls.  The 
majority of controls had abnormally elevated concentrations of TC and LDL-C 
(74.5% and 84.3% respectively).  Although 28 (51.9%) SLE patients had normal 
TC concentrations, 33 (61.1%) also had abnormally elevated LDL-C.  Compared 
with controls, SLE patients had significantly lower median TC, LDL-C, HDL-C, 
HDL2-C, HDL3-C and apoA-I concentrations.  Moreover, 53.7% of patients had 
low HDL-C concentrations, compared with 31.4% of controls (p = 0.02).  There 
were no differences in the TG components, ApoB, Lp(a) or TC : HDL-C and 
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ApoB : apoA-I ratios between both groups, although there were fewer SLE 
patients with elevated apoB concentrations compared with controls (5.6% vs 
17.6%).  LpL and HL activities were not performed in the control group.  
 
Table 4.2 shows the correlations between baseline aCL GPL levels with 
lipoprotein concentrations and lipase activity.  There were statistically significant 
negative correlations between aCL GPL levels and TC, HDL3-C, apoA-I and LpL 
activity, with similar trends for HDL-C and LDL-C.  
 
Ten (18.5%) patients developed subsequent CVEs. The mean (SD) time to the 
subsequent CVE was 5.5 (3.8) years (range 1 - 12 years).  Eight of these patients 
developed IHD, 1 patient had a TIA and 1 patient developed PVD.  Table 4.3A 
shows the univariate associations of subsequent CVEs with predictor variables of 
baseline lipoproteins and CV risk factors that developed during the follow-up 
period.  Table 4.3B shows the associations of baseline antibodies and SLE-related 
factors with CVEs which developed over the follow-up period.  There were no 
significant associations of age, sex, hypertension, smoking or 
hypercholesterolaemia with the development of subsequent CVEs, although there 
was a trend towards for DM (p = 0.07).  Both TC : HDL-C and apoB : apoA-I 
ratios were predictors of future CVEs (p = 0.02 and p = 0.05 respectively).  TG 
was a significant predictor for future CVEs, with LDL-TG as the relevant 
component.  Of the SLE-related factors, longer duration of prednisolone use and 
renal disease were predictors, with positive trends for longer disease duration and 
anti-Sm positivity. 
 
Table 4.4 shows the retained factors in the final age and sex-adjusted multivariate 
analysis model of lipoproteins and risk factors compared with subsequent CVEs.  
This model included longer disease duration, increased TC : HDL-C ratio and 
higher aCL GPL levels as significant factors, with male sex as a contributory 




Two of the 14 deceased patients died during the first 5 years of the follow-up 
period (ages at death - 74 and 83 years) and one third died before the end of the 
10-year follow-up period (age at death - 59).  The overall survival for the 13-year 
period of follow-up for the cohort was 40/51 (78.4%) compared with an expected 
survival of 50.5/51 (99.1%) for UK population cohorts matched for age and sex 
during the same time period (p < 0.0001).  The 5-year survival for the cohort 
from year of diagnosis was 50/52 (96.1%), compared with an expected 5-year 
survival of 51.7/52 (99.4%) for age- and sex-matched UK population cohorts (p = 
0.002).  The 10-year survival of the cohort was 44/51 (86.3%), compared with an 
expected survival of 50.6/51 (99.1%) for age- and sex-matched UK population 
cohorts (p < 0.0001).  Patients who had subsequent CVEs had a significantly 
increased mortality risk (OR 6.75, 95% CI 1.54, 29.62, p = 0.01).  Six of the 10 
patients (60%) with subsequent CVEs died, compared with 8 of 44 patients 
(18.2%) who did not develop CVEs.  Table 4.5 shows the causes of death for the 
14 deceased patients. The cause of death was unknown for 1 patient (aged 83), 
and disease duration at the time of death was unknown for 3 patients.  However, 
of the remaining 10 deceased patients with at least 10 years' disease duration, 6 
(60%) patients died from atherosclerosis-related causes.  Two patients died from 
malignancy and 2 from infection. 
 
Tables 4.6A and 4.6B list the univariate associations of mortality with predictor 
variables of baseline lipoproteins and antibodies, CV and SLE factors.  Older age, 
as well as elevated TC, LDL-C and LDL-TG were significant predictors of 
mortality (p = 0.02 and p = 0.03 respectively), with positive trends for Lp(a) and 
disease duration (p = 0.08 and p = 0.09 respectively). 
 
Table 4.7 shows the retained variables in the final age and sex-adjusted 
multivariate analysis model of lipoproteins and risk factors compared with 
mortality.  The final model included the independent baseline factors of increased 
TC : HDL-C ratio, increased Lp(a) concentrations, higher aCL GPL levels and 
longer disease duration.  The AUC ROC curve for this model was 0.90. 
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Table 4.1.  Baseline lipoprotein profiles of SLE patients & controls 
Lipoprotein concentration /           
Lipase activity 
SLE (n = 54)                       
Median (IQR) 
Controls (n = 51)     
Median (IQR) p - value 
TC (mmol/L) 4.97 (2.13) 5.96 (1.90) 0.0004 
TC > 5.0 mmol/L, n (%) 26.0 (48.1) 38.0 (74.5) 0.005 
VLDL-C (mmol/L) 0.43 (0.29) 0.44 (0.32) 0.6 
LDL-C (mmol/L) 3.39 (1.70) 3.93 (1.87) 0.007 
LDL-C > 3.0 mmol/L, n (%) 33 (61.1) 43 (84.3) 0.007 
HDL-C (mmol/L) 1.09 (0.51) 1.32 (0.50) 0.002 
HDL-C < 1.0 mmol/L (males) or           
< 1.2 mmol/L (females), n (%) 
29 (53.7) 16 (31.4) 0.02 
HDL2-C (mmol/L) 0.43 (0.36) 0.57 (0.40) 0.007 
HDL3-C (mmol/L) 0.64 (0.28) 0.73 (0.25) 0.02 
TG (mmol/L) 1.10 (0.64) 1.10 (0.70) 0.2 
TG > 1.7 mmol/L, n (%) 8 (14.8) 11 (21.6) 0.4 
VLDL-TG (mmol/L) 0.32 (0.48) 0.30 (0.28) 0.4 
LDL-TG (mmol/L) 0.53 (0.35) 0.56 (0.49) 0.2 
HDL-TG (mmol/L) 0.22 (0.80) 0.22 (0.10) 0.6 
ApoB (mg/dL) 62.0 (28.0) 74.0 (32.0) 0.01 
ApoB > 98 mg/dL, n (%) 3 (5.6) 9 (17.6) 0.05 
ApoA-I (mg/dL) 117.0 (18.0) 135.0 (35.5) 0.0001 
Lp(a) (mg/L) 114.5 (301.7) 148.5 (270.0) 0.6 
Lp(a) > 300 mg/L, n (%) 16 (32.0) 7 (21.9) 0.3 
TC : HDL-C ratio 4.73 (1.87) 4.52 (1.93) 0.3 
TC : HDL-C ratio > 6, n (%) 11 (20.4) 6 (11.8) 0.2 
ApoB : apoA-I ratio 0.55 (0.23) 0.52 (0.29) 0.5 
LpL activity (μmol/mL/hr) 3.46 (3.31) - - 
HL activity (μmol/mL/hr) 2.05 (1.78) - - 
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Table 4.2.  Correlations between baseline aCL GPL levels and lipoproteins 






TC (mmol/L) - 0.300 0.03 - 0.286 0.04 
VLDL-C (mmol/L) 0.014 0.9 - 0.104 0.5 
LDL-C (mmol/L) - 0.285 0.04 - 0.227 0.1 
HDL-C (mmol/L) - 0.169 0.20 - 0.257 0.06 
HDL2-C (mmol/L) 0.030 0.8 - 0.103 0.5 
HDL3-C (mmol/L) - 0.363 0.007 - 0.292 0.03 
Total TG (mmol/L) 0.021 0.9 - 0.027 0.9 
VLDL-TG (mmol/L) 0.003 1.0 - 0.091 0.5 
LDL-TG (mmol/L) 0.030 0.8 0.067 0.6 
HDL-TG (mmol/L) - 0.013 0.9 - 0.013 0.9 
ApoB (mg/dL) - 0.068 0.6 - 0.107 0.5 
ApoA-I (mg/dL) - 0.270 0.05 - 0.281 0.04 
Lp(a) (mg/L) - 0.157 0.3 - 0.210 0.1 
LpL activity (μmol/mL/hr) - 0.352 0.01 - 0.315 0.03 
HL activity (μmol/mL/hr) - 0.217 0.1 - 0.144 0.3 
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Table 4.3A.   Univariate associations of CV risk factors and baseline lipoproteins with 
subsequent cardiovascular events 
Variable OR (95% CI) p-value 
Female sex 0.33 (0.06, 1.73) 0.2 
Age (years) 1.035 (0.98, 1.09) 0.2 
Hypertension 1 (0.19, 5.15) 1.0 
Smoker 0.85 (0.14, 5.28) 0.9 
Hypercholesterolaemia 2.00 (0.47, 8.56) 0.4 
Diabetes mellitus 13.2 (1.00, 173.88) 0.07 
TC (mmol/L) 1.39 (0.78, 2.47) 0.3 
TC > 5.0 mmol/L, n (%) 3.07 (0.70, 13.46) 0.1 
VLDL-C (mmol/L) 5.79 (0.48, 69.60) 0.2 
LDL-C (mmol/L) 1.70 (0.84, 3.43) 0.1 
LDL-C > 3.0 mmol/L, n (%) 7.50 (0.87, 64.35) 0.07 
HDL-C (mmol/L) 0.15 (0.01, 1.48) 0.1 
HDL-C < 1.0 mmol/L (males) or                    
< 1.2 mmol/L (females), n (%) 
2.33 (0.53, 10.21) 0.3 
HDL2-C (mmol/L) 0.18 (0.01, 3.64) 0.3 
HDL3-C (mmol/L) 0.09 (0.002, 4.16) 0.2 
TG (mmol/L) 5.18 (1.35, 19.90) 0.02 
TG > 1.7 mmol/L, n (%) 6.67 (1.31, 34.03) 0.03 
VLDL-TG (mmol/L) 4.21 (0.43, 41.03) 0.2 
LDL-TG (mmol/L) 41.67 (2.65, 655.09) 0.008 
HDL-TG (mmol/L) 6173.34 (0.02, 2.22 x 10-9) 0.2 
ApoB (mg/dL) 1.02 (0.99, 1.05) 0.2 
ApoA-I (mg/dL) 0.98 (0.95, 1.01) 0.3 
Lp(a) (mg/L) 1.001 (0.997, 1.004) 0.7 
TC : HDL-C ratio 2.03 (1.10, 3.76) 0.02 
TC : HDL-C ratio > 6.0, (n %) 3.53 (0.79, 15.81) 0.1 
ApoB : apoA-I ratio 28.10 (1.05, 750.69) 0.05 
LpL activity (μmol/mL/hr) 1.06 (0.76, 1.47) 0.8 
HL activity (μmol/mL/hr) 0.72 (0.38, 1.36) 0.3 
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Table 4.3B.   Univariate associations of SLE risk factors and baseline antibodies with 
subsequent cardiovascular events 
Variable OR (95% CI) p-value 
Age at diagnosis (years) 1.03 90.97, 1.08) 0.3 
Disease duration (years) 1.10 (0.99, 1.22) 0.08 
NP-SLE 1.83 (0.29, 11.43) 0.5 
Renal disease 6.8 (1.28, 36.26) 0.03 
Antiphospholipid syndrome 0.63 (0.07, 5.92) 0.7 
Duration of prednisolone use (years to 2006) 1.15 (1.04, 1.27) 0.007 
ACL GPL (U) 1.02 (0.99, 1.04) 0.1 
ACL GPL + 1.35 (0.23, 7.91) 0.7 
ACL MPL + 4.57 (0.25, 82.25) 0.3 
Anti-dsDNA + 1.73 (0.39, 7.66) 0.5 
Anti-Ro/SSA + - 0.2 
Anti-La/SSB + - 0.2 
Anti-U1RNP + 2.33 (0.57, 9.58) 0.2 




Table 4.4.    Final age and sex-adjusted multivariate model comparing baseline 
lipoproteins and risk factors with subsequent cardiovascular events  
Factor β-coefficient (SE) Odds Ratio (95% CI) p - value 
Age (years) 0.056 (0.049) 1.06 (0.96, 1.16) 0.3 
Male sex 3.045 (1.811) 21.00 (0.60, 731.15) 0.09 
    Lipoprotein 
   TC : HDL ratio 1.937 (0.887) 6.94 (1.22, 39.49) 0.03 
    SLE Factor 
   ACL GPL (U) 0.051 (0.021) 1.05 (1.01, 1.10) 0.02 





Figure 4.1.   ROC curve for the final multivariate model comparing CV and risk factors 
with subsequent CVEs 
           
           
          
                       Area under the ROC curve = 0.95 (0.87, 1.00)  
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(years) Cause of death 
1 F 41 1999 46 80 9 CCF, SLE 
2 F 58 1993 58 81.5 10 MI, CCF, pulmonary 
fibrosis 
3 F 69 2001 77 83.9 11 Pulmonary fibrosis 
4 F 69 1999 74 83.9 11 Pulmonary oedema, 
CCF, IHD 
5 F 52 2006 66 80.8 14 Pulmonary embolus, 
deep vein thrombosis 
6 F 18 2006 31 79.5 16 MI, intracerebral 
haemorrhage, SLE, APS 
7 F 22 2006 34 79.5 16 Rhabdomyosarcoma, 
APS 
8 F 71 2004 82 84.5 22 Pneumonia 
9 F 51 1998 55 80.7 28 MI 
10 F 60 2002 69 81.8 35 Respiratory failure, 
kyphoscoliosis, 
osteoporosis, SLE 
11 M 49 2003 59 76 36 MI, IHD, SLE 
12 F 42 2001 49 80.1 ND Pneumonia, SLE, 
peripheral vascular 
disease 
13 F 72 1995 74 82.9 ND PE, pulmonary 
hypertension, 
bronchogenic carcinoma 
14 F 82 1994 83 89.1 ND ND 
 
CCF: congestive cardiac failure, ND: no data available 
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Table 4.6A.   Univariate associations of CV risk factors and baseline lipoproteins with 
subsequent mortality 
Variable OR (95% CI) p-value 
Female sex 2.76 (0.31, 24.67) 0.7 
Age (years) 1.05 (1.01, 1.10) 0.02 
Hypertension 0.68 (0.12, 3.85) 0.7 
Smoker 3.00 (0.44, 20.44) 0.3 
Hypercholesterolaemia 1.47 (0.40, 5.35) 0.7 
Diabetes mellitus 3.40 (0.26, 44.76) 0.4 
TC (mmol/L) 1.44 (0.87, 2.39) 0.2 
TC > 5.0 mmol/L, n (%) 3.75 (1.00,  14.05) 0.04 
VLDL-C (mmol/L) 1.14 (0.11, 11.91) 0.9 
LDL-C (mmol/L) 1.72 (0.93, 31.90) 0.09 
LDL-C > 3.0 mmol/L, n (%) 5.43 (1.07, 27.44) 0.02 
HDL-C (mmol/L) 1.15 (0.20, 6.74) 0.9 
HDL-C < 1.0 mmol/L (males) or                         
< 1.2 mmol/L (females), n (%) 
0.82 (0.24, 2.77) 1.0 
HDL2-C (mmol/L) 1.32 (0.14, 14.42) 0.8 
HDL3-C (mmol/L) 0.91 (0.05, 16.68) 0.9 
TG (mmol/L) 1.95 (0.64, 5.95) 0.2 
TG > 1.7 mmol/L, n (%) 1.26 (0.22, 7.33) 1.0 
VLDL-TG (mmol/L) 1.06 (0.13, 8.74) 1.0 
LDL-TG (mmol/L) 10.62 (1.20, 94.34) 0.03 
HDL-TG (mmol/L) 91.08 (0.001, 9050089.24) 0.4 
ApoA-I (mg/dL) 1.00 (0.98, 1.02) 0.9 
ApoB (mg/dL) 1.01 (0.98, 1.04) 0.6 
Lp(a) (mg/L) 1.002 (1.000, 1.005) 0.08 
TC : HDL-C ratio 1.41 (0.93, 2.12) 0.1 
TC : HDL-C ratio > 6 3.1 (0.78, 12.7) 0.1 
ApoB : apoA-I ratio 3.87 (0.22, 67.48) 0.4 
LpL activity (μmol/mL/hr) 1.00 (0.75, 1.34) 1.0 
HL activity (μmol/mL/hr) 0.73 (0.43, 1.25) 0.3 
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Table 4.6B.   Univariate associations of SLE risk factors and baseline antibodies with 
subsequent mortality 
Variable OR (95% CI) p-value 
Age at diagnosis (years) 1.04 (0.99, 1.09) 0.2 
Disease duration (years) 1.09 (0.99, 1.21) 0.09 
NP-SLE 1.89 (0.30, 11.77) 0.6 
Renal disease 3.40 (0.64, 18.13) 0.2 
Antiphospholipid syndrome 1.17 (0.20, 6.82) 1.0 
ACL GPL (U) 1.02 (0.99, 1.04) 0.2 
ACL GPL + 1.70 (0.36, 8.05) 0.5 
ACL MPL + 4.0 (0.23, 71.12) 0.4 
Anti-dsDNA + 0.60 (0.18, 2.05) 0.5 
Anti-Ro/SSA + 2.27 (0.53, 9.65) 0.3 
Anti-La/SSB + 3.17 (0.40, 24.96) 0.3 
Anti-U1RNP + 0.51 (0.12, 2.12) 0.3 
Anti-Sm + 1.46 (0.12, 17.48) 1.0 
Cumulative duration of prednisolone use 
(years to 2006) 




Table 4.7.  Final age- and sex-adjusted model comparing baseline lipoprotein and risk 
factors with mortality 
Factor β-coefficient (SE) Odds Ratio (95% CI) p - value 
Age (years) 0.026 (0.037) 1.03 (0.96, 1.10) 0.5 
Male sex - 1.409 (1.541) 0.24 (0.01, 5.01) 0.4 
  
   Lipoprotein 
   TC : HDL-C ratio 1.055 (0.471) 2.87 (1.14, 7.22) 0.03 
Lp(a) (mg/L) 0.005 (0.002) 1.01 (1.00, 1.01) 0.04 
  
   SLE Factor 
   ACL GPL (U) 0.033 (0.016) 1.03 (1.00, 1.07) 0.04 





Figure 4.2.   ROC curve for the final age and sex-adjusted model comparing baseline 
lipoproteins and risk factors with mortality 
          




This study showed that SLE patients had lower TC, LDL-C, HDL-C and apoA-I 
concentrations compared with age and sex-matched controls.  Moreover, 53.7% 
of patients had low HDL-C concentrations. These findings are consistent with 
Borba and Bonfá's previous report in 1997 of low HDL-C levels in 79% of 
patients with active SLE (as measured by SLEDAI) and 29% of SLE patients 
with inactive disease368.  The lower proportion of patients with low HDL-C in our 
group is most likely explained by lower cut-off values for HDL-C used in our 
study, as recommended in the 2005 JBS 2 guidelines418.  As both HDL-C 
subfractions of HDL2-C and HDL3-C were lower in our SLE patients compared 
with controls (p = 0.007 and p = 0.02 respectively), both were contributory 
factors to the low HDL-C concentrations.  As apoA-I is the major lipoprotein 
component of HDL, it is not surprising that apoA-I concentrations were lower in 
our SLE patients.  Borba and Bonfá also reported elevated TG and VLDL in their 
SLE cohort, however, these findings were not replicated in our study.  Our results 
also differed slightly from the results of Ettinger et al., which showed lower 
HDL2-C levels in SLE patients compared with controls, but similar HDL-C, 
HDL3-C and apoA-I levels in both groups383. The differences in our study results 
may be explained by variations in disease activity or glucocorticoid use, however, 
this baseline information was not available in our study.  In Borba and Bonfa's 
study, lower TC and LDL-C concentrations were present in SLE patients with 
active disease, compared with patients with inactive disease or controls368.  This 
suggests that low TC and LDL-C could act as added markers of disease activity.  
However, as our study did not have baseline measures of disease activity, this 
could not be confirmed.  
 
We found that aCL GPL levels were negatively correlated with TC, HDL3-C, 
apoA-I, and LpL activity in patients with SLE.  Our findings support Lahita et 
al.'s previous observation of lower TC, HDL-C and apoA-I levels in aCL GPL 
positive SLE patients400.  Delgado Alves et al. demonstrated that antibodies 
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directed against HDL and apoA-I from SLE sera also cross-reacted with 
cardiolipin399.  Other studies have shown that higher IgG anti-HDL and anti-
apoA-I titres were associated with increased disease activity and damage, and 
remained elevated during persistent disease activity374, 403.  Anti-LpL antibodies 
have been detected in SLE patients407, and found to be associated with aCL GPL 
and increased disease activity in SLE408.  Anti-LpL may play an inhibitory role 
on LpL and hence account for reduced LpL activity in SLE compared with 
healthy individuals404.  As low HDL levels have been associated with reduced 
LpL activity406, it is possible that the low HDL-C levels seen in our patients may 
be an indirect result of aCL inhibition of LpL activity.  However, as LpL activity 
was not performed in controls, we were unable to confirm that LpL activity was 
indeed lower in SLE patients, as would be expected.  Overall, our results provide 
further evidence for a pathogenic role of aCL in the inflammatory process of 
SLE, possibly through cross-reaction with PL-binding proteins on apoA-I in 
HDL, and/or inhibition of LpL activity.  Furthermore, in the multivariate 
analyses, higher aCL GPL levels independently predicted subsequent CVEs and 
mortality in SLE.  High-titre aCL are predictors for future arterial thrombosis42, 52 
including stroke60, however, the association of aCL with atherosclerotic CVEs, 
such as MI, is controversial49, 61, 83, 84 and there have been very few studies that 
have shown the association of aPL with mortality247, 270, 271, 273.  Our study 
provides further support for the utility of aCL GPL as a biomarker for both future 
atherosclerotic CVEs and mortality.  
 
The TC : HDL ratio is used as an important criterion for CV risk assessment in 
the general population418.  In the univariate analysis, the TC : HDL ratio was a 
significant predictor for future CVEs, confirming its importance as a CV risk 
factor.  Furthermore, in the multivariate analysis, higher TC : HDL-C ratios 
independently predicted both future CVEs and mortality, with ORs of 6.94 and 
4.11 respectively.  Although elevated TG was a significant predictor variable for 
future CVEs in the univariate analysis, it was not retained in the final multivariate 
regression model adjusted for age and sex.  High TG and low HDL-C 
concentrations may occur together in both SLE (part of the "lupus pattern" of 
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dyslipidaemia) and the MetS, however different pathogenic mechanisms may be 
involved in SLE, thereby contributing to the relative importance of HDL over TG 
as a predictive factor.  Furthermore, the independence of TG as a CV risk 
predictor has been questioned within the general population387.  The TC : HDL-C 
ratio may effectively reflect the "lupus pattern" of dyslipidaemia,  and hence this 
ratio may prove to be a reliable marker for CV and mortality risk, particularly in 
the setting of low or normal TC, LDL-C and TG concentrations, as in our cohort.  
Moreover, as the ratio is calculated from a fasting lipid profile, it is a simple and 
cost-effective clinical tool, which could be included in routine clinical monitoring 
of SLE patients.   
 
Recent studies have demonstrated that the apoB : apoA-I ratio may be a more 
reliable predictor of IHD risk than the TC : HDL ratio419, 420.  Although the apoB 
: apoA-I ratio was a predictor for subsequent CVEs in the univariate analysis, the 
95% CI was wide and the ratio was not an independent factor in the multivariate 
analysis.  Larger studies are required to further investigate the apoB : apoA-I 
ratio as a possible marker for IHD risk in SLE. 
 
With respect to traditional CV risk factors such as smoking, hypertension and 
older age as predictors of CVEs, we found no significant associations.  Since this 
was a retrospective study in a small sample of patients, it is possible that despite 
careful review of patient records, missing data would have contributed to these 
negative results. Nevertheless, we were able to show that male gender was a 
contributory factor in the final multivariate model, in keeping with findings from 
other SLE studies283, 286.  In the univariate analyses, SLE-related factors 
predicting future CVEs included renal disease and longer duration of 
prednisolone use, with similar trends for longer disease duration and the presence 
of anti-Sm at baseline. However, these factors were not independent variables in 
the multivariate analysis, in contrast to previous reports of longer duration of 
disease84, 276, 278 and glucocorticoid use276, 278 being independent predictors of 
CVEs.  Once again, the most likely explanation for the difference in our results is 




The overall survival rate from the date of diagnosis for our cohort over the 13-
year follow-up period was 78.4%, which is comparable with 15-year follow-up 
data from the 1990s, with previous studies reporting survival rates of 78 - 79%50, 
218-221.   The 5-year survival rate for our SLE cohort was 96.1%, and the 10-year 
survival rate was 86.3%.  These findings are comparable to other published 
reports from the 1990s showing survival rates of 93% - 97% at 5 years and 83% - 
92% at 10 years50, 218-221.  The survival rates for our cohort were significantly 
lower than expected for age- and sex-matched UK population cohorts, which 
further confirms previous evidence that patients with SLE have an increased 
mortality risk, compared with the general population50, 225-228.  Six of the 11 
patients who developed subsequent CVEs died, confirming the importance of 
atherosclerosis as a major cause of death in SLE227, 229, 236.  Furthermore, of the 10 
deceased patients with at least 10 years' disease duration at the time of death, 6 
(60%) patients died from atherosclerosis-related causes, confirming Urowitz et 
al.'s "bimodal mortality pattern" of late deaths from CV-related causes231. 
 
Predictors of mortality from the univariate analysis were older age, elevated TC, 
elevated LDL-C and higher LDL-TG levels (p = 0.02, 0.04, 0.02 and 0.03 
respectively).  There were positive trends for Lp(a) (p = 0.08) and longer disease 
duration (p = 0.09).  In the multivariate analysis, the final age and sex-adjusted 
model retained the independent variables of longer disease duration, higher TC : 
HDL ratios, increased Lp(a) and higher aCL GPL levels.  Longer disease 
duration as a risk factor in the final model most likely reflects the reduced 
survival prognosis of SLE cohorts from earlier decades183, 218.  Elevated Lp(a) 
concentrations independently predict for IHD, ischaemic stroke and coronary 
mortality in general populations, although the effect is relatively weak (adjusted 
RR 1.1 for all outcomes)409.  Elevated levels of Lp(a) have been detected in 
patients with SLE414-416, however to our knowledge, this is the first study 
showing Lp(a) as a novel independent risk factor for mortality in SLE.  
Moreover, as Lp(a) levels are not influenced by disease activity or glucocorticoid 
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therapy415, Lp(a) may be a prove to be a reliable predictor of mortality, in 
combination with other factors. 
Conclusions 
The findings of this study confirmed previous reports of the "lupus pattern" of 
dyslipidaemia and showed inverse correlations of TC, HDL3-C, apoA-I and LpL 
activity with aCL GPL, supporting the hypothesis that aCL plays a pathogenic 
role in lipoprotein-associated pathways of atherogenesis.  Furthermore, aCL GPL 
was an independent predictor of both future CVEs and mortality, lending support 
to its atherogenic role. The TC : HDL ratio was another independent predictor of 
CVEs and mortality in this study and should be considered for inclusion in the 
routine clinical monitoring of patients with SLE. To our knowledge, this is the 
first study showing Lp(a) as an independent predictor of mortality, and further 




Associations of antiphospholipid antibodies with 
subclinical atherosclerosis in SLE -  
a cross-sectional study 
 
Background 
Patients with SLE have a significantly increased risk of developing accelerated 
atherosclerosis. Traditional CV risk factors do not fully account for this and 
lupus-specific factors have been implicated. The prevalence of subclinical 
atherosclerosis is increased in SLE and associated with both classic CV risk 
factors and SLE-related factors. In a previous cross-sectional study, Ahmad et al. 
demonstrated that the SLE-related factors of azathioprine therapy, increased 
neutrophil count, previous coronary and/or cerebral events, and persistent aCL 
and/or LA were independently associated with the presence of carotid plaque85.  
In contrast, the association of aPL with carotid plaque has not been confirmed in 
other studies86, 350, 364, 372.  Furthermore, although the pathogenic actions of aPL 
such as aCL and anti-β2GPI have been well-defined, their potential utility as 
biomarkers of atherosclerosis remain controversial and the effect of other aPL 
such as anti-AnxA5 and anti-PT are unknown. 
 
Aim 
To determine the associations of SLE-related risk factors, including aPL 
comprising aCL, anti-β2GPI, anti-PT and anti-AnxA5, with the presence of 





This study was approved by the North West Multi-Centre Research Ethics 
Committee and written informed consent was obtained from each participant.  
 
Personal contribution by the candidate  
This study was designed by the candidate as a cross-sectional study. This 
ancillary study examined baseline aPL subtypes as additional predictive factors 
for a longitudinal non-inception SLE cohort study previously designed by Prof 
Ian Bruce and Dr Yasmeen Ahmad at the Arthritis Research UK Epidemiology 
Unit in Manchester.  In the initial cross-sectional study, study subjects and 
controls were consecutively recruited between 2000 and 2003 by Dr Yasmeen 
Ahmad, Prof Bruce and others.  Prof Bruce's team collected the study subjects' 
clinical, serological and carotid ultrasound data and carried out the original cross-
sectional data analysis.  Between 2006 and 2009, Dr Sahena Haque, Prof Bruce 
and his team collected the study subjects' follow-up clinical, serological and 
carotid ultrasound data.  In 2008, the candidate retrieved the stored baseline 
serology samples for this study with the assistance of Dr Allen Yates, Manchester 
Royal Infirmary (MRI). ACL, anti-β2GPI, anti-PT and anti-AnxA5 ELISAs were 
performed by Mrs Dunphy and Mrs Owen at BIRD in Bath.  Additional data 
analysis was performed by the candidate for this substudy using the collected 
information above stored in an Access database at the University of Manchester 
and managed by Ms Nicola Dale.  Advice and assistance with statistical analysis 
was provided by Prof Dhaliwal, Curtin University (Perth). 
 
Sample size 
In 2003, Roman et al. published a cross-sectional study examining factors 
associated with the presence of carotid plaque in 197 SLE patients with 197 
matched controls86.  For Prof Bruce's original study, he estimated that a study 
sample size of 200 female patients SLE and 100 female controls would be similar 
in number to Roman et al.'s study, and this would provide adequate power for the 
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study to detect a difference between SLE patients with carotid plaque and those 
without plaque.  As this study was an ancillary study, no power calculations were 
performed prior to this study.   
 
Patients 
Patients with SLE were selected for this study from Ahmad et al.'s original 
Manchester cohort of 200 female British Caucasian SLE patients85 who were 
initially assessed between 2000 and 2003 and later returned for follow-up 
assessments between 2006 and 2009.  Data collected at baseline was used for this 
study.  Other female SLE patients were added to the Manchester cohort during 
the period between 2006 and 2009, and included younger women with shorter 
disease durations and women from other ethnic groups. Patients were recruited 
from rheumatology clinics at Manchester Royal Infirmary (MRI), North 
Manchester General Hospital, Blackburn Royal Infirmary and other centres in the 
North-West of England and through Lupus UK, the national patient support 
group.  All patients were over 18 years of age and fulfilled > 4 of the 1997 
updated ACR criteria for SLE425.  Patients were on stable therapy for at least 2 
months.  Women who were pregnant or lactating mothers within 6 months were 
excluded.  
 
Patients underwent a clinical interview and examination at the MRI Lupus 
Research Clinic, according to a standard protocol that included demographic 
information, family history and lifestyle factors.  Patients were assessed for the 
presence of prevalent CVD and a history of prior CVEs, namely MI, angina, 
stroke, transient ischaemic attacks (TIA), or peripheral vascular disease (PVD). 
Traditional CV risk factors were also recorded, including hypertension, 
hyperlipidaemia, diabetes mellitus, smoking history, anthropomorphic measures, 
family history of premature IHD, and the metabolic syndrome, using standard 
definitions300, 418, 440. SLE-related factors that were assessed included clinical 
features, previous arterial and venous thromboembolism and the absence and/or 
presence of APS.  SLE disease activity and cumulative damage were measured 
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on the day of the assessment, using SLEDAI-2K441 and SLICC DI respectively442 
(see Appendix).  Information collected about drug therapy included the use of 
glucocorticoids and immunosuppressive agents, including antimalarial drugs, as 
well as antihypertensive and statin therapy.  
 
Controls 
Healthy female controls from the same ethnic background and geographical 
region were recruited using a ‘best friend’ system. As the prevalence of carotid 
plaque is very low in healthy young women, older patients were asked to invite a 
friend (non-relative) to take part in the study. This allowed inclusion of 
traditional CV factors associated with subclinical atherosclerosis for the controls. 
Controls were excluded if they had any history of systemic autoimmune disease.  
 
Laboratory assessment (Manchester) 
Following avoidance of alcohol for 48 hours and an overnight 12 hour fast, a 50 
mL blood sample was drawn for laboratory studies at the baseline time point. As 
part of the routine clinical care, the following blood samples were assessed: full 
blood count, blood glucose level, lipid profile and serum creatinine. The 
estimated glomerular filtration rate (eGFR) was calculated using the modified 
Cockcroft-Gault formula.  Baseline serological tests carried out on SLE serum 
samples in Manchester included ANA, anti-dsDNA, anti-Ro/SSA, anti-La/SSB, 
anti-U1RNP, anti-Sm, and complement C3 and C4 levels.  Patient positivity for 
aCL GPL, aCL MPL or LA was also recorded. A patient was defined to be 'ever 
positive' for aCL if she had a history of two positive tests (> 16 U) at least 6 
weeks apart.  Similarly, LA was determined by dRVVT and defined as 'ever 
positive' if present on two occasions at least 6 weeks apart.   In addition, apoA-I 
and apoB concentrations were determined in a subgroup of 78 patients from the 





Antiphospholipid antibody testing (Bath) 
APL testing was performed on baseline serum samples taken at the time of the 
initial assessment for patients from Ahmad et al.'s original SLE cohort85 who 
returned for follow-up assessments.  Serum samples were also obtained at the 
time of assessment from SLE patients and sex-matched controls recruited to the 
study between 2006 and 2009. Samples were tested using commercially available 
ELISA kits at the Bath Institute of Rheumatic Diseases (BIRD) in Bath for the 
following aPL antibodies: aCL GPL and MPL (INOVA Diagnostics Inc., San 
Diego, CA, USA), anti-β2GPI GPL and MPL, and anti-AnxA5 GPL and MPL 
(AESKU.Diagnostics, Wendelsheim, Germany).  A subgroup of serum samples 
from the first consecutive 120 SLE patients and 29 controls studied between 2006 
and 2008 were also tested for PS-dependent anti-PT GPL and MPL 
(AESKU.Diagnostics, Wendelsheim, Germany). The concentration of aPLs in 
each sample was calculated directly from the absorbency readings by software 
attached to the plate reader (Multiskan Ascent; Labsystems, Helsinki, Finland).  
Inter-assay and intra-assay reliability was determined using the coefficient of 
variation (%CV).  ELISA intra-assay %CVs were as follows: aCL GPL - 4.2%, 
aCL MPL - 13.2%, anti-β2GPI GPL - 8.1%, anti-β2GPI MPL - 6.9%, anti-AnxA5 
GPL - 12.0%, anti-AnxA5 MPL - 5.7%, anti-PT GPL - 7.6%, and anti-PT MPL - 
7.6%.  Inter-assay %CVs were as follows: aCL GPL - 15.4%, aCL MPL - 11.6%, 
anti-β2GPI GPL - 17.4%, anti-β2GPI MPL - 17.4%, anti-AnxA5 GPL - 14.3%, 
and anti-AnxA5 MPL - 12.5%, anti-PT GPL - 1.7%, and anti-PT MPL - 15.3%.  
A positive result was set as the cut-off value above the 95th percentile for control 
sample results, and at > 20U for anti-β2GPI GPL, according to the 95th percentile 
for combined patient and control samples.   
 
Vascular assessment  
All study subjects underwent assessment of their carotid arteries at the MRI 
Vascular Laboratory using a standard protocol with B-mode Doppler ultrasound.  
Scans were performed with an ATL HDI 5000 scanner equipped with a 7-4 MHz 
linear array transducer, by operators who were blinded to the subjects' diagnoses.  
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IMT measurements were made in a longitudinal plane at a point of maximum 
thickness in the right and left common carotid artery (CCA), along a 1 cm section 
proximal to the carotid bulb.  Maximal IMT measurements were repeated 3 times 
on each side and all 6 measurements were then used to calculate the mean IMT, 
as described by Sidhu and Desai85, 342.  The right and left common carotid artery 
(CCA), carotid bulb and the first 1.5 cm of the internal and external carotid 
arteries were examined in the longitudinal and cross-sectional planes for the 
presence of focal carotid plaques, as defined by Li et al.343.  Carotid plaque was 
defined if 2 of the following 3 conditions were met: a distinct area of protrusion > 
50% into vessel lumen, increased echogenicity compared with adjacent 
boundaries, or IMT > 0.15 cm.  In a prior study, intra-observer reliability for 
these scanning techniques was found to be very high, with an intra-class 
correlation coefficient for repeat assessments of 0.92 (95% CI 0.84, 1.00) for one 
of the operators85.   
 
Statistical analysis  
The chi-square test was employed for comparisons of categorical data and the 
Mann-Whitney U test for comparisons of continuous data.  Pearson's and 
Spearman's rho correlations were also used to compare normally-distributed and 
non-parametric continuous data respectively.  Statistical significance was set at a 
p-value of < 0.05.   In univariate analyses, binary logistic regression was used to 
assess the relationships between predictor variables and the presence of carotid 
plaque.  For multivariate analyses, backward, stepwise logistic regression models 
were used.  Known clinical predictor variables, as well as appropriate variables 
significant at p < 0.2 in the univariate analyses, were included in the multivariate 
regression models.  The predicted probability of each model was used to generate 
a receiver operator characteristic (ROC) curve.  The areas under the ROC curves 
(AUC ROC curve) were then used to determine the accuracy of the final models.  
Statistical analysis was performed using the SPSS Statistics 17.0 software 





Of the 156 female patients with SLE studied, 120 patients were from Ahmad et 
al.'s original cohort.  The mean (SD) age at the time of assessment was 48.9 
(10.2) years.  The majority of patients (91.7%) were of British Caucasian descent.  
The ethnic origins of the remaining patients were African or Afro-Caribbean (n = 
5, 3.2%), South Asian (n = 4, 2.6%) and Chinese (n = 1, 0.6%).  SLE-related 
characteristics of the patients are summarised in Table 5.1.  Overall, the group 
had low disease activity (median SLEDAI-2K score 2).  Median (IQR) disease 
duration was 9.5 (14.8) years.  Arthritis, rash and serositis were common features, 
whereas renal disease and NP-SLE were uncommon. A history of APS was 
present in 17.3% of patients. 
 
Twenty-nine sex-matched controls were included in the study.  Table 5.2 shows 
the characteristics of patients and controls with respect to traditional CV risk 
factors. Patients had a lower median age compared with controls, as intended in 
the study design (49 years vs 62 years, p = 0.02).  Diastolic BP was higher in 
patients (median 76 mm Hg in patients vs 70 mm Hg in controls, p = 0.008).  
HDL-C and fasting glucose levels were lower in patients (p = 0.03 and 0.01 
respectively), with a trends for lower TC concentrations and more frequent 
history of CVD in patients.  
 
Table 5.3 shows the associations of aPL with thrombosis and CVEs. There was a 
significant association of aCL GPL with APS, as well as for 5 of the other 7 aPL 
tested. There were significant associations for aCL GPL, anti-β2GPI GPL, anti-
AnxA5 GPL and anti-PT MPL with arterial thrombosis. A similar trend was 
found for anti-β2GPI GPL with venous thromboembolism (p = 0.06).  ACL GPL, 
anti-β2GPI GPL, anti-AnxA5 GPL and anti-AnxA5 MPL were significantly 
associated with cerebrovascular events, however, there were no significant 





APL correlations with HDL and apoA-I  
HDL-C was strongly correlated with apoA-I (r = 0.82, p < 0.001, ρ = 0.80, p < 
0.0001).  Anti-β2GPI GPL levels were negatively correlated with apoA-I (ρ = - 
0.35, p = 0.002). Other GPLs were also negatively correlated with apoA-I (aCL 
GPL ρ = - 0.29, p = 0.01; anti-AnxA5 GPL ρ = - 0.31, p = 0.006; anti-PT GPL ρ 
= - 0.28, p = 0.03).  There were no significant correlations between HDL-C 
concentrations and aPL levels. 
 
Univariate analysis of CV factors compared with carotid plaque  
Table 5.4 shows the results from univariate analyses of CV risk factors compared 
with the presence of carotid plaque. Increasing age, postmenopausal status, 
history of smoking, hypertension, higher systolic BP at assessment, lower eGFR, 
and a previous history of IHD and/or cerebrovascular events were significant 
factors associated with the presence of plaque. Antihypertensive therapy was also 
a significant factor with a positive effect.  
 
Univariate analysis of SLE factors compared with carotid plaque  
Table 5.5 shows significant associations for the presence of plaque with older age 
at SLE diagnosis, higher SLICC DI scores, previous arterial thrombosis, higher 
white cell and neutrophil count, lower eGFR, and longer duration of 
glucocorticoid use.  Similar associations approaching significance were found for 
APS, higher lymphocyte count, and methotrexate use.  A history of persistent 
aCL (including aCL MPL) was also significantly associated with the presence of 
plaque, with positive but associations approaching significance for persistent aCL 
GPL, history of aCL and/or LA positivity, and anti-AnxA5 GPL.  
 
Multivariate analyses of factors compared with carotid plaque  
Table 5.8 shows the final multivariate model for CV and SLE factors compared 
with the presence of carotid plaque. The CV factors with independent 
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associations included a prior history of CVD, history of smoking, and 
hypertension.  There was a trend towards fewer postmenopausal women with 
baseline carotid plaque (p = 0.06).  SLE-related factors with independent positive 
associations included older age at SLE diagnosis and longer disease duration. 
Higher daily prednisolone doses in the past 6 months and anti-AnxA5 GPL 
showed positive associations with carotid plaque that approached significance (p 
= 0.06 and 0.07 respectively).  The AUC ROC curve for the model was 0.89. 
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Table 5.1.  Disease-related features of SLE patients 
Variable n (%)* 
British Caucasian ethnicity 143 (91.7) 
Median (IQR) age at diagnosis (years) 35.0 (17.8) 
Median (IQR) disease duration (years) 9.5 (14.8) 
Median no. of (IQR) ACR SLE criteria 5.5 (2.0) 
Discoid or malar rash 88 (56.4) 
Serositis 60 (38.5) 
Arthritis 128 (82.1) 
Renal disease 29 (18.6) 
NP-SLE 15 (9.6) 
Previous arterial thromboembolism 16 (10.3) 
Previous venous thromboembolism 17 (10.9) 
Ever anti-dsDNA + 99 (63.5) 
Ever aCL or LA + 55 (35.3) 
Ever aCL GPL + 42 (26.9) 
Ever aCL MPL + 26 (16.7) 
Ever LA + 32 (20.5) 
Antiphospholipid syndrome 27 (17.3) 
Median (IQR) SLEDAI-2K 2 (2) 
Median (IQR) SLICC DI 0 (2) 
Current glucocorticoid therapy 91 (58.3) 
Median (IQR) average daily prednisolone dose in past 6 months (mg) 5.0 (8.0) 
HCQ therapy, past or present 104 (66.7) 
Azathioprine therapy, past or present 60 (38.5) 
Methotrexate therapy, past or present 30 (19.2) 
 
*Variables presented as n (%) unless indicated otherwise 
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Table 5.2.  Comparisons of demographic and classic risk factors in SLE patients and 
controls 
Risk factor 
SLE patients (n= 156) 
median (IQR)* 
Controls (n=29)            
median (IQR)* p - value 
Age (years) 49 (14) 62 (60) 0.02 
Post-menopausal, n (%) 85 (54.5) 20 (69.0) 0.2 
Total cholesterol (mmol/L) 4.86 (1.54) 5.93 (1.38) 0.06 
HDL-C (mmol/L) 1.62 (1.64) 1.77 (0.54) 0.03 
TC : HDL-C ratio 2.94 (1.25) 2.98 (1.34) 0.6 
Triglycerides (mmol/L) 1.07 (0.60) 1.04 (0.78) 0.08 
Current smoker, n (%) 22 (14.1) 7 (24.1) 0.2 
Smoker (pack-years) 0 (0) 2.2 (16.9) 0.3 
Hypertension, n (%) 73 (46.8) 9 (32.1) 0.2 
Systolic BP (mm Hg) 126 (25) 133 (28) 1.0 
Diastolic BP (mm Hg) 76 (10)  70 (20) 0.008 
eGFR (mL/min) 77.6 (26.6) 84.5 (17.0) 0.5 
Diabetes mellitus, n (%) 4 (2.6) 0 (0) 1.0 
Fasting glucose (mmol/L) 4.5 (0.6) 4.8 (0.4) 0.01 
BMI (kg/m2) 25.6 (7.2) 26.2 (7.5) 0.3 
Metabolic syndrome, n (%) 37 (23.7) 4 (13.8) 0.2 
History of CVD, n (%) 26 (16.7) 1 (3.4) 0.08 
Family history of premature IHD, n (%) 34 (21.8) 7 (24.1) 0.8 
 







Table 5.3.  Associations of aPL with thrombosis and cardiovascular events in SLE patients (n = 156) 
aPL* n (%) 






















aCL GPL+ 15 (9.6) 7.34 (2.39, 22.57) 0.001 8.67 (2.57, 29.26) 0.001 2.27 (0.57, 9.02) 0.2 7.35 (2.33, 23.14) 0.001 2.56 (0.49, 13.33) 0.2 
aCL MPL+ 11 (7.1) 3.03 (0..82, 11.20) 0.1 2.06 (0.41, 10.51) 0.4 0.81 (0.10, 6.72) 0.8 2.49 (0.60, 10.21) 0.2 1.51 (0.17, 13.15) 0.7 
Anti-β2GPI GPL+ 9 (5.8) 7.10 (1.77, 28.53) 0.008 5.12 (1.14, 22.89) 0.05 4.75 (1.07, 21.10) 0.06 5.73 (1.41, 23.35) 0.02 1.92 (0.22, 17.05) 1.0 
Anti-β2GPI MPL+ 8 (5.1) 5.44 (1.27, 23.30) 0.03 3.17 (0.58, 17.20) 0.2 1.18 (0.14, 10.21) 0.9 4.07 (0.90, 18.44) 0.09 2.21 (0.24, 19.93) 0.5 
Anti-AnxA5 GPL+ 19 (12.2) 5.95 (2.13, 16.63) 0.001 5.82 (1.82, 18.59) 0.006 1.65 (0.43, 6.36) 0.5 6.39 (2.20, 18.54) 0.001 1.90 (0.37, 9.68) 0.4 
Anti-AnxA5 MPL+ 6 (3.8) 5.25 (1.00, 27.58) 0.07 4.82 (0.81, 28.72) 0.1 1.68 (0.18, 15.25) 0.6 6.90 (1.30, 36.67) 0.04 3.13 (0.33, 29.74) 0.3 
Anti-PT GPL+ 16 (10.3) 6.99 (2.28, 21.48) 0.001 3.44 (0.92, 12.92) 0.08 2.41 (0.58, 10.07) 0.2 2.53 (0.70, 9.11) 0.2 0.91 (0.11, 7.97) 0.9 
Anti-PT MPL+ 8 (5.1) 14.53 (2.72, 77.54) 0.001 6.00 (1.24, 28.90) 0.04 1.30 (0.15, 11.56) 0.8 4.52 (0.97, 21.18) 0.07 2.12 (0.23, 19.75) 0.5 
 
APS: antiphospholipid syndrome 
*Baseline serum samples tested in BIRD, Bath 
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Table 5.4.  Associations of traditional CV risk factors with the presence of carotid 
plaque  
CV risk factor 
Plaque presence 
OR (95% CI) p-value 
Age (years) 1.12 (1.07, 1.18) < 0.001 
Postmenopausal 3.12 (1.46, 6.66) 0.003 
TC (mmol/L) 1.24 (0.92, 1.68) 0.2 
HDL-C (mmol/L) 1.11 (0.52, 2.36) 0.8 
TC : HDL-C ratio 1.19 (0.90, 1.57) 0.2 
TG (mmol/L) 1.6 (0.94, 2.72) 0.08 
LDL-C (calculated) (mmol/L) 1.18 (0.84, 1.66) 0.3 
ApoB (mg/dL) 3.28 (0.43, 24.96) 0.3 
ApoA-I (mg/dL) 0.87 (0.14, 5.22) 0.9 
ApoB : apoA-I ratio 4.10 (0.43, 38.80) 0.2 
Current smoker 2.36 (0.94, 5.94) 0.07 
Smoker ever 4.19 (1.95, 8.98) < 0.001 
Smoking history (pack-years) 1.06 (1.03, 1.09) < 0.001 
Hypertension 5.71 (2.61, 12.49) < 0.001 
Systolic BP (mm Hg) 1.03 (1.01, 1.04) 0.003 
Diastolic BP (mm Hg) 1.03 (0.99, 1.06) 0.1 
eGFR (mL/min) 0.98 (0.96, 0.99) 0.01 
Fasting glucose (mmol/L) 1.47 (0.93, 2.33) 0.1 
Diabetes mellitus 0.82 (0.08, 8.08) 0.9 
BMI (kg/m2) 1.03 (0.97, 1.09) 0.3 
Metabolic syndrome 1.73 (0.79, 3.77) 0.2 
Family history of premature IHD 0.86 (0.37, 2.02) 0.7 
Previous history of CVD 10.86 (4.13, 28.56) < 0.001 
Previous cerebrovascular event 5.82 (2.23, 15.14) < 0.001 
History of IHD 11.78 (2.39, 58) 0.002 
Antihypertensive therapy 3.39 (1.64, 7.00) 0.001 
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OR (95% CI) p-value 
Age at SLE diagnosis (years) 1.05 (1.02, 1.08) 0.001 
Disease duration (years) 1.02 (0.99, 1.06) 0.2 
Rash 0.74 (0.37, 1.48) 0.4 
Serositis 1.1 (0.54, 2.23) 0.8 
Arthritis 1.27 (0.5, 3.23) 0.6 
Renal disease 1.38 (0.59, 3.27) 0.5 
NP-SLE 2.37 (0.81, 6.99) 0.1 
Haematological disorder 0.68 (0.31, 1.49) 0.3 
SLEDAI-2K 0.96 (0.84, 1.09) 0.5 
SLICC DI 1.41 (1.08, 1.83) 0.01 
Ever ACL GPL+ 2.06 (0.98, 4.37) 0.06 
Ever ACL MPL+ 2.47 (1.04, 5.87) 0.04 
Ever ACL+ 2.28 (1.09, 4.77) 0.03 
Ever LA+ 1.16 (0.5, 2.69) 0.7 
Ever ACL and/or LA+ 1.98 (0.97, 4.04) 0.06 
ACL MPL+  1.45 (0.4, 5.22) 0.6 
ACL GPL+ 11.26 (0.41, 3.92) 0.7 
Anti-β2GPI MPL+  1.51 (0.35, 6.62) 0.6 
Anti-β2GPI GPL+  2.07 (0.53, 8.09) 0.8 
Anti-PT MPL+  1.42 (0.32, 6.28) 0.6 
Anti-PT GPL+ 0.74 (0.22, 2.47) 0.6 
Anti-AnxA5 MPL+ 2.57 (0.5, 13.25) 0.3 
Anti-AnxA5 GPL+ 2.52 (0.95, 6.71) 0.06 
Antiphospholipid syndrome 1.92 (0.81, 4.55) 0.1 
Previous arterial thrombosis 9.64 (2.91, 31.90) < 0.001 
Previous venous thromboembolism 1.86 (0.66, 5.24) 0.2 
ANA+ 1.05 (0.20, 5.66) 0.1 
Anti-dsDNA+ 0.94 (0.44, 2.01) 0.9 
Anti-Ro/SSA+ 0.67 (0.31, 1.45) 0.3 
Anti-La/SSB+ 0.69 (0.24, 2.00) 0.5 
Anti-U1RNP+ 0.91 (0.33, 2.51) 0.9 
Anti-Sm+ - 1.0 
White cell count (x 10-9/L) 1.16 (1.01, 1.33) 0.03 
Neutrophil count (x 10-9/L) 1.23 (1.02, 1.49) 0.03 
Lymphocyte count (x 10-9/L) 1.5 (0.96, 2.36) 0.08 
Complement C3 (g/L) 1.82 (0.55, 6.01) 0.3 
Complement C4 (g/L) 1.60 (0.02, 158.62) 0.8 
eGFR (mL/min) 0.98 (0.96, 0.99) 0.01 




Odds ratio (95% CI) p-value 
Glucocorticoid therapy ever                           1.79 (0.68, 4.74) 0.2 
Duration of glucocorticoid therapy (years) 1.04 (1.00, 1.08) 0.05 
Average daily prednisolone dose  
in past 6 months (mg) 1.04 (0.99, 1.10) 0.1 
Antimalarial therapy ever 0.6 (0.27, 1.33) 0.2 
HCQ therapy ever 0.66 (0.32, 1.36) 0.3 
Azathioprine therapy ever 1.62 (0.80, 3.26) 0.2 
Methotrexate therapy ever 1.86 (0.81, 4.27) 0.1 
Cyclophosphamide therapy ever 0.87 (0.29, 2.56) 0.8 
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Table 5.6.  Final multivariate model comparing CV and SLE factors with the presence 
of carotid plaque 
Factor β-coefficient (SE) OR (95% CI) p-value 
CV Factor 
   Previous history of CVD 1.586 (0.600) 4.88 (1.51, 15.82) 0.008 
Smoker ever 1.442 (0.505) 4.230 (1.57, 11.39) 0.004 
Hypertension 1.104 (0.525) 3.02 (1.08, 8.44) 0.04 







Age at SLE diagnosis (years) 0.158 (0.044) 1.17 (1.07, 1.28) < 0.0001 
Disease duration (years) 0.160 (0.050) 1.17 (1.06, 1.30) 0.001 
Average daily prednisolone dose 
in past 6 months (mg)  
0.065 (0.034) 1.07 (1.00, 1.14) 0.06 





Figure 5.1.  ROC curve for the final age-adjusted model comparing CV and SLE factors 
with the presence of carotid plaque 
        
 Area under the ROC curve for CV factors only = 0.86 (0.80, 0.93) 
 Area under the ROC curve for CV + SLE factors = 0.89 (0.84, 0.94) 
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Discussion 
This study was conducted on a cohort of mainly British Caucasian women with 
SLE.  Compared with Ahmad et al.'s original SLE cohort85, this cohort was 
similar with respect to the clinical features of median age at SLE diagnosis, 
previous cerebrovascular and coronary events, those receiving current 
glucocorticoid therapy, those ever aCL and /or LA positive, and SLEDAI-2K and 
SLICC DI scores.  However, this cohort differed slightly to Ahmad et al.'s cohort 
in that all patients fulfilled at least 4 updated ACR classification criteria, 
compared with 96% of Ahmad's cohort.  There was also a slightly higher 
prevalence of APS (17.3% vs 10.5%).  Patients were younger in this cohort 
(median age 49 vs 53 years) and disease duration was shorter (median 9.5 vs 11.7 
years), according to the study design.  The frequencies of aCL and LA in this 
group were similar to the overall prevalence reported in other studies41, 42, 443.  
However, the prevalence of APS (17.3%) in this SLE group was slightly lower 
compared with other studies which have reported a prevalence of between 23% 
and 42%41, 42, 443.  The differences may reflect possible selection bias from 
specialist APS cohorts.   
 
As shown in Table 5.2, compared with the older, sex-matched controls, SLE 
patients had similar CV risk factors, apart from higher mean diastolic BPs and 
lower HDL-C and fasting glucose levels. There was also a trend towards lower 
TC concentrations. The lower HDL-C and possibly lower TC concentrations may 
reflect the "lupus pattern" of dyslipidaemia, as discussed in detail in chapter 4. 
There was a higher proportion of SLE patients with a history of CVD in this 
study (16.7% of patients vs 3.4% of controls, p = 0.08). As the SLE group was 
younger than the control group, this finding supports a previous report of CVEs 
occurring at an earlier age in SLE278, as well as results of other studies suggesting 
that SLE-related factors may be related to CVD in SLE patients293, 294.  
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Table 5.3 showed a significant association between aCL GPL with APS, with 
significant associations for 5 of the other 7 aPL tested. There were significant 
associations of aCL GPL, anti-β2GPI GPL, anti-AnxA5 GPL and anti-PT MPL 
with arterial thrombosis, and a trend for an association of anti-β2GPI GPL with 
venous thromboembolism. ACL GPL, anti-β2GPI GPL, anti-AnxA5 GPL and 
anti-AnxA5 MPL were significantly associated with cerebrovascular events, but 
none of the aPL tested were associated with IHD. The lack of association of aPL 
with IHD in this study is consistent with the lack of association of aCL with IHD 
reported in chapter 3.  APL levels are known to fluctuate, with higher levels 
occurring at times of increased disease activity61.  As the aPL we studied were 
tested at a single time point in this cohort with mainly low disease activity 
(median SLEDAI-2K score 2), the prevalence of aPL was low, ranging from 
3.8% to 12.2%, in contrast to the higher incidence of persistent aCL GPL and 
MPL  (25.9% and 16.7% respectively, Table 5.1).  It is likely that with repeated 
testing over time, more frequent associations of these aPL with thrombo-embolic 
events may become apparent.  
 
Since apoA-I is a component of HDL, it was not surprising that HDL-C 
concentrations were strongly correlated with apoA-I concentrations (p < 0.001).  
ACL GPL levels were negatively correlated with apoA-I (p = 0.01), confirming 
the findings in chapter 4 of negative correlations of aCL GPL levels with HDL3-
C and apoA-I concentrations.  There were also negative correlations of other 
GPLs with apoA-I, with anti-β2GPI GPL showing the strongest correlation.  As 
cardiolipin is a component of HDL and may be bound to β2GPI within HDL, it is 
possible that these aPL may have pathogenic effects on apoA-I.  Moreover, 
antibodies from SLE sera directed against HDL and apoA-I have been shown to 
cross-react with cardiolipin399, and anti-apoA-I antibodies have been associated 
with anti-β2GPI GPL in SLE401, providing further support for this hypothesis. 
 
The significant associations of known CV risk factors with carotid plaque as 
shown in Table 5.4 were not unexpected in this cohort of women, of whom 
54.5% were postmenopausal.   
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The univariate analysis of SLE factors compared with the presence of carotid 
plaque revealed that carotid plaque was associated with older age at SLE 
diagnosis, higher SLICC DI scores, previous arterial thrombosis, aCL MPL, 
higher white cell and neutrophil counts, lower eGFR and longer duration of 
glucocorticoid therapy.  These findings are consistent with the univariate analysis 
from Ahmad et al.'s previous study85. The trend for an association of aCL GPL 
with carotid plaque in this study (p = 0.06) most likely reflects the slight 
differences in patient characteristics of this cohort compared with Ahmad et al.'s 
cohort.   
 
The multivariate model comparing CV and SLE factors with the presence of 
carotid plaque confirmed the importance of the known CV factors of previous 
CVD, smoking and hypertension as independent risk factors in SLE 
atherogenesis. This model had a good predictive accuracy (AUC ROC curve 
0.89).  The SLE factors of older age at disease diagnosis and longer disease 
duration are consistent with Ahmad et al.'s previous results, however  their 
previous finding of the presence of aCL and/or LA as an independent risk factor 
was no longer retained in this multivariate model and instead, anti-AnxA5 GPL 
was retained as a contributory factor (p = 0.07).  This result supports Cederholm 
et al.'s hypothesis that AnxA5 acts as a stabiliser of atherosclerotic plaque as well 
as  their report demonstrating that aCL from SLE sera inhibited AnxA5 
binding444.  The trend towards a reduced likelihood of postmenopausal women 
developing plaque in the final model (p = 0.06) suggests that the association of 
postmenopausal status with plaque in the univariate analysis was mainly due to 
age. When corrected for this factor, it would appear that accelerated 
atherosclerosis occurs in younger women, confirming Ahmad et al.'s previous 
findings and those of other authors85, 278.  The trend for an association of plaque 
with higher average prednisolone doses during the last 6 months is consistent 
with a previous report of increased glucocorticoid use being associated with 
carotid plaque in SLE348.   
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In this study, the association of aCL and/or LA with carotid plaque was no longer 
significant, compared with the previously published report85, which may be due 
to the smaller size of the study sample.  Other studies have found no significant 
associations of aPL with carotid plaque86, 350, 364, 372.  However, these studies 
defined aCL positivity according to the APS classification criteria of moderate to 
high levels for aCL or anti-β2GPI44.  Where a definite APS diagnosis is required, 
the APS criteria would be most appropriate, however the recommended cut-off 
levels for a positive aPL result are likely to be too high for aPL to be a useful 
biomarker in the setting of atherosclerosis.  Ahmad et al. used lower cut-off 
levels for aCL positivity, which may have contributed to their results, and this 
study further explored other aPL associations with subclinical atherosclerosis. 
Another possible explanation for the differences in results is that varying aPL 
specificities may manifest at different stages of the atherosclerotic process in 
SLE, resulting in variable results, which may account for the association of anti-
AnxA5 GPL with carotid plaque.   
 
Figure 5.1 shows both ROC curves for the final multivariate models of CV 
factors only, and CV and SLE factors combined, compared with the presence of 
plaque. Although the ROC curve for traditional CV risk factors only had a good 
predictive accuracy (AUC ROC curve = 0.86), the addition of SLE-related factors 
increased the predictive accuracy of the model further (AUC ROC curve = 0.89). 
The finding that the combination of both traditional CV and SLE-related factors 
are important factors associated with the presence of carotid plaque supports 
previous reports that CV factors alone do not fully explain the increased 
atherosclerotic risk of SLE patients, and that SLE-related factors are also 
important275, 279, 288, 293, 294. 
 
Conclusions 
This cross-sectional study confirmed the associations of known CV risk factors 
with the presence of carotid plaque.  The trend towards an association of anti-
 172 
AnxA5 GPL with the presence of carotid plaque suggests a possible pathogenic 




Antiphospholipid antibodies as predictors of  
accelerated atherosclerosis in SLE 
 
Background 
The prevalence of subclinical atherosclerosis is increased in SLE and associated 
with both traditional CV risk factors and SLE-related factors. In a previous cross-
sectional study, Ahmad et al. demonstrated that the SLE-related factors of 
azathioprine therapy, increased neutrophil count , a history of previous coronary 
and/or cerebral events, and persistent aCL and/or LA were independently 
associated with the presence of carotid plaque85.  In contrast, the association of 
aPL with carotid plaque has not been confirmed in other studies86, 350, 364, 372.  
APL have been shown to be associated with CVEs83, 84, however, thrombotic 
events occur only occasionally, despite the persistence of aPL64, and pro-
atherogenic effects of aPL may be involved.  The pro-atherogenic effects of anti-
β2GPI have indeed been demonstrated in in-vitro studies92, 94, 96-99.  However, it is 
unknown whether aPL with differing specificities may be able to act as markers 
of subclinical atheromatous progression in SLE.   
 
Aim 
To determine the associations of carotid plaque progression with baseline CV and 






Personal contribution by the candidate  
This study was designed by the candidate as a substudy examining baseline aPL 
subtypes as additional predictor factors for plaque progression for Prof Ian 
Bruce's longitudinal non-inception SLE cohort study described in chapter 5.  The 
personal contribution by the candidate to this study is outlined in the methods 
section of chapter 5.   
 
Sample size 
Prof Bruce's original study recruited a sample size of 200 SLE patients with 100 
controls in order to detect a difference in traditional and SLE-related factors in 
patients with carotid plaque compared with those without plaque.  As this study 
was an ancillary study performed afterwards, no power calculations were 
performed for this study.   
 
Patients 
This was a prospective longitudinal study of subjects from Ahmad et al.'s original 
cohort of 200 female British Caucasian patients with SLE studied between 2000 
and 200385, who returned for follow-up assessments between 2006 and 2009. All 
patients fulfilled at least 4 updated 1997 ACR criteria for SLE in this study.  
Baseline clinical and laboratory data were collected as described in chapter 5.  At 
the follow-up assessment, clinical information collected included SLE-related 
clinical and serological factors, traditional CV risk factors, and the development 
of CVEs during the follow-up period. Baseline aCL GPL and MPL, anti-β2GPI 
GPL and MPL, anti-AnxA5 GPL and MPL, and anti-PT GPL and MPL were 





Patients underwent baseline and follow-up B-mode Doppler ultrasound scans of 
their carotid arteries, using a standard protocol as described in chapter 5.  Follow-
up scans were performed by the same operators who had performed the baseline 
scans.  Clinical information and the previous carotid scan results for any 
individual patient were unknown to the operator at the time of the second scan.  
 
Determination of carotid plaque progression 
Patients without carotid plaque at baseline and follow-up were defined as having 
'no plaque', patients with plaque at baseline and the same number of plaques at 
follow-up were defined as having 'stable plaque', and patients with plaque at 
baseline and more plaques at follow-up  were defined as having 'more plaque'.  
Patients with fewer plaques at follow-up compared with baseline were also 
considered to have stable plaque.  Plaque progression was defined as an increase 
in number of plaques, adjusted for baseline plaque value and time between scans.   
 
Statistical analysis  
Statistical analysis was carried out using the SPSS Statistics 17.0 software 
package (IBM Corporation, Armonk, NY, USA).  Comparison of continuous data 
was carried out using the Mann–Whitney U-test. For categorical data, the chi-
square test was employed.  Statistical significance was set at a p-value of < 0.05.  
Logistic regression analysis adjusted for age at baseline was used to determine 
associations between baseline predictor variables and plaque progression.  
Univariate associations with significance p < 0.02, as well as known risk factor 
variables, were used to select the covariates for backwards stepwise logistic 





Of the original 200 patients from Ahmad et al.'s cohort85, 127 patients (63.5%) 
were reassessed with follow-up carotid scans by Haque et al445.  For this study, a 
further 8 patients were excluded, as 2 patients met 3 of the updated 1997 ACR 
criteria for SLE, and baseline serum samples were not available for 6 patients.  
The mean (SD) age of the 119 patients studied was 54.7 (9.3) years at the time of 
the follow-up assessment and the mean (SD) time interval between baseline and 
follow-up assessments was 5.2 (0.8) years.  
 
Table 6.1 shows the characteristics of patients who were re-assessed in this study 
(n = 119) compared with those who were not re-assessed (n = 79).   Re-assessed 
patients were older (median age 49 vs 46, p = 0.04) compared with those who 
were not reassessed, with a trend for more postmenopausal women (58.8% vs 
45.6%, p = 0.07).  Re-assessed patients had higher systolic BPs at baseline 
(median systolic BP 128 mm Hg vs 124 mm Hg, p = 0.02), less malar rash 
(42.0% vs 58.2%, p = 0.03), with trends for fewer ACR criteria (5 vs 6, p = 0.07) 
and more anti-malarial use (86.6% vs 77.2%, p = 0.09).   
 
Cardiovascular events during the follow-up period 
Eleven of the 119 patients (9.2%) had CVEs following their baseline assessment. 
Three of these patients had pre-existing CVD at baseline.  Two patients had a 
subsequent MI and 5 patients developed angina. Three patients had a subsequent 
stroke, with 2 confirmed to be thrombotic in nature. One of the 3 patients with 
strokes had a TIA 6 months prior to her stroke. One patient developed PVD.  
There were no associations of subsequent CVEs with the presence of carotid 
plaque at baseline (OR 2.50, 95% CI 0.71, 8.85, p = 0.2).  
 
Figure 6.1 shows the proportions of patients who developed new carotid plaques 
over the follow-up period. There were 87 (73.1%) patients who were free of 
plaque at baseline.  New plaques developed in 31 patients over the study period 
(35.6%, 26.1% of the total cohort). There were 32 (26.9%) patients with plaque at 
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baseline, and 20 of these patients developed more plaque (62.5%, 16.8% of total 
cohort).  Overall, plaque progressed in 51 (42.9%) patients, with a plaque 
progression rate of 8.2% per annum.  Fifty-six (47.0%) patients remained free of 
carotid plaque at follow-up.  The mean (SD) age at these patients was 49.7 (8.5) 
years, with mean (SD) age at SLE diagnosis of 33.4 (10.0) years and median 
(IQR) disease duration of 11.0 (13.5) years.  Twenty-three of the patients who 
remained plaque-free (41.1%) were post-menopausal. 
 
Four (3.4%) patients had plaque regression. These patients had a median (IQR) 
age of 61 (23) years, with median (IQR) age at SLE diagnosis of 33 (27) years 
and disease duration of 12.5 (20.2) years at baseline.  All 4 patients had a history 
of hypertension and were taking antihypertensive medications both at baseline 
and at follow-up.  Antihypertensive medications included ACE-inhibitors, 
calcium-channel antagonists and diuretics, with 3 patients taking a combination 
of these medications. Two patients were taking aspirin at baseline and neither 
was taking a statin.  The remaining 8 (6.7%) patients had no change in their 
plaque status at follow up. Baseline antihypertensive therapy was associated with 
stable plaque (OR 5.38, 95% CI 1.51, 19.23, p = 0.008) and plaque regression (p 
= 0.008) at follow-up. 
 
Associations of CV factors with plaque progression 
Table 6.2 shows the age-adjusted associations of baseline CV risk factors with 
plaque progression.  Significant factors included older age and lower HDL-C 
concentrations. There were positive associations that did not reach significance 
for increased TC : HDL ratio, hypertension, cumulative smoking exposure 
(cigarette pack-years) and previous cerebrovascular event.  
 
Associations of SLE-related factors with plaque progression 
Table 6.3 shows the age-adjusted associations of baseline SLE factors with 
plaque progression. The only significant factor was the presence of anti-AnxA5 
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GPL (p = 0.03).  There were similar positive associations approaching 
significance for hydroxychloroquine therapy, the presence of aCL GPL, anti-
β2GPI GPL and anti-dsDNA.  
 
Table 6.4 shows the multivariate model (adjusted for baseline plaque value) 
comparing baseline CV and SLE factors with plaque progression. The significant 
CV factors retained in the model included older age, previous cerebrovascular 
event, lower HDL-C concentrations and a protective effect for anti-hypertensive 
therapy.  Contributory factors retained in the model included statin therapy and 
smoking history (pack-years).  Fewer patients with a family history of premature 
IHD were likely to develop plaque progression.  The significant SLE factors 
retained in the model included hydroxychloroquine and cyclophosphamide 
therapy, and the presence of anti-AnxA5 GPL.  The presence of a haematological 
disorder was also retained in the model, although it was not significant. 
 
Figure 6.2 shows the 2 ROC curves for CV factors only and for CV and SLE 
factors combined.  The AUC ROC curve for CV factors was 0.87, with an 
improvement in the AUC ROC curve to 0.91 after SLE factors were added to the 
final model. 
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Table 6.1A.  Comparisons of baseline demographics and CV risk factors between SLE 
patients re-assessed and not re-assessed  





Median (IQR) age at baseline (years) 49 (14) 46 (18) 0.04 
Postmenopausal 70 (58.8) 36 (45.6) 0.07 
Smoker ever 54 (45.4) 42 (53.2) 0.3 
Hypertension 39 (32.8) 23 (29.1) 0.6 
Median (IQR) systolic BP (mm Hg) 128 (30) 124 (24) 0.02 
Median (IQR) diastolic BP (mm Hg) 78 (12) 76 (13) 0.3 
Diabetes mellitus 4 (3.4) 2 (2.5) 1.0 
Median (IQR) fasting glucose (mmol/L) 4.5 (0.6) 4.6 (0.6) 0.3 
Median (IQR) TC (mmol/L) 5 (1.7) 5.2 (1.6) 0.5 
Median (IQR) HDL-C (mmol/L) 1.6 (0.7) 1.5 (0.7) 0.5 
Median (IQR) TG (mmol/L) 1 (0.6) 1.2 (0.8) 0.1 
Median (IQR) BMI (kg/m2) 25.6 (7.3) 26.1 (5.8) 0.6 
Family history of IHD 31 (26.9) 26 (32.9) 0.9 
Presence of carotid plaque 32 (27.1) 82 (31.7) 0.4 
 
*variables are presented as n (%) unless indicated otherwise 
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Table 6.1B.     Comparisons of baseline SLE-related factors between SLE patients         
re-assessed and not re-assessed 





Median (IQR) disease duration (years) 10 (14) 8 (12) 0.1 
Median (IQR) no. of ACR criteria 5 (2) 6 (2) 0.07 
Malar rash 50 (42.0) 46 (58.2) 0.03 
Discoid rash 9 (7.6) 10 (12.7) 0.2 
Serositis 50 (42.0) 31 (39.2) 0.7 
Arthritis 102 (85.7) 67 (84.8) 0.9 
NP-SLE 8 (6.7) 6 (7.6) 0.2 
Renal disease 16 (13.4) 16 (20.3) 0.2 
Haematological disorder 99 (83.2) 63 (79.7) 0.5 
Median (IQR) eGFR (mL/min) 76.1 (26.1) 82.5 (30.4) 0.2 
Previous arterial thromboembolism 12 (10.1) 10 (12.7) 0.6 
Previous venous thromboembolism 16 (13.4) 10 (12.7) 0.9 
Anti-dsDNA + 68 (57.1) 47 (59.5) 0.7 
Anti-Ro/SSA + 43 (36.1) 27 (34.2) 0.8 
ACL and/or LA + 42 (35.3) 30 (38.0) 0.7 
ACL+ 37 (31.1) 24 (30.4) 0.9 
Median (IQR) SLEDAI 1 (4) 2 (3.5) 0.9 
Median (IQR) SLICC DI 0 (1) 0 (2) 0.5 
Glucocorticoid therapy ever 93 (78.2) 66 (83.5) 0.3 
Antimalarial therapy ever 103 (86.6) 61 (77.2) 0.09 
 
*variables are presented as n (%) unless indicated otherwise 
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Figure 6.1.    Change in carotid plaque in SLE patients at follow-up assessment 
 
 
 No plaque:       no plaque at both baseline and follow up (n = 56, 47.1%)) 
 New plaque:     no plaque at baseline, but plaque present at follow up (n = 31, 26.1%) 
 Stable plaque:  plaque present at baseline and not increased at follow up (n = 12, 10.1%) 
 More plaque:    plaque present at baseline, with increased plaque number at follow up  
                                (n = 20, 16.8%) 
 182 
Table 6.2.   Age-adjusted associations of CV risk factors with plaque progression           
Baseline CV risk factor 
Plaque progression                             
age-adjusted OR (95% CI) p-value 
Age (years) 1.15 (1.08, 1.22) < 0.0001 
Postmenopausal 1.16 (0.36, 3.70) 0.8 
TC (mmol/L) 0.92 (0.64, 1.33) 0.7 
HDL-C (mmol/L) 0.28 (0.10, 0.79) 0.02 
TC : HDL-C ratio 1.41 (0.96, 2.07) 0.08 
TG (mmol/L) 1.27 (0.63, 2.56) 0.5 
LDL-C (calculated) (mmol/L) 1.11 (0.73, 1.69) 0.6 
ApoB (mg/dL) 0.70 (0.09, 5.76) 0.7 
ApoA-I (mg/dL) 0.27 (0.04, 2.08) 0.2 
ApoB : apoA-I ratio 1.79 (0.19, 17.19) 0.6 
Current smoker 1.11 (0.33, 3.75) 0.9 
Smoker ever 1.99 (0.86, 4.63) 0.1 
Smoking history (pack-years) 1.05 (1.00, 1.10) 0.07 
Hypertension 0.44 (0.17, 1.16) 0.1 
Systolic BP (mm Hg) 1.00 (0.98, 1.03) 0.9 
Diastolic BP (mm Hg) 1.00 (0.96, 1.04) 1.0 
eGFR (mL/min) 1.01 (0.99, 1.03) 0.6 
Fasting glucose (mmol/L) 0.83 (0.52, 1.33) 0.4 
Diabetes mellitus 0.72 (0.08, 6.12) 0.8 
BMI (kg/m2) 1.03 (0.95, 1.10) 0.5 
Metabolic syndrome 1.04 (0.38, 2.89) 0.9 
Family history of premature IHD 0.57 (0.20, 1.66) 0.3 
Previous history of CVD 1.51 (0.46, 4.89) 0.5 
Previous cerebrovascular event 1.81 (0.57, 5.72) 0.3 
History of IHD 1.05 (0.17, 6.61) 1.0 
Antihypertensive therapy 0.56 (0.21, 1.46) 0.2 
Statin therapy 3.01 (0.72, 12.57) 0.1 
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Table 6.3.  Age-adjusted associations of SLE factors with plaque progression  
SLE factor 
Plaque progression                              
age-adjusted OR (95% CI) p-value 
Age at SLE diagnosis (years) 1.01 (0.97, 1.05) 0.7 
Disease duration (years) 0.99 (0.95, 1.04) 0.7 
Rash 0.71 (0.31, 1.63) 0.4 
Serositis 0.75 (0.32, 1.77) 0.5 
Arthritis 0.68 (0.19, 2.39) 0.5 
Renal disease 0.85 (0.25, 2.94) 0.8 
NP-SLE 1.00 (0.21, 4.78) 1.0 
Haematological disorder 2.02 (0.62, 6.62) 0.2 
SLEDAI -2K 0.90 (0.73, 1.10) 0.3 
SLICC DI 1.10 (0.75, 1.59) 0.6 
Ever aCL GPL+ 2.30 (0.86, 6.16) 0.1 
Ever aCL MPL+ 2.23 (0.73, 6.84) 0.2 
Ever aCL+ 2.13 (0.82, 5.52) 0.2 
Ever LA+ 1.07 (0.36, 3.17) 0.9 
Ever aCL and/or LA+ 1.94 (0.77, 4.89) 0.2 
ACL MPL+  1.54 (0.24, 9.98) 0.7 
ACL GPL+ 1.13 (0.24, 5.32) 0.9 
Anti-β2GPI MPL+  0.79 (0.10, 6.30) 0.8 
Anti-β2GPI GPL+  4.54 (0.74, 27.93) 0.1 
Anti-PT MPL+  1.05 (0.11, 10.22) 1.0 
Anti-PT GPL+  2.29 (0.42, 12.42) 0.3 
Anti-AnxA5 MPL+  2.00 (0.18, 22.55) 0.6 
Anti-AnxA5 GPL+  4.69 (1.15, 19.16) 0.03 
Antiphospholipid syndrome                                        1.27 (0.38, 4.18) 0.7 
Previous arterial thromboembolism  2.19 (0.47, 10.18) 0.3 
Previous venous thromboembolism 1.87 (0.57, 6.16) 0.3 
ANA+ 1.41 (0.14, 14.54) 0.8 
Anti-dsDNA+ 2.11 (0.85, 5.25) 0.1 
Anti-Ro/SSA+ 1.46 (0.62, 3.41) 0.4 
Anti-La/SSB+ 1.28 (0.43, 3.85) 0.7 
Anti-U1RNP+ 1.14 (0.34, 3.85) 0.8 
Anti-Sm+ - 1.0 
White cell count (x 10-9/L) 1.01 (0.84, 1.22) 0.9 
Neutrophil count (x 10-9/L) 1.04 (0.80, 1.34) 0.8 
Lymphocyte count (x 10-9/L) 0.92 (0.51, 1.66) 0.8 
Complement C3 levels (g/L) 1.65 (0.39, 6.96) 0.5 
Complement C4 levels (g/L) 4.81 (0.02, 1160.44) 0.6 
eGFR (mL/min) 1.01 (0.99, 1.03) 0.6 
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SLE factor 
Plaque progression                              
age-adjusted OR (95% CI) p-value 
Glucocorticoid therapy ever                           0.76 (0.27, 2.13) 0.6 
Duration of glucocorticoid therapy 
(years) 
1.02 (0.97, 1.07) 0.5 
Average daily prednisolone dose in 
past 6 months (mg) 
1.01 (0.94, 1.09) 0.7 
HCQ therapy ever 2.41 (0.94, 6.21) 0.07 
Azathioprine therapy ever 1.12 (0.47, 2.69) 0.8 
Methotrexate therapy ever 1.19 (0.42, 3.35) 0.7 
Cyclophosphamide therapy ever 1.55 (0.45, 5.41) 0.5 
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Table 6.4.  Final multivariate model comparing baseline CV and SLE factors with 
plaque progression* 
Baseline factor β-coefficient (SE) OR (95% CI) p-value 
CV Factor 
   Age  0.245 (0.055) 1.28 (1.15, 1.42) < 0.0001 
Previous cerebrovascular event 3.801 (1.530) 44.75 (2.23, 897.13) 0.01 
HDL-C - 1.927 (0.789) 0.15 (0.03, 0.68) 0.02 
Anti-hypertensive therapy - 1.877 (0.787) 0.15 (0.03, 0.72) 0.02 
Statin therapy 2.477 (1.288) 11.91 (0.96, 148.56) 0.05 
Family history of premature IHD - 1.495 (0.778) 0.22 (0.05, 1.03) 0.06 
Smoking history (pack-years) 0.069 (0.036) 1.07 (1.00, 1.15) 0.06 
    SLE Factor 
   HCQ therapy ever 1.670 (0.681) 5.31, (1.40, 20.16) 0.01 
Cyclophosphamide therapy ever 2.281 (1.037) 9.79 (1.28, 74.74) 0.03 
Anti-AnxA5 GPL+ 2.527 (1.207) 12.52 (1.18, 133.37) 0.04 
Haematological disorder 1.371 (0.733) 3.94 (0.94, 16.58) 0.06 
 





Figure 6.2.  ROC curve for both final models comparing plaque progression with CV 
and SLE factors  
         
         Area under the ROC curve for CV factors only = 0.87 (0.81, 0.93) 
                         Area under the ROC curve for CV + SLE factors = 0.91 (0.86, 0.96) 
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Discussion 
Of Ahmad et al.'s original cohort of 200 women with SLE85, 81(40.5%) were not 
included in this study.  Haque et al. assessed 127 of the original patients from 
Ahmad et al.'s cohort at a median interval of 5.8 years later445.  As patients were 
recruited from a mainly urban area with a significant amount of migration, 42 of 
the original 73 patients not assessed were lost to follow-up.  A further 20 patients 
declined to participate in the follow-up assessment, largely because of social 
reasons. Ten patients (5%) died during the follow-up period.  Causes of death 
included malignancy in 4 patients (cervical, intracerebral, lung and liver), 1 
ruptured aortic aneurysm, 1 cerebral haemorrhage, 1 gastric haemorrhage and 1 
suicide. The cause of death was unknown for 2 patients.  This study assessed 119 
patients, as baseline serum samples were not available for 6 patients and 2 
patients met 3 of the updated ACR criteria for SLE.  There is a risk of selection 
bias occurring with this proportion of patients lost to follow up, however, Haque 
et al. found no differences in clinical features of the patients who were followed 
up in their study (n = 127) compared with those who were not followed up (n = 
73)445.  The patients re-assessed in this study were older (median age 49 vs 46, p 
= 0.04) compared with those who were not reassessed, with a trend for more 
postmenopausal women (58.8% vs 45.6%, p = 0.07).  Re-assessed patients had 
higher systolic BPs at baseline (median systolic BP 128 vs 124, p = 0.02), less 
malar rash (42.0% vs 58.2%, p = 0.03), with trends for fewer ACR criteria 
features (5 vs 6, p = 0.07) and more anti-malarial use (86.6% vs 77.2%, p = 0.09).  
Given the older age and higher baseline systolic BPs of the re-assessed group, it 
is possible that re-assessed patients may have had an overall increased CV risk, 
compared with patients who were not re-assessed.  Although the re-assessed 
group had less malar rash, this factor was unlikely to affect atherosclerotic 
progression and overall the SLE-related clinical features for both groups were 
similar, making selection bias less likely.  Furthermore, Gladman et al. reported 
that in their cohort of SLE patients, of whom 39.8% were potentially lost to 




There was no significant association of the presence of carotid plaque at baseline 
with subsequent CVEs.  Carotid plaque has been shown to be an independent 
predictor of future CVEs in the general population, where large patient numbers 
were followed for up to a mean of 7.2 years345, 346.  The most likely explanation 
for the lack of association of carotid plaque at baseline with subsequent CVEs in 
this study is the relatively short time interval between baseline and follow-up 
scans,  and the small numbers of CVEs (11/119, 9.2%) occurring during the 
follow-up period in this relatively small study sample.  
 
Plaque progression occurred in 51 (42.9%) of the 119 patients, with a plaque 
progression rate of 8.2% per annum.  In comparison, in the EVA study, a French 
general population-based study of 1010 subjects aged between 59 – 71 years at 
baseline, plaque progression occurred in 14.8% of women over 4 years, with a 
plaque progression rate of 3.7% per annum447.  Although there may be 
differences in ethnicity and CV risk factors for the EVA study cohort compared 
with this study cohort, it would appear that the progression of plaque observed in 
this study was far greater than would be expected in the general population. 
Moreover, the mean age of the patients in this study at baseline was 49 years, 
providing further evidence for acceleration of the atherosclerotic process in SLE.  
There have been 4 other longitudinal studies of plaque progression in SLE. 
Thompson et al. studied 217 patients with SLE for a mean follow-up duration of 
4.2 years and reported a plaque progression rate of 6.4% per annum353.  Two 
other North American studies were conducted over an average of 2 years and 
reported higher plaque progression rates of 10% - 12% per annum267, 367.  The 
differences in plaque progression rates may be due to other study cohorts 
comprising younger patients (mean ages 37 - 45.1 years) with different 
ethnicities, and including males.  Variations in carotid artery measurement 
protocols may have also accounted for the differences.  Overall, our plaque 
progression rate of 8.2% per annum was comparable to the rates reported in other 
studies.   
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Four (3.4%) patients had plaque regression at follow-up and 8 patients (6.7%) 
had no change in their plaque status at follow-up (stable plaque).  All 4 patients 
with plaque regression had hypertension and were taking antihypertensive 
medications both at baseline and at follow-up.  Antihypertensive medications 
included ACE-inhibitors, calcium-channel antagonists and diuretics, with 3 
patients taking a combination of these medications.  Antihypertensive therapy 
was significantly associated with plaque regression in these patients.  These 
findings are consistent with previous reports of the associations of calcium-
channel antagonist therapy with carotid plaque regression and ACE-inhibitors 
modifying carotid IMT progression in the general population448-450.  Two patients 
with plaque regression were also taking aspirin at the baseline assessment. It is 
possible that operator error accounted for plaque regression readings, however 
given the high intra-class correlation coefficient for repeat ultrasound 
assessments, this explanation seems less likely. 
 
In the age-adjusted analyses, plaque progression was associated with known 
baseline CV risk factors of older age and lower HDL-C concentrations.  The 
classic risk factors of hypertension, cumulative smoking exposure (pack-years), 
increased TC : HDL ratio and previous cerebrovascular events demonstrated 
positive associations approaching significance.  The only significant age-adjusted 
baseline SLE-factor was the presence of anti-AnxA5 GPL (p = 0.03).  
Hydroxychloroquine therapy was the only other factor that approached 
significance (p = 0.07).   
 
In the multivariate model, older age at baseline, lower HDL-C concentrations, 
previous cerebrovascular events and antihypertensive therapy were retained as 
independent risk factors.  A reduced HDL-C concentration is a strong 
independent predictor for future CVD and CV-related mortality in the general 
population389-391.  As lower HDL-C concentrations are a typical feature of the 
"lupus pattern" of dyslipidaemia, a pattern associated with increased disease 
activity368, 373, 374, it is possible that SLE patients with low HDL-C may have a 
higher CV risk compared with their counterparts in the general population.  
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Furthermore, the inverse association of HDL-C with plaque progression supports 
the hypothesis that inflammatory mechanisms in SLE promote acceleration of 
atherogenesis in SLE.  HDL-C may therefore prove to be a more useful marker of 
CV risk for patients with SLE than the commonly recommended TC : HDL ratio.  
The known independent CV risk factors of older age, previous cerebrovascular 
events and contributory factor of increased tobacco exposure highlight the 
requirement for aggressive management of CV risk factors in patients with SLE. 
The significant protective effect of antihypertensive therapy and weaker 
protective effect of statin therapy emphasise the benefits of controlling 
hypertension and hyperlipidaemia in this group of patients with increased CV 
risk. The finding of plaque progression being associated with fewer patients with 
a family history of premature IHD (p = 0.06) suggests that SLE-related factors 
may have more impact on CV risk when compared with certain CV risk factors. 
 
In the final multivariate model, both hydroxychloroquine therapy and 
cyclophosphamide therapy were retained as independent factors associated with 
carotid plaque progression.  Hydroxychloroquine has been shown to be protective 
against thrombosis69 and to have a beneficial effect on survival in SLE70, 229, 268, 
269.  As immunosuppressant therapy is prescribed for SLE patients with active 
and/or severe disease, both immunosuppressive agents hydroxychloroquine and 
cyclophosphamide are likely to be markers of a subset of SLE patients with 
persistent disease activity and/or disease severity, providing further support for 
pathogenic SLE-related inflammatory or autoimmune mechanisms in accelerated 
atherosclerosis. The presence of a SLE-related haematological disorder as a 
weaker predictor of plaque progression also supports the pathogenic role of 
autoimmune mechanisms in atherogenesis in SLE. 
 
Anti-AnxA5 GPL was found to be an independent predictor of carotid plaque 
progression in the final multivariate model (OR 12.52, p = 0.04). Although 
samples were only tested once for anti-AnxA5, its association with 
cerebrovascular events was still significant in the univariate analyses. It is 
noteworthy that anti-AnxA5 GPL was an independent baseline predictor of 
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carotid plaque progression in chapter 6, suggesting a possible mechanism for the 
association of anti-AnxA5 with cerebrovascular events.  Since aPL levels are 
known to fluctuate451, one would expect that with repeated testing over time, 
more frequent associations of novel aPL with thrombo-embolic events may 
become apparent.   In support of this novel finding, anti-AnxA5 GPL was also 
positively associated with the presence of carotid plaque in chapter 5, although 
this finding did reach significance (OR 4.24, p = 0.07).  AnxA5 is thought to act 
as a stabiliser of atherosclerotic plaque and aCL from SLE sera have been 
demonstrated to inhibit AnxA5 binding124.  Future studies may delineate the 
exact role of anti-AnxA5 GPL in atherogenesis, whether as a low avidity marker 
of the presence of AnxA5 in association with increasing plaque burden, or as a 
truly pathogenic antibody through the inhibition of AnxA5 binding to 
atherosclerotic plaque at sites prone to rupture, as previously demonstrated by 
Cederholm et al124.  Furthermore, the association of anti-AnxA5 with plaque 
progression may explain in part the discordant reports of a positive association of 
aCL and/or LA with the presence of carotid plaque in Ahmad et al.'s study85, but 
negative findings in other studies86, 350, 364, 372.  The possibility of aPL with 
differing specificities influencing different stages of atherogenesis remains 
intriguing, and future studies may provide further information.  Our results 
overall provide further support for the utility of anti-AnxA5 GPL as a biomarker 
for subclinical atherosclerosis.  
 
Figure 6.2 shows both ROC curves for the final multivariate models of CV 
factors and CV + SLE factors compared with plaque progression. Although the 
ROC curve for traditional CV risk factors had a good predictive accuracy (AUC 
ROC curve = 0.87), the addition of SLE-related factors increased the predictive 
accuracy of the model further (AUC ROC curve = 0.91). The finding that the 
combination of both traditional CV and SLE-related factors are important 
predictors of subclinical atherosclerosis progression supports previous reports 
that CV factors alone do not fully explain the increased atherosclerotic risk of 




In this longitudinal study of British Caucasian women with SLE, subclinical 
atherosclerosis progressed at a faster rate than would be expected for the general 
population.  This study also supported the findings of recent studies, which 
overall showed similar rates of carotid plaque progression in patients with SLE.  
The importance of traditional CV risk factors affecting the progression of 
subclinical atherosclerosis was highlighted in this study, and HDL-C may be a 
particularly useful marker in this regard.  Furthermore, SLE-related risk factors 
such as immunosuppressant therapy with hydroxychloroquine and 
cyclophosphamide in association with plaque progression support the role of 
inflammatory and autoimmune mechanisms in accelerated atherogenesis.  The 
finding of the novel marker of anti-AnxA5 GPL as an independent predictor of 
carotid plaque progression supports the pathogenic role of aPL in atherogenesis.  
Further studies are required to confirm the utility of anti-AnxA5 GPL as a novel 




The previous chapters described the research undertaken to identify potential 
serological and other biomarkers in SLE.  This chapter summarises and discusses 
the results, conclusions, limitations and implications of the studies, as well as 
proposals for future research. 
 
1.  Summary of results 
1.1.  ACPA as a marker of "rhupus" 
In chapter 2, we found that 12 of 104 patients (11%) had EA, of whom 6 had 
major erosions and 6 had minor erosions. Seven patients with EA also met the 
1987 ACR criteria for RA.  Four of the 6 patients with major erosions were 
ACPA+ and 3 of these patients were homozygous for the SE.  Most of the 
patients with EA had a haematological disorder and over half had skin 
involvement, serositis and were anti-dsDNA+ and anti-U1RNP+.  Patients with 
overlapping features of both SLE and RA may be defined as belonging to a 
"rhupus" subset of SLE and ACPA was a marker of this in chapter 2.  Further 
support for this was provided by Damián-Abrego et al., who found that all 9 
rhupus patients in their study were positive for ACPA423.  Moreover, 2 other 
studies have reported the presence of ACPA in their rhupus patients421, 431.  Apart 
from polyarthritis, clinical features that occur more frequently in rhupus patients 
include malar rash, DLE, photosensitivity, LN, anaemia, leucopenia, and 
thrombocytopenia191.  Most of these features were also present in our EA 
patients.  As 5 of the 8 ACPA+ patients in this study were carriers of the SE, 
pathogenic ACPAs appear to be due to a dose effect of the SE204, 205, and HLA-
DR genotyping may provide further predictive information for EA.  Furthermore, 
all 6 patients with major erosions were carriers of the SE-associated allele, HLA-
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DQB1*0302.  These associations were similar to the known associations of 
specific MHC class II alleles (including the SE and HLA-DQB1*0302433-435).  
 
1.2.  TC : HDL-C ratio as a marker of CV risk in SLE 
The TC : HDL-C ratio is used as an important criterion for CVD risk assessment 
in the general population and the JBS 2 guidelines recommend active treatment 
of CV risk factors if this ratio is > 6.0418.  In chapter 4, the TC : HDL-C ratio was 
an independent predictor for future CVEs and mortality, confirming its 
importance as a CV risk factor in SLE.  In chapter 5, the TC : HDL-C ratio was 
not significantly associated with the presence of carotid plaque.  In chapter 6, 
there was a positive association with plaque progression in the univariate 
analysis, although this did not reach statistically significance (OR = 1.41, 95% CI 
0.96, 2.07, p = 0.08).  Although our results were overall inconclusive with respect 
to the TC : HDL-C ratio as a marker of subclinical atherosclerosis, this remains 
an important CV marker both in the general population and in SLE. 
 
1.3.  HDL-C as a marker of CV risk in SLE 
In chapter 4, the concentrations of HDL-C and its components HDL2-C and 
HDL3-C were significantly lower in patients with SLE compared with controls. 
Moreover, the prevalence of below accepted normal concentrations of HDL-C in 
SLE patients was 53.7%.  HDL-C was not significantly associated with CVEs or 
mortality in the small group of SLE patients studied, although this has been 
reported in the general population389-391.  In chapter 5, HDL-C was not associated 
with the presence of carotid plaque, however, in chapter 6, lower HDL-C 
concentrations were inversely associated with carotid plaque progression (OR 






1.4.  ApoA-I and atherosclerosis in SLE 
Chapter 4 showed that SLE patients were more likely to have low apoA-I 
concentrations compared with controls.  In chapters 4 and 5, aCL GPL levels 
were negatively correlated with apoA-I concentrations in both Bath and 
Manchester SLE cohorts.  Our findings support Lahita et al.'s previous 
observation of lower HDL-C and apoA-I levels in aCL GPL positive patients 
with SLE400.  Delgado Alves et al. demonstrated that antibodies directed against 
HDL and apoA-I from SLE sera also cross-reacted with cardiolipin399.  Other 
studies have shown that higher IgG anti-HDL and anti-apoA-I titres were 
associated with increased disease activity and damage, and remained elevated 
during persistent disease activity374, 403.  Moreover, chapter 5 also showed inverse 
correlations of other GPLs with apoA-I concentrations, with anti-β2GPI GPL 
showing the strongest correlation.  As cardiolipin is a component of HDL and 
may be bound to β2GPI within HDL, it is possible that these aPL may have 
pathogenic effects on apoA-I.  Furthermore, antibodies from SLE sera directed 
against HDL and apoA-I have been shown to cross-react with cardiolipin399, and 
anti-apoA-I antibodies have been associated with anti-β2GPI GPL in SLE401, 
providing further support for this hypothesis.  
 
1.5.  The apoB : apoA-I ratio as a marker of CVD risk in SLE 
Recent studies have demonstrated that the apoB : apoA-I ratio may be a more 
reliable predictor of IHD risk than the TC : HDL ratio419, 420.  As lower apoA-I 
concentrations occur in SLE, the apoB : apoA-I ratio may be a useful marker of 
CVD risk in this disease.  However, in chapter 4, although this ratio was a 
predictor for subsequent CVEs in the univariate analysis, it was not an 
independent predictor in the multivariate analysis.  Furthermore, in chapters 5 
and 6, there were no significant associations of apoB, apoA-I or the apoB : apoA-
I ratio with carotid plaque at baseline or with plaque progression.  Our results 




1.6.  APL as markers of cerebrovascular events 
In chapter 4, increased aCL GPL levels were associated with future CVEs.  In 
chapters 3 and 5, we found an association of aCL GPL with cerebrovascular 
events in both the Bath and Manchester cohorts.  The positive association of aCL 
GPL with cerebrovascular events confirms previous studies of aPL as predictors 
of CV events83, 84.  However, in both cohorts, there were no associations of aCL 
with IHD.  These results confirm the previous findings of Petri et al. in the 
Hopkins Lupus Cohort, that showed significant associations of aCL with stroke 
and TIA, but no association with MI49, 61.  In chapter 5, anti-β2GPI GPL, anti-
AnxA5 GPL and anti-AnxA5 MPL were significantly associated with 
cerebrovascular events, however none of the aPL tested were associated with 
IHD. The lack of associations of anti-β2GPI, anti-AnxA5 or anti-PT with IHD 
found in chapter 5 is consistent with previous reports of a lack of association of 
aCL with IHD in SLE.  
 
1.7.  Lp(a) as a predictor of mortality 
In chapter 4, Lp(a) was an independent predictor of mortality in patients with 
SLE.  Elevated levels of Lp(a) have been detected in patients with SLE414-416, 
however to our knowledge, this is the first study showing Lp(a) as a novel 
independent predictor for mortality in SLE.   
 
1.8.  ACL as predictors of mortality 
The 5- and 10-year survival results for both Bath cohorts from chapters 3 and 4 
were comparable to the survival rates of recent SLE cohorts223, 224, 246.  However, 
10-year survival for both Bath cohorts was significantly reduced compared with 
the expected survival for age- and sex- matched cohorts in the general UK 
population.  This confirms previous reports that patients with SLE have an 
increased mortality risk compared with the general population50, 225-228.   Of note, 
in chapter 3, reduced 10-year survival occurred in the aCL+ and aCL GPL+ 
patient groups, whereas 10-year survival was not reduced in the aCL- group, 
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suggesting that aCL may have a weak or indirect effect on mortality.  Although 
there was no direct association of aCL with mortality in the univariate analysis in 
chapter 3, the hypothesis that aCL has an influence on mortality was supported in 
the final multivariate model, where aCL GPL was retained as a contributory 
factor (OR 6.29, p = 0.06).  Moreover, higher aCL GPL levels were 
independently associated with mortality in chapter 4 (OR 1.04, p = 0.05).   
 
In chapter 3, 5 of the 10 deceased patients died from IHD-related causes and one 
patient from a presumed IHD-related cause at the age of 84. In chapter 4, of the 
known causes of death in 13 deceased patients, 6 were due to IHD-related causes.  
These results confirm the importance of atherosclerosis as a major cause of death 
in SLE227, 229, 236.  Of the patients who died of IHD-related causes, patients from 
the cohort in chapter 3 had disease durations of at least 11 years and patients from 
the cohort in chapter 4 had disease durations of at least 9 years at the time of 
death.   These results also confirm Urowitz et al.'s "bimodal mortality pattern" of 
late deaths from CV-related causes231. 
 
1.9.  Anti-AnxA5 GPL as a predictor of subclinical atherosclerosis 
In chapter 5, anti-AnxA5 GPL was associated with the presence of carotid plaque 
in the univariate analysis, although this finding was not statistically significant 
(OR 2.52, 95% CI 0.95, 6.71, p = 0.06).  However, anti-AnxA5 GPL was retained 
as a contributory factor in the multivariate model (OR 4.24, 95% CI 0.91, 19.76, 
p = 0.07), which suggests that this association is of probable clinical significance.  
In chapter 6, anti-AnxA5 GPL was found to be an independent predictor of 
carotid plaque progression (OR 12.52, 95% CI 1.18, 133.37, p = 0.04).  To our 
knowledge, this is the first study demonstrating anti-AnxA5 GPL as a predictor 
of carotid plaque progression.  This result also supports Cederholm et al.'s 
hypothesis that AnxA5 acts as a stabiliser of atherosclerotic plaque, as well as  
their report demonstrating that aCL from SLE sera inhibited AnxA5 binding124.   
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2.  Study limitations and strengths 
There are several limitations related to the studies presented in this thesis. 
 
2.1.  Chapter 2 
This study was designed as a pilot study, hence power and study sample 
calculations were not performed.  However, there were more patients tested for 
ACPA in our study than those previously tested in Mediwake et al.'s report (n = 
104 vs n = 66 respectively)187.  Moreover we employed second generation ACPA 
ELISAs for our study, compared with Mediwake et al.'s first generation ACPA 
tests. This reduced the probability of a Type I error (false rejection of the null 
hypothesis) occurring. 
 
EA is an uncommon feature of lupus arthritis and affected 12 (11%) of our study 
group of 104 SLE patients.  As this was a retrospective study, incomplete clinical 
information may have affected the study results.  In order to reduce bias, we used 
clinical and x-ray data related to the dates of the samples tested, however it is 
possible that some serum samples may not have been available for testing.  In 
addition, as x-rays were only requested based on clinical decisions, it is possible 
that some patients with EA have been missed.  Hence the strength of association 
of ACPA with EA in our study may be conservative.   
 
A major strength of this study is that it identifies a group of patients with 
characteristics of "rhupus" who are ACPA+ve.  Another major strength is that it 
provides insight into the possible immunogenetic mechanisms of MHC class II 
associations with ACPA that may be shared between RA and EA in SLE.  Recent 
reports have shown that ACPA predicts for erosive arthritis in RA and that SE 
alleles are associated with the development of ACPA205, 452.  The genetic analyses 
were also performed on small subgroups of patients with specific HLA-DR or -
DQ alleles.  Although the probability of a Type I error exists due to the small 
numbers in our study and we were unable to demonstrate statistically significant 
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associations between SE alleles and ACPA, our findings are still consistent with 
these observations in RA and of also potential clinical importance.  
 
Another major strength of this study is that patients were followed for a long 
period of time.  Median [IQR] disease duration for patients with EA was longer 
(20 [10] years) than for those NEA (9 [6] years) (Table 2.1).  The mean [SD] 
time to the earliest erosion detected on x-ray was 11.3 [6.8] years (Table 2.3).  
The results of this study are likely indicative of the true prevalence of EA and 
ACPA in long-standing SLE, and may be important for understanding the 
progression of minor erosions.   
 
2.2.  Chapter 3 
Subjects for this retrospective pilot study were derived from a database of 
patients attending the RNHRD CTD clinic. As no inception cohort was used, 
survivor bias and/or immortal time bias may have been introduced.   It is possible 
that patients with more severe disease outcomes or events (including death) were 
prevented from attending the RNHRD CTD clinic and therefore excluded from 
this study. However, the numbers of such patients would be very small and 
unlikely to affect our results.  Nevertheless, it is possible that both CVEs and 
mortality were under-reported in this study, which may partly account for the 
lack of association of aPL with IHD and the non-significant association of aPL 
with cerebrovascular disease. These results are likely to be conservative, since 
previous studies have demonstrated significant associations of aPL with CVEs in 
SLE83, 84.   
 
Other study limitations include possible non-responder bias arising from the 60% 
response rate to the questionnaire.  For respondents, questionnaire responses may 
have been affected by their memory (recall bias) and inaccurate responses may 
have been given to lifestyle questions such as weight or smoking habits (attention 
bias).  This may have resulted in under-reporting of factors or events, thus 
providing conservative results.  
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As this study was designed as a pilot study, power and study sample calculations 
were not performed.  There was incomplete data available from medical records 
and SLE questionnaires with respect to the dates of onset for predictor factors and 
CVEs.  Due to these limitations, it was not possible to perform Kaplan-Meier or 
Cox-proportional hazards analyses.  The decision was therefore made by the 
candidate to utilise unconditional binary logistic regression to compare predictor 
factors with the outcome variables of CVEs and mortality.  For the same reasons, 
the χ2 Goodness-of-fit test was employed to compare survival of SLE subgroups 
with age- and sex-matched UK population survival data.  Unconditional logistic 
regression analysis reduces the probability of obtaining positive results.  
Therefore our results demonstrating the associations of aPL with mortality are 
likely to be conservative.   
 
Another limitation of this study is the small study numbers, which increases the 
probability of a Type I error occurring with respect to aPL associations with 
mortality.  However, our study results support those of previous studies that 
showed the associations of aCL and APS with early mortality259, 270, 271.   
 
The laboratory cut-off levels for aCL were lower than the levels considered 
clinically significant for a diagnosis of APS (> 14U/mL for aCL GPL and > 
10U/mL for MPL for the study, compared with > 40U GPL or MPL for APS).  
From the evidence presented in Chapter 1, aPL are also involved in non-
thrombotic, auto-immune mechanisms in the pathogenesis of atherosclerosis.  
Although higher aPL levels are considered important for the diagnosis of APS, 
this requirement may not be applicable in the setting of atherosclerosis.  The 
decision to use the lower laboratory cut-off levels for aCL was based on the 
hypothesis that the persistence of aPL is an important factor influencing 
atherogenesis, a chronic inflammatory condition, thereby increasing CVE and 
mortality risks.  However, the use of lower cut-off levels for aCL in this study 
may have increased the probability of a Type I error occurring and may also 
partly explain the lack of association found between aCL and IHD.   
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The results from this study include the reduced 10-year survival of aCL+ve 
patients, the association of CVEs with mortality and the contribution of aCL to 
mortality in the multivariate analyses.  Taken together, these results support the 
hypothesis that aCL-associated pathogenic mechanisms contribute to early 
mortality, which is the major strength of this study. 
 
2.3.  Chapter 4  
As this study was designed as a pilot study, power and study sample calculations 
not performed. The possible biases outlined above for chapter 3 also apply to this 
chapter, namely survivor bias for the study cohort, and nonresponder, recall or 
attention bias for the questionnaires.  These factors would give conservative 
results for this study. 
 
As for chapter 3, due incomplete data for the dates of onset of predictor factors 
and CVEs, it was not possible to perform Kaplan-Meier or Cox-proportional 
hazards analyses.  Therefore unconditional binary logistic regression was used to 
compare predictor factors with outcome variables of CVEs and mortality.   
 
In this study, SLE patients had median (IQR) TC concentrations of 4.97 (2.13) 
mmol/L and LDL-C of 3.39 (1.87) mmol/L.  In comparison, the healthy control 
group had median (IQR) TC concentrations of 5.96 (1.9) mmol/L and LDL-C of 
3.93 (1.87) mmol/L.  Although the control group's TC and LDL-C concentrations 
would be considered unusually high today, they were not so during the time of 
the initial study between 1992 and 1993.  Control lipoprotein levels were 
comparable with lipoprotein levels from a Scottish population-based study of 10 
359 subjects in 1990453, which reported mean TC concentrations of 6.1 - 6.5 
mmol/L for men and 6.3 - 6.9 mmol/L for women.  The British Hyperlipidaemia 
Association's 1993 guidelines defined severe hyperlipidaemia as TC > 7.8 
mmol/L, fasting TG > 4.5 mmol/L, or HDL-C < 1.0 mmol/L.  Moreover, the 
guidelines  recommended initiating cholesterol-lowering therapy only at TC > 7.8 
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mmol/L or LDL-C > 6.0 mmol/L for asymptomatic males or postmenopausal 
females, the contemporaneous equivalents of our study controls454. Taking the 
above-mentioned criteria for hyperlipidaemia into consideration, it is possible 
that the higher TC and LDL-C concentrations in the healthy controls may have 
increased the probability of a Type II error (acceptance of the false null 
hypothesis), and may partly account for the results of similar VLDL-C levels 
between SLE and controls, with possibly exaggerated differences between groups 
for TC, LDL-C and HDL-C.  In the SLE patient group, 48.1% had TC > 5.0 
mmol/L and 61.1% had LDL-C > 3.0 mmol/L. Notwithstanding the healthy 
control results, SLE patient lipoprotein levels in this study are comparable with 
the results of Petri et al.'s study in 1992, in which 51% of SLE patients without 
IHD and 94% with IHD had TC > 5.18 mmol/L276. Furthermore, there was a 
trend towards a higher TC in the Manchester control group in chapter 5 (p = 
0.06), which suggests that the results of chapter 4 are not unexpected. 
 
Another limitation of this study is its retrospective nature.  There was incomplete 
data available on patients' glucocorticoid therapy. Glucocorticoid use is 
associated with raised TC and LDL-C concentrations in SLE383, 455.  It is possible 
that absent or low-dose glucocorticoid therapy in this group of SLE patients may 
have also resulted in lower TC and LDL-C concentrations compared with the 
healthy controls.  
 
The major strength of this study is the long period of follow-up for this group of 
SLE patients.  It confirms that 10-year survival in SLE patients is significantly 
reduced compared with the normal UK population and that CV-related mortality 
is a major cause of death in SLE.  Furthermore, the results suggest that TC : 
HDL-C ratio and Lp(a) may add prognostic value in assessing future mortality 






2.4.  Chapters 5 and 6 
Power calculations not performed for the studies in chapters 5 and 6, as both were 
ancillary studies performed according to the design of the original study that was 
first undertaken between 2000 and 2003. The protocol for the follow-up study 
undertaken between 2006 and 2009 was the same as the initial study. According 
to the study design, all SLE patients were female of British Caucasian ethnicity. 
These results therefore cannot be generalised to other races or males.  
 
Chapter 5 described a cross-sectional study of patients with established SLE. As 
this study did not have an inception cohort, survivor and/or immortal time bias 
may have been introduced, which would increase the probability of a Type I error 
occurring when compared with controls.  Ahmad et al.'s original study was 
designed to include a healthy control group whose mean age (53 years) was 
higher than that of the SLE group (48 years, p < 0.01)85.  This took into account 
the fact that the prevalence of carotid plaque in young healthy controls is 
extremely low.  By including older controls in the study, this reduced the 
probability of a Type I error occurring, but then increased the probability of a 
Type II error.  However, as the study found that the prevalence of carotid plaque 
was increased in SLE patients in all age groups including younger patients, these 
results were conservative and therefore both statistically significant and clinically 
menaingful.   
 
The cut-off levels for aCL for both studies were lower than those considered 
clinically significant for a diagnosis of APS (> 16U aCL GPL and > 16U MPL 
compared with > 40 GPL or MPL for APS).  The decision to use the lower 
laboratory cut-off levels for aCL was based on the evidence to date on the non-
thrombotic roles of aPL in atherogenesis, such as the associations of aPL with 
endothelial perturbation and EC apoptosis326.  High aCL levels are required for 
the diagnosis of APS because this increases the likelihood of detecting 
pathogenic aCL causing a thrombotic event.  However, in the setting of 
atherosclerosis, a chronic inflammatory condition, lower aCL levels may still be 
useful predictors of subclinical atherosclerosis, given their known effects in the 
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chronic atherogenic process.  The low aCL levels used in the study may have 
increased the probability of a Type I error occurring.  However with respect to 
the associations of aPL subtypes with CVEs (Table 5.3), the expected 
associations of APS with aCL, anti-β2GPI, anti-AnxA5 and anti-PT GPL were 
still detected, reducing the likelihood of a Type I error. 
 
Patient serum samples were only tested once for anti-AnxA5 GPL. Since aPL 
levels are known to fluctuate with time451 and the diagnostic criteria for APS 
include persistently positive aPL at least 3 months apart (Appendix 1.4), single 
aPL testing increases the probability of a Type I error occurring.  AnxA5 binds 
endothelium, improving endothelial function123 and probably stabilises 
atherosclerotic plaque via the formation of 2D shield that inhibits coagulation115, 
124.   A pathogenic effect of anti-AnxA5 is to inhibit AnxA5 binding to 
endothelium, thereby causing endothelial dysfunction and an unstable 
atherosclerotic plaque that is prone to rupture.  Chapter 5 suggests a potentially 
clinically significant association of anti-AnxA5 GPL with the presence of carotid 
plaque.  Likewise, chapter 6 demonstrates a statistically and clinically significant 
association of anti-AnxA5 GPL with carotid plaque progression, which not only 
provides proof of the concepts above, but also suggests that it may be a useful 
clinical prognostic marker for accelerated atherosclerosis.  This is the major 
strength of both studies. Our results are likely to be conservative given our 
relatively small study number and larger studies would be able to determine the 
significance of these findings. Repeated testing over time of anti-AnxA5 would 
also provide further information on the association of anti-AnxA5 with markers 








3.  Implications 
3.1.  ACPA as a marker of "rhupus" 
Chapter 2 shows that ACPA, particularly in high titres, predicts major erosive 
arthritis in SLE.  Furthermore, this study's findings support those of others that 
suggest that ACPA is not as specific a marker for RA as previously thought, but a 
marker for a phenotype of EA that is mediated by ACPA.  Furthermore, ACPA 
appears to be a useful marker for the rhupus subset in SLE.  The major clinical 
implication of this study is requesting ACPA is worthwhile for a SLE patient 
presenting with synovitis, since it is an easily accessible test.  A positive ACPA 
result, particularly in a high titre, predicts EA and this information is useful when 
the physician is considering whether to take more a aggressive approach with 
respect to disease-modifying therapy for lupus arthritis.  Moreover, the genetic 
markers that are associated with progression of erosions in RA provide further 
information on the subset of SLE with specific genetic and antibody features, the 
"rhupus" subset. 
 
3.2.  Assessment of CV risk in SLE 
SLE patients are at increased risk of developing accelerated atherosclerosis.  
However, not all subgroups of SLE patients are at risk, as shown in chapter 6, 
where 47.0% of female SLE patients remained free of carotid plaque at follow-up 
and 41.1% of these women were post-menopausal.  Furthermore, patients with 
SLE are unlikely to have an increased CV risk compared with the general 
population if a standard CV risk assessment is undertaken according to current 
guidelines293, 418.  Hence a more accurate prediction of CVD risk for a patient 
with SLE would require an overall CV risk assessment, with the addition of novel 





3.2.1.  TC : HDL-C ratio 
According to the JBS 2 guidelines418, the TC : HDL-C ratio is an important factor 
in CVD risk assessment for the general UK population.  In chapter 4, the TC : 
HDL-C ratio was an independent predictor for future CVEs and mortality, 
confirming its importance as a CV risk factor in SLE.  In chapter 5, the ratio was 
not significantly associated with the presence of carotid plaque.  In chapter 6, the 
ratio had an association with plaque progression of probable clinical significance 
in the univariate analysis (OR 1.42, 95% CI 0.96, 2.09, p = 0.08), although it was 
not an independent association in the multivariate analysis.  As a marker of 
subclinical atherosclerosis, the TC : HDL-C ratio appears to be less useful in 
patients with SLE.  Nevertheless, as this ratio is calculated from a fasting lipid 
profile and is a simple and cost-effective clinical tool, it could easily be included 
as part of regular CV risk assessment in routine clinical monitoring of SLE 
patients.  Although overall, our results were inconclusive with respect to the TC : 
HDL-C ratio as a marker of subclinical atherosclerosis, this remains an important 
CV marker in the general population and should be considered in SLE. 
 
3.2.2.  HDL-C 
Low HDL-C concentrations reflect the "lupus pattern" of dyslipidaemia, which is 
enhanced with increased disease activity368.  The inverse association of HDL-C 
with plaque progression in chapter 6 supports the hypothesis that inflammatory 
mechanisms in SLE promote acceleration of atherogenesis in SLE.  The negative 
correlation of HDL3-C with aCL GPL in chapter 4 provides further support for 
the pathogenic role of SLE-related autoimmune mechanisms in accelerated 
atherosclerosis.  Hence HDL-C may prove to be a useful marker of CV risk in 
SLE patients with persistent disease activity and should be included as a risk 





3.2.3.  Lp(a) 
Elevated Lp(a) concentrations independently predict for IHD, ischaemic stroke 
and coronary mortality in the general population, although the effect is relatively 
weak (adjusted RR 1.1 for all outcomes)409.  Elevated levels of Lp(a) have been 
detected in patients with SLE414-416.  In chapter 4, Lp(a) was an independent 
predictor of mortality in patients with SLE.  As Lp(a) levels are not influenced by 
disease activity or glucocorticoid therapy415, Lp(a) may be a useful factor in 
combination with other factors in the overall CV risk assessment of SLE patients.   
 
3.2.4.  Anti-AnxA5 GPL 
In chapter 5, the association of anti-AnxA5 GPL with the presence of carotid 
plaque approached statistical significance, a finding that is of probable clinical 
significance.  In chapter 6, anti-AnxA5 GPL was an independent predictor of 
carotid plaque progression.  Both these findings provide support for anti-AnxA5 
GPL as a pathogenic aPL in atherogenesis.  Moreover, these results provide 
support for the hypothesis that aPL with differing specificities influence the 
overall clinical effects of aPL at different stages of atherogenesis.  This 
hypothesis may provide an explanation for the discordant reports of a positive 
association of aCL and/or LA with the presence of carotid plaque in Ahmad et 
al.'s study85, but negative findings in other studies86, 350, 364, 372.    
 
4.  Perspectives for future research 
The findings from the studies presented in this thesis, including the study 
limitations discussed above, form the basis for the suggestions outlined below 





4.1.  Lupus arthritis 
Chapter 2 provides insight into the possible immunogenetic mechanisms of MHC 
class II associations with ACPA that may be shared between RA and EA in SLE.  
Given the small study numbers in this study, future studies with larger subject 
numbers may be able to confirm the association of SE alleles with ACPA 
production in the setting of lupus arthritis. 
 
In chapter 2, one patient with major erosions had low ACPA levels and was also 
negative for the SE. Recent genetic studies have demonstrated that several SNPs 
at the IRF5, STAT4, BLK and TNFAIP3 loci are shared by SLE and RA171, 210, 211.  
In mice, interference with the function of the TNFAIP3 protein product A20 
resulted in a destructive, erosive polyarthritis212.  The IRF5 locus was also found 
to be shared by patients with SLE and the RF-negative polyarthritis subtype of 
JIA213.  These studies suggest that the pathogenesis of arthritis in SLE involves at 
least several complex immunological pathways that do not involve the MHC or 
ACPA-related pathways. Future studies could aim to determine the associations 
of these immunogenetic pathways with arthritis and other clinical subsets of SLE. 
 
4.2.  Predictors of CV risk and mortality in SLE 
4.2.1.  Study populations 
Chapters 2, 3 and 4 studied SLE patients from a database of patients attending the 
RNHRD CTD clinic.  Future studies could be extended to include SLE patients 
from multiple centres, and be designed as prospective inception cohorts of 
patients with early disease.  The studies presented in chapters 5 and 6 were 
limited to women of mainly British Caucasian descent.  Future studies could be 
extended to include men, more SLE patients with early disease, and individuals 




4.2.2.  Lipoproteins 
The studies presented in this thesis found associations of the TC : HDL-C ratio 
with CVEs and a possible association with carotid plaque progression.  HDL-C 
levels were inversely associated with carotid plaque progression in chapter 6.  
Future studies with larger patient numbers could further examine whether the TC 
: HDL-C ratio and HDL-C could be useful as  specific markers of subclinical 
atherosclerosis, and/or markers of future CVEs and mortality.  The apoB : apoA-I 
ratio was a possible predictor of CVEs in chapter 4.  As this ratio predicts IHD 
risk in the general population419, 420, larger studies could explore the apoB : apoA-
I ratio as a potential marker of future CVEs or subclinical atherosclerosis in SLE.  
Lp(a) was a predictor of mortality in chapter 4.  Further studies could also 
confirm the utility of Lp(a) as a marker of CV risk and mortality in SLE.  
 
4.2.3.  ACL GPL 
In chapter 4, increased aCL GPL levels were associated with future CVEs and 
increased mortality.  It is difficult to conduct clinical studies to determine auto-
antibodies as CV predictive factors, a fact borne out by the very few studies 
published to date.   In atherosclerosis, pathogenic auto-antibodies such as aCL 
GPL may only play a mechanistic role in complex auto-immune processes 
involving multiple inflammatory mediators, so that their direct clinical 
associations may be difficult to appreciate.  Future studies examining CVE risk or 
mortality outcomes could focus on aPL with known actions and specificities in 
the atherosclerotic process, such as anti-β2GPI.  
 
4.2.4.  Anti-AnxA5 GPL 
Anti-AnxA5 GPL was associated with carotid plaque progression in chapter 6 
and probably associated with the presence of carotid plaque in chapter 5.  Further 
studies could provide more information on the role of anti-AnxA5 in 
atherogenesis, whether as a marker of the presence of increased AnxA5 levels in 
association with increased plaque, or as a truly pathogenic antibody, via 
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inhibition of AnxA5 binding.   Furthermore, future studies could further test the 
hypothesis that aPL with differing specificities influence the overall clinical 
effects of aPL at different stages of atherogenesis.  Finally, larger studies are 
required to confirm the utility of anti-AnxA5 GPL as a marker of subclinical 
atherosclerosis in SLE.   
 
In summary, the challenge for future research remains to find biomarkers with 
clear pathogenic processes in SLE that can predict future clinical outcomes.  




As SLE is a heterogeneous disease, it is unlikely that any single biomarker will 
be applicable to all patients.  The research carried out for this thesis identified 
ACPA as a marker of a phenotype of SLE with EA and features of RA - 
"rhupus". All 6 patients with major erosions were carriers of the SE-associated 
allele, HLA-DQB1*0302.  This research also identified several serological 
markers of CV risk - increased TC : HDL-C ratio and anti-AnxA5 GPL.  Lower 
HDL-C concentrations were also a marker of CV risk.  Strategies to incorporate 
these new markers into clinical CV risk assessments may be useful to distinguish 
the subset of SLE patients most at risk of developing accelerated atherosclerosis.  
Furthermore, aCL GPL and Lp(a) were identified as markers of mortality risk.  
Future studies may be able to provide further information on the pathogenic 
effects of these markers and their potential utility in routine clinical practice. 
 210 
REFERENCES 
1. Nightingale AL, Farmer RDT, de Vries CS. Incidence of clinically diagnosed systemic 
lupus erythematosus 1992–1998 using the UK General Practice Research Database. 
Pharmacoepidemiol Drug Saf 2006;15:656-61. 
2. Hopkinson ND, Doherty M, Powell RJ. The prevalence and incidence of systemic lupus 
erythematosus in Nottingham, UK, 1989–1990. Rheumatology (Oxford) 1993;32:110-5. 
3. Hopkinson ND, Doherty M, Powell RJ. Clinical features and race-specific 
incidence/prevalence rates of systemic lupus erythematosus in a geographically complete 
cohort of patients. Ann Rheum Dis 1994;53:675-80. 
4. Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic 
lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of 
birth. Arthritis Rheum 1995;38:551-8. 
5. Somers EC, Thomas SL, Smeeth L, Schoonen WM, Hall AJ. Incidence of systemic lupus 
erythematosus in the United Kingdom, 1990–1999. Arthritis Care Res 2007;57:612-8. 
6. Samanta A, Feehally J, Roy S, Nichol FE, Sheldon PJ, Walls J. High prevalence of 
systemic disease and mortality in Asian subjects with systemic lupus erythematosus. Ann 
Rheum Dis 1991;50:490-2. 
7. Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: 
preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95. 
8. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of 
systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7. 
9. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus 
erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis 
Rheum 2004;34:501-37. 
10. Op De Beeck K, Vermeersch P, Verschueren P, et al. Detection of antinuclear antibodies 
by indirect immunofluorescence and by solid phase assay. Autoimmun Rev 2011;10:801-8. 
11. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-39. 
12. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before 
the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33. 
13. Azizah MR, Azila MN, Zulkifli MN, Norita TY. The prevalence of antinuclear, anti-
dsDNA, anti-Sm and anti-RNP antibodies in a group of healthy blood donors. Asian Pac J 
Allergy Immunol 1996;14:125-8. 
14. Boutjdir M, Chen L, Zhang Z-H, et al. Arrhythmogenicity of IgG and anti–52-kD SSA/Ro 
affinity-purified antibodies from mothers of children with congenital heart block. Circ Res 
1997;80:354-62. 
 211 
15. Ikematsu W, Luan F-L, La Rosa L, et al. Human anticardiolipin monoclonal autoantibodies 
cause placental necrosis and fetal loss in BALB/c mice. Arthritis Rheum 1998;41:1026-39. 
16. Holers VM, Girardi G, Mo L, et al. Complement C3 activation is required for 
antiphospholipid antibody-induced fetal loss. J Exp Med 2002;195:211-20. 
17. Van Horn JT, Craven C, Ward K, Branch DW, Silver RM. Histologic features of placentas 
and abortion specimens from women with antiphospholipid and antiphospholipid-like 
syndromes. Placenta 2004;25:642-8. 
18. Rand JH, Wu X-X, Quinn AS, et al. Human monoclonal antiphospholipid antibodies 
disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence 
from atomic force microscopy and functional assay. Am J Pathol 2003;163:1193-200. 
19. Rand JH, Wu X-X, Guller S, Scher J, Andree HAM, Lockwood CJ. Antiphospholipid 
immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical 
membranes and in culture media of placental villi. Am J Obstet Gynecol 1997;177:918-23. 
20. Ehrenstein MR, Katz DR, Griffiths MH, et al. Human IgG anti-DNA antibodies deposit in 
kidneys and induce proteinuria in SCID mice. Kidney Int 1995;48:705-11. 
21. Ravirajan CT, Rahman MA, Papadaki L, et al. Genetic, structural and functional properties 
of an IgG DNA-binding monoclonal antibody from a lupus patient with nephritis. Eur J 
Immunol 1998;28:339-50. 
22. Okamura M, Kanayama Y, Amastu K, et al. Significance of enzyme linked immunosorbent 
assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with 
lupus nephritis: correlation with severity of renal histology. Ann Rheum Dis 1993;52:14-
20. 
23. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases 
in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in 
systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 
1990;33:634-43. 
24. Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent 
systemic lupus erythematosus: a discordance between clinical and serologic features. Am J 
Med 1979;66:210-5. 
25. Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and 
immunologic patterns of disease expression in a cohort of 1,000 patients. Medicine 
(Baltimore) 1993;72:113-24. 
26. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus 
erythematosus during a 5-year period: a multicenter prospective study of 1,000 patients. 
Medicine (Baltimore) 1999;78:167-75. 
27. Cervera R, Khamashta MA, Hughes GRV. The Euro-lupus project: epidemiology of 
systemic lupus erythematosus in Europe. Lupus 2009;18:869-74. 
28. Hitchon CA, Peschken CA. Sm antibodies increase risk of death in systemic lupus 
erythematosus. Lupus 2007;16:186-94. 
 212 
29. Witte T, Hartung K, Sachse C, et al. Rheumatoid factors in systemic lupus erythematosus: 
association with clinical and laboratory parameters. Rheumatol Int 2000;19:107-11. 
30. David-Bajar KM, Bennion SD, DeSpain JD, Golitz LE, Lee LA. Clinical, histologic, and 
immunofluorescent distinctions between subacute cutaneous lupus erythematosus and 
discoid lupus erythematosus. J Invest Dermatol 1992;99:251-7. 
31. Buyon JP, Winchester RJ, Slade SG, et al. Identification of mothers at risk for congenital 
heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-
linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-
SS-B/La antibodies. Arthritis Rheum 1993;36:1263-73. 
32. Lockshin MD, Bonfa E, Elkon K, Druzin ML. Neonatal lupus risk to newborns of mothers 
with systemic lupus erythematosus. Arthritis Rheum 1988;31:697-701. 
33. Alexander EL, Arnett FC, Provost TT, Stevens MB. Sjögren's syndrome: association of 
anti-Ro(SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic 
hyperreactivity. Ann Intern Med 1983;98:155-9. 
34. Lian F, Chen D, Wang Y, et al. Clinical features and independent predictors of pulmonary 
arterial hypertension in systemic lupus erythematosus. Rheumatol Int 2012;32:1727-31. 
35. Mittoo S, Gelber AC, Hitchon CA, et al. Clinical and serologic factors associated with 
lupus pleuritis. J Rheumatol 2010;37:747-53. 
36. ter Borg EJ, Groen H, Horst G, Limburg PC, Wouda AA, Kallenberg CG. Clinical 
associations of antiribonucleoprotein antibodies in patients with systemic lupus 
erythematosus. Semin Arthritis Rheum 1990;20:164-73. 
37. Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus 
anticoagulants and other "antiphospholipid" autoantibodies. Blood 1994;84:2854-67. 
38. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous 
thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 
2002;29:2531-6. 
39. von Landenberg P, Scholmerich J, von Kempis J, Lackner KJ. The combination of 
different antiphospholipid antibody subgroups in the sera of patients with autoimmune 
diseases is a strong predictor for thrombosis: A retrospective study from a single center. 
Immunobiology 2003;207:65-71. 
40. Alarcón-Segovia DMD, Deleze MMD, Oria CVBS, et al. Antiphospholipid antibodies and 
the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 
500 consecutive patients. Medicine (Baltimore) 1989;68:353-65. 
41. Pérez-Vázquez ME, Villa AR, Drenkard C, Cabiedes J, Alarcón-Segovia D. Influence of 
disease duration, continued followup and further antiphospholipid testing on the frequency 
and classification category of antiphospholipid syndrome in a cohort of patients with 
systemic lupus erythematosus. J Rheumatol 1993;20:437-42. 
 213 
42. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus 
anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. 
Prevalence and clinical significance. Ann Intern Med 1990;112:682-98. 
43. McNeil HP, Hunt JE, Krilis SA. Antiphospholipid antibodies - new insights into their 
specificity and clinical importance. Scand J Immunol 1992;36:647-52. 
44. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update 
of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb 
Haemost 2006;4:295-306. 
45. Galli M, Barbui T, Comfurius P, et al. Anticardiolipin antibodies (ACA) directed not to 
cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-7. 
46. de Bandt M, Benali K, Guillevin L, et al. Longitudinal determination of antiphospholipid 
antibodies in lupus patients without previous manifestations of antiphospholipid syndrome. 
A prospective study. J Rheumatol 1999;26:91-6. 
47. Safa O, Crippa L, Della Valle P, Sabbadini MG, Vigano D'Angelo S, D'Angelo A. IgG 
reactivity to phospholipid-bound b2-glycoprotein I is the main determinant of the fraction 
of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid 
in patients with the clinical suspicion of antiphospholipid-antibody syndrome. 
Haematologica 1999;84:829-38. 
48. Horbach DA, van Oort E, Donders RCJM, Derksen RHWM, de Groot PG. Lupus 
anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients 
with systemic lupus erythematosus. Comparison between different assays for the detection 
of antiphospholipid antibodies. Thromb Haemost 1996;76:916-24. 
49. Danowski A, de Azevedo MNL, de Souza Papi JA, Petri M. Determinants of risk for 
venous and arterial thrombosis in primary antiphospholipid syndrome and in 
antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 
2009;36:1195-9. 
50. Manger K, Manger B, Repp R, et al. Definition of risk factors for death, end stage renal 
disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic 
lupus erythematosus. Ann Rheum Dis 2002;61:1065-70. 
51. Shah NM, Khamashta MA, Atsumi T, Hughes GRV. Outcome of patients with 
anticardiolipin antibodies: A 10 year follow- up of 52 patients. Lupus 1998;7:3-6. 
52. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 
360 patients with antiphospholipid antibodies: a four-year prospective study from the 
Italian registry. Am J Med 1996;100:530-6. 
53. Wahl DG, Guillemin F, de ME, Perret C, Lecompte T, Thibaut G. Risk for venous 
thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus. A 
meta-analysis. Lupus 1997;6:467-73. 
54. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for 
thrombosis and primary thrombosis prevention in patients with systemic lupus 
 214 
erythematosus with or without antiphospholipid antibodies. Arthritis Care Res 2009;61:29-
36. 
55. Tarr T, Lakos G, Bhattoa HP, Shoenfeld Y, Szegedi G, Kiss E. Analysis of risk factors for 
the development of thrombotic complications in antiphospholipid antibody positive lupus 
patients. Lupus 2007;16:39-45. 
56. Vaarala O, Manttari M, Manninen V, et al. Anti-cardiolipin antibodies and risk of 
myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995;91:23-
7. 
57. Wu R, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK. Antibodies against 
cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial 
infarction. Arterioscler Thromb Vasc Biol 1997;17:3159-63. 
58. Hanly JG, Urowitz MB, Su L, et al. Autoantibodies as biomarkers for the prediction of 
neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 2011;70:1726-
32. 
59. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors 
for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a 
systematic review of the literature. Blood 2003;101:1827-32. 
60. Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus 
erythematosus: data from the Maryland Lupus cohort. Rheumatology (Oxford) 
2004;43:1555-60. 
61. Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort. 
Lupus 2010;19:419-23. 
62. Danowski A, Kickler TS, Petri M. Anti-b2-glycoprotein I: prevalence, clinical correlations, 
and importance of persistent positivity in patients with antiphospholipid syndrome and 
systemic lupus erythematosus. J Rheumatol 2006;33:1775-9. 
63. Ho KT, Ahn CW, Alarcon GS, et al. Systemic lupus erythematosus in a multiethnic cohort 
(LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 
2005;44:1303-7. 
64. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: 
understanding the antibodies. Nat Rev Rheumatol 2011;7:330-9. 
65. Rauch J, Dieudé M, Subang R, Levine JS. The dual role of innate immunity in the 
antiphospholipid syndrome. Lupus 2010;19:347-53. 
66. de Laat B, Mertens K, de Groot PG. Mechanisms of disease: antiphospholipid antibodies - 
from clinical association to pathologic mechanism. Nat Clin Pract Rheumatol 2008;4:192-
9. 
67. Galli M. Antiphospholipid antibodies and thrombosis: do test patterns identify the patients' 
risk? Thromb Res 2004;114:597-601. 
 215 
68. Dieudé M, Senécal J-L, Rauch J, et al. Association of autoantibodies to nuclear lamin B1 
with thromboprotection in systemic lupus erythematosus: lack of evidence for a direct role 
of lamin B1 in apoptotic blebs. Arthritis Rheum 2002;46:2695-707. 
69. Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in 
systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 
2009;68:238-41. 
70. Ruiz-Irastorza G, Egurbide M-V, Pijoan J-I, et al. Effect of antimalarials on thrombosis and 
survival in patients with systemic lupus erythematosus. Lupus 2006;15:577-83. 
71. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction 
between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus 
erythematosus. Lancet 1993;341:923-5. 
72. Deguchi H, Fernández JA, Hackeng TM, Banka CL, Griffin JH. Cardiolipin is a normal 
component of human plasma lipoproteins. Proc Natl Acad Sci USA 2000;97:1743-8. 
73. Mustafa A, Nityanand S, Berglund L, Lithell H, Lefvert AK. Circulating immune 
complexes in 50-year-old men as a strong and independent risk factor for myocardial 
infarction. Circulation 2000;102:2576-81. 
74. Adler Y, Finkelstein Y, Zandeman-Goddard G, et al. The presence of antiphospholipid 
antibodies in acute myocardial infarction. Lupus 1995;4:309-13. 
75. Bili A, Moss AJ, Francis CW, et al. Anticardiolipin antibodies and recurrent coronary 
events : a prospective study of 1150 patients. Circulation 2000;102:1258-63. 
76. Hamsten A, Björkholm M, Norberg R, De Faire U, Holm G. Antibodies to cardiolipin in 
young survivors of myocardial infarction: an association with recurrent cardiovascular 
events. Lancet 1986;327:113-6. 
77. Brey RL, Abbott RD, Curb JD, et al. b2-glycoprotein 1-dependent anticardiolipin 
antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu Heart 
Program. Stroke 2001;32:1701-6. 
78. Edwards T, Thomas RD, McHugh NJ. Anticardiolipin antibodies in ischaemic heart 
disease. Lancet 1993;342:988-9. 
79. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, Groot PGd, Algra A. Antiphospholipid 
antibodies and risk of myocardial infarction and ischaemic stroke in young women in the 
RATIO study: a case-control study. Lancet Neurol 2009;8:998-1005. 
80. Tsakiris DA, Marbet GA, Burkart F, Duckert F. Anticardiolipin antibodies and coronary 
heart disease. Eur Heart J 1992;13:1645-8. 
81. Brey RL. Antiphospholipid antibodies in young adults with stroke. J Thromb Thrombolysis 
2005;20:105-12. 
82. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin 
antibodies are an independent risk factor for first ischemic stroke. Neurology 
1993;43:2069-73. 
 216 
83. Gustafsson J, Gunnarsson I, Borjesson O, et al. Predictors of the first cardiovascular event 
in patients with systemic lupus erythematosus - a prospective cohort study. Arthritis Res 
Ther 2009;11:R186. 
84. Toloza SMA, Uribe AG, Gerald McGwin Jr., et al. Systemic lupus erythematosus in a 
multiethnic US cohort (LUMINA): XXIII. Baseline predictors of vascular events. Arthritis 
Rheum 2004;50:3947-57. 
85. Ahmad Y, Shelmerdine J, Bodill H, et al. Subclinical atherosclerosis in systemic lupus 
erythematosus (SLE): the relative contribution of classic risk factors and the lupus 
phenotype. Rheumatology (Oxford) 2007;46:983-8. 
86. Roman MJ, Shanker B-A, Davis A, et al. Prevalence and correlates of accelerated 
atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406. 
87. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in 
systemic lupus erythematosus. N Engl J Med 2003;349:2407-15. 
88. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not 
atherosclerosis): Hopkins Lupus Cohort. Thromb Res 2004;114:593-5. 
89. Miyakis S, Giannakopoulos B, Krilis SA. Beta 2 glycoprotein I-function in health and 
disease. Thromb Res 2004;114:335-46. 
90. Kobayashi K, Tada K, Itabe H, et al. Distinguished effects of antiphospholipid antibodies 
and anti-oxidized LDL antibodies on oxidized LDL uptake by macrophages. Lupus 
2007;16:929-38. 
91. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of b2-
glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density 
lipoprotein uptake by macrophages. Clin Exp Immunol 1997;107:569-73. 
92. Meroni PL, Raschi E, Testoni C, Borghi MO. Endothelial cell activation by 
antiphospholipid antibodies. Clin Immunol 2004;112:169-74. 
93. Hulstein JJJ, Lenting PJ, de Laat B, Derksen RHWM, Fijnheer R, de Groot PG. b2-
glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. 
Blood 2007;110:1483-91. 
94. Kobayashi K, Matsuura E, Liu Q, et al. A specific ligand for b2-glycoprotein I mediates 
autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J 
Lipid Res 2001;42:697-709. 
95. George J, Harats D, Gilburd B, et al. Immunolocalization of b2-glycoprotein I 
(apolipoprotein H) to human atherosclerotic plaques : potential implications for lesion 
progression. Circulation 1999;99:2227-30. 
96. Del Papa N, Guidali L, Sala A, et al. Endothelial cells as target for antiphospholipid 
antibodies. Human polyclonal and monoclonal anti-b2-glycoprotein I antibodies react in 
vitro with endothelial cells through adherent b2-glycoprotein I and induce endothelial 
activation. Arthritis Rheum 1997;40:551-61. 
 217 
97. Del Papa N, Guidali L, Spatola L, et al. Relationship between anti-phospholipid and anti-
endothelial cell antibodies III: b2-glycoprotein I mediates the antibody binding to 
endothelial membranes and induces the expression of adhesion molecules. Clin Exp 
Rheumatol 1995;13:179-85. 
98. Allen KL, Fonseca FV, Betapudi V, Willard B, Zhang J, McCrae KR. A novel pathway for 
human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies. 
Blood 2012;119:884-93. 
99. Raschi E, Testoni C, Bosisio D, et al. Role of the MyD88 transduction signaling pathway 
in endothelial activation by antiphospholipid antibodies. Blood 2003;101:3495-500. 
100. Sorice M, Longo A, Capozzi A, et al. Anti–β2-glycoprotein I antibodies induce monocyte 
release of tumor necrosis factor α and tissue factor by signal transduction pathways 
involving lipid rafts. Arthritis Rheum 2007;56:2687-97. 
101. Lambrianides A, Carroll CJ, Pierangeli SS, et al. Effects of polyclonal IgG derived from 
patients with different clinical types of the antiphospholipid syndrome on monocyte 
signaling pathways. J Immunol 2010;184:6622-8. 
102. Meroni PL, Peyvandi F, Foco L, et al. Anti-beta 2 glycoprotein I antibodies and the risk of 
myocardial infarction in young premenopausal women. J Thromb Haemost 2007;5:2421-8. 
103. Veres K, Lakos G, Kerényi A, et al. Antiphospholipid antibodies in acute coronary 
syndrome. Lupus 2004;13:423-7. 
104. Greco TP, Conti-Kelly AM, Greco T, et al. Newer antiphospholipid antibodies predict 
adverse outcomes in patients with acute coronary syndrome. Am J Clin Pathol 
2009;132:613-20. 
105. Kobayashi K, Kishi M, Atsumi T, et al. Circulating oxidized LDL forms complexes with 
b2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 2003;44:716-26. 
106. Lopez LR, Salazar PM, Palafox SC, Hurley BL, Matsuura E, Garcia DLTI. Oxidized low-
density lipoprotein and b2-glycoprotein I in patients with systemic lupus erythematosus and 
increased carotid intima-media thickness: implications in autoimmune-mediated 
atherosclerosis. Lupus 2006;15:80-6. 
107. Amengual O, Atsumi T, Koike T. Specificities, properties, and clinical significance of 
antiprothrombin antibodies. Arthritis Rheum 2003;48:886-95. 
108. D'Agnillo P, Levine JS, Subang R, Rauch J. Prothrombin binds to the surface of apoptotic, 
but not viable, cells and serves as a target of lupus anticoagulant autoantibodies. J Immunol 
2003;170:3408-22. 
109. Bertolaccini ML, Atsumi T, Koike T, Hughes GR, Khamashta MA. Antiprothrombin 
antibodies detected in two different assay systems. Prevalence and clinical significance in 
systemic lupus erythematosus. Thromb Haemost 2005;93:289-97. 
110. Nojima J, Iwatani Y, Suehisa E, Kuratsune H, Kanakura Y. The presence of anti-
phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous 
 218 
thrombosis in patients with systemic lupus erythematosus. Haematologica 2006;91:699-
702. 
111. Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the 
phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid 
syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000;43:1982-93. 
112. Vaarala O, Puurunen M, Manttari M, Manninen V, Aho K, Palosuo T. Antibodies to 
prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 
1996;75:456-9. 
113. Reutelingsperger CPM, van Heerde WL. Annexin V, the regulator of phosphatidylserine-
catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci 1997;53:527-
32. 
114. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus 
erythematosus are clustered in two populations of surface structures on apoptotic 
keratinocytes. J Exp Med 1994;179:1317-30. 
115. van Genderen HO, Kenis H, Hofstra L, Narula J, Reutelingsperger CPM. Extracellular 
annexin A5: functions of phosphatidylserine-binding and two-dimensional crystallization. 
Biochim Biophys Acta Mol Cell Res 2008;1783:953-63. 
116. Gidon-Jeangirard C, Hugel B, Holl V, et al. Annexin V delays apoptosis while exerting an 
external constraint preventing the release of CD4+ and PrPc+ membrane particles in a 
human T lymphocyte model. J Immunol 1999;162:5712-8. 
117. Bouter A, Gounou C, Berat R, et al. Annexin-A5 assembled into two-dimensional arrays 
promotes cell membrane repair. Nat Commun 2011;2:270. 
118. Frostegard AG, Su J, von Landenberg P, Frostegard J. Effects of anti-cardiolipin antibodies 
and IVIg on annexin A5 binding to endothelial cells: implications for cardiovascular 
disease. Scand J Rheumatol 2010;39:77-83. 
119. Rand JH, Wu X-X, Lapinski R, et al. Detection of antibody-mediated reduction of annexin 
A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 
2004;104:2783-90. 
120. Wu XX, Pierangeli SS, Rand JH. Resistance to annexin A5 binding and anticoagulant 
activity in plasmas from patients with the antiphospholipid syndrome but not with syphilis. 
J Thromb Haemost 2006;4:271-3. 
121. Kaburaki J, Kuwana M, Yamamoto M, Kawai S, Ikeda Y. Clinical significance of anti-
annexin V antibodies in patients with systemic lupus erythematosus. Am J Hematol 
1997;54:209-13. 
122. van Tits L, de Graaf J, Toenhake H, van Heerde W, Stalenhoef A. C-reactive protein and 
annexin A5 bind to distinct sites of negatively charged phospholipids present in oxidized 
low-density lipoprotein. Arterioscler Thromb Vasc Biol 2005;25:717-22. 
 219 
123. Ewing MM, de Vries MR, Nordzell M, et al. Annexin A5 therapy attenuates vascular 
inflammation and remodeling and improves endothelial function in mice. Arterioscler 
Thromb Vasc Biol 2011;31:95-101. 
124. Cederholm A, Svenungsson E, Jensen-Urstad K, et al. Decreased binding of annexin V to 
endothelial cells: a potential mechanism in atherothrombosis of patients with systemic 
lupus erythematosus. Arterioscler Thromb Vasc Biol 2005;25:198-203. 
125. Rand JH, Wu X-X, Quinn AS, et al. Hydroxychloroquine protects the annexin A5 
anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel 
effect for an old antimalarial drug. Blood 2010;115:2292-9. 
126. Bastian HM, Roseman JM, McGwin Jr G, et al. Systemic lupus erythematosus in three 
ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002;11:152-60. 
127. Bertolaccini ML, Atsumi T, Khamashta MA, Amengual O, Hughes GR. Autoantibodies to 
human prothrombin and clinical manifestations in 207 patients with systemic lupus 
erythematosus. J Rheumatol 1998;25:1104-8. 
128. Lakos G, Kiss E, Regeczy N, et al. Antiprothrombin and antiannexin V antibodies imply 
risk of thrombosis in patients with systemic autoimmune diseases. J Rheumatol 
2000;27:924-9. 
129. Chan MT, Owen P, Dunphy J, et al. Associations of erosive arthritis with anti-cyclic 
citrullinated peptide antibodies and MHC class II alleles in systemic lupus erythematosus. J 
Rheumatol 2008;35:77-83. 
130. Qing Y-F, Zhang Q-B, Zhou J-G, et al. The detecting and clinical value of anti-cyclic 
citrullinated peptide antibodies in patients with systemic lupus erythematosus. Lupus 
2009;18:713-7. 
131. Zhao Y, Li J, Li X-X, Li C, Li L, Li Z-G. What can we learn from the presence of anti-
cyclic citrullinated peptide antibodies in systemic lupus erythematosus? Joint Bone Spine 
2009;76:501-7. 
132. Neefjes J, Jongsma MLM, Paul P, Bakke O. Towards a systems understanding of MHC 
class I and MHC class II antigen presentation. Nat Rev Immunol 2011;11:823-36. 
133. Shiina T, Hosomichi K, Inoko H, Kulski JK. The HLA genomic loci map: expression, 
interaction, diversity and disease. J Hum Genet 2009;54:15-39. 
134. Price P, Witt C, Allock R, et al. The genetic basis for the association of the 8.1 ancestral 
haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev 
1999;167:257-74. 
135. Hartung K, Baur MP, Coldewey R, et al. Major histocompatibility complex haplotypes and 
complement C4 alleles in systemic lupus erythematosus. Results of a multicenter study. J 
Clin Invest 1992;90:1346-51. 
136. Yao Z, Kimura A, Hartung K, et al. Polymorphism of the DQA1 promoter region (QAP) 
and DRB1, QAP, DQA1, DQB1 haplotypes in systemic lupus erythematosus. 
Immunogenetics 1993;38:421-9. 
 220 
137. Worrall JG, Snaith ML, Batchelor JR, Isenberg DA. SLE: a rheumatological view. 
Analysis of the clinical features, serology and immunogenetics of 100 SLE patients during 
long-term follow-up. QJM 1990;74:319-30. 
138. Candore G, Lio D, Colonna Romano G, Caruso C. Pathogenesis of autoimmune diseases 
associated with 8.1 ancestral haplotype: effect of multiple gene interactions. Autoimmun 
Rev 2002;1:29-35. 
139. Graham RR, Ortmann WA, Langefeld CD, et al. Visualizing human leukocyte antigen 
class II risk haplotypes in human systemic lupus erythematosus. Am J Hum Genet 
2002;71:543-53. 
140. Deng Y, Tsao BP. Genetic susceptibility to systemic lupus erythematosus in the genomic 
era. Nat Rev Rheumatol 2010;6:683-92. 
141. Pickering MC, Walport MJ. Links between complement abnormalities and systemic lupus 
erythematosus. Rheumatology (Oxford) 2000;39:133-41. 
142. Millard TP, Kondeatis E, Cox A, et al. A candidate gene analysis of three related 
photosensitivity disorders: cutaneous lupus erythematosus, polymorphic light eruption and 
actinic prurigo. Br J Dermatol 2001;145:229-36. 
143. Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a 
prototypic subset (subphenotype) of lupus erythematosus defined by characteristic 
cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev 
2005;4:253-63. 
144. Werth VP, Zhang W, Dortzbach K, Sullivan K. Association of a promoter polymorphism 
of tumor necrosis factor-a with subacute cutaneous lupus erythematosus and distinct 
photoregulation of transcription. J Invest Dermatol 2000;115:726-30. 
145. McHugh NJ, Owen P, Cox B, Dunphy J, Welsh K. MHC class II, tumour necrosis factor a, 
and lymphotoxin a gene haplotype associations with serological subsets of systemic lupus 
erythematosus. Ann Rheum Dis 2006;65:488-94. 
146. Tsao BP. Update on human systemic lupus erythematosus genetics. Curr Opin Rheumatol 
2004;16:513-21. 
147. Hochberg MC, Boyd RE, Ahearn JM, et al. Systemic lupus erythematosus: a review of 
clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on 
demographic subsets. Medicine (Baltimore) 1985;64:285-95. 
148. Smolen JS, Klippel JH, Penner E, et al. HLA-DR antigens in systemic lupus 
erythematosus: association with specificity of autoantibody responses to nuclear antigens. 
Ann Rheum Dis 1987;46:457-62. 
149. Graham RR, Ortmann W, Rodine P, et al. Specific combinations of HLA-DR2 and DR3 
class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in 
human SLE. Eur J Hum Genet 2007;15:823-30. 
 221 
150. Galeazzi M, Sebastiani GD, Morozzi G, et al. HLA class II DNA typing in a large series of 
European patients with systemic lupus erythematosus: correlations with clinical and 
autoantibody subsets. Medicine (Baltimore) 2002;81:169-78. 
151. Hamilton RG, Harley JB, Bias WB, et al. Two Ro (SS-A) autoantibody responses in 
systemic lupus erythematosus: correlation of HLA-DR/DQ specificities with quantitative 
expression of Ro (SS-A) autoantibody. Arthritis Rheum 1988;31:496-505. 
152. McHugh NJ, Maddison PJ, Savi M, et al. HLA-DR antigens and anticardiolipin antibodies 
in patients with systemic lupus erythematosus. Arthritis Rheum 1989;32:1623-4. 
153. Watson RM, Lane AT, Barnett NK, Bias WB, Arnett FC, Provost TT. Neonatal lupus 
erythematosus. A clinical, serological and immunogenetic study with review of the 
literature. Medicine (Baltimore) 1984;63:362-78. 
154. Sontheimer RD, Stastny P, Gilliam JN. Human histocompatibility antigen associations in 
subacute cutaneous lupus erythematosus. J Clin Invest 1981;67:312-6. 
155. Provost TT, Talal N, Bias W, Harley JB, Reichlin M, Alexander EL. Ro(SS-A) Positive 
Sjogren's/Lupus Erythematosus (SC/LE) Overlap Patients Are Associated with the HLA-
DR3 and/or DRw6 Phenotypes. J Invest Dermatol 1988;91:369-71. 
156. Arnett FC, Thiagarajan P, Ahn C, Reveille JD. Associations of anti-β2-glycoprotein I 
autoantibodies with HLA class II alleles in three ethnic groups. Arthritis Rheum 
1999;42:268-74. 
157. Galeazzi M, Sebastiani GD, Tincani A, et al. HLA class II alleles associations of 
anticardiolipin and anti-b2GPI antibodies in a large series of European patients with 
systemic lupus erythematosus. Lupus 2000;9:47-55. 
158. Hartung K, Coldewey R, Corvetta A, et al. MHC gene products and anticardiolipin 
antibodies in systemic lupus erythematosus Results of a multicenter study. Autoimmunity 
1992;13:95-9. 
159. Arnett FC, Olsen ML, Anderson KL, Reveille JD. Molecular analysis of major 
histocompatibility complex alleles associated with the lupus anticoagulant. J Clin Invest 
1991;87:1490-95. 
160. Harley JB, Alarcon-Riquelme ME, Criswell LA, et al. Genome-wide association scan in 
women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, 
PXK, KIAA1542 and other loci. Nat Genet 2008;40:204-10. 
161. Hall JC, Rosen A. Type I interferons: crucial participants in disease amplification in 
autoimmunity. Nat Rev Rheumatol 2010;6:40-9. 
162. Karageorgas TP, Tseronis DD, Mavragani CP. Activation of type I interferon pathway in 
systemic lupus erythematosus: association with distinct clinical phenotypes. J Biomed 
Biotechnol 2011:doi:10.1155/2011/273907. 
163. Kirou KA, Lee C, George S, Louca K, Peterson MGE, Crow MK. Activation of the 
interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with 
distinct serologic features and active disease. Arthritis Rheum 2005;52:1491-503. 
 222 
164. Lee H-S, Bae S-C. What can we learn from genetic studies of systemic lupus 
erythematosus? Implications of genetic heterogeneity among populations in SLE. Lupus 
2010;19:1452-9. 
165. Ramos PS, Brown EE, Kimberly RP, Langefeld CD. Genetic factors predisposing to 
systemic lupus erythematosus and lupus nephritis. Semin Nephrol 2010;30:164-76. 
166. Graham RR, Hom G, Ortmann W, Behrens TW. Review of recent genome-wide 
association scans in lupus. J Intern Med 2009;265:680-8. 
167. Niewold TB, Kelly JA, Kariuki SN, et al. IRF5 haplotypes demonstrate diverse serological 
associations which predict serum interferon-a activity and explain the majority of the 
genetic association with systemic lupus erythematosus. Ann Rheum Dis 2012;71:463-9. 
168. Graham RR, Kyogoku C, Sigurdsson S, et al. Three functional variants of IFN regulatory 
factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci 
USA 2007;104:6758-63. 
169. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK. Association of the 
IRF5 risk haplotype with high serum interferon-α activity in systemic lupus erythematosus 
patients. Arthritis Rheum 2008;58:2481-7. 
170. Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O'Shea JJ. Signaling by IL-12 
and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 2004;202:139-56. 
171. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and 
systemic lupus erythematosus. N Engl J Med 2007;357:977-86. 
172. Taylor KE, Remmers EF, Lee AT, et al. Specificity of the STAT4 genetic association for 
severe disease manifestations of systemic lupus erythematosus. PloS Genet 
2008;4:e1000084. 
173. Rhodes B, Vyse TJ. The genetics of SLE: an update in the light of genome-wide 
association studies. Rheumatology (Oxford) 2008;47:1603-11. 
174. Järvinen TM, Hellquist A, Koskenmies S, et al. Polymorphisms of the ITGAM gene confer 
higher risk of discoid cutaneous than of systemic lupus erythematosus. PLoS ONE 
2010;5:e14212. 
175. Kuhn A, Rondinone R, Doria A, Shoenfeld Y. 1st International Conference on Cutaneous 
Lupus Erythematosus Düsseldorf, Germany, September 1–5, 2004. Autoimmun Rev 
2005;4:66-78. 
176. Taylor KE, Chung SA, Graham RR, et al. Risk alleles for systemic lupus erythematosus in 
a large case-control collection and associations with clinical subphenotypes. PloS Genet 
2011;7:e1001311. 
177. Hom G, Graham RR, Modrek B, et al. Association of systemic lupus erythematosus with 
C8orf13–BLK and ITGAM–ITGAX. N Engl J Med 2008;358:900-9. 
178. Coornaert B, Carpentier I, Beyaert R. A20: central gatekeeper in inflammation and 
immunity. J Biol Chem 2009;284:8217-21. 
 223 
179. Savi M, Ferraccioli GF, Neri TM, et al. HLA-DR antigens and anticardiolipin antibodies in 
northern Italian systemic lupus erythematosus patients. Arthritis Rheum 1988;31:1568-70. 
180. Racila DM, Sontheimer CJ, Sheffield A, Wisnieski JJ, Racila E, Sontheimer RD. 
Homozygous single nucleotide polymorphism of the complement C1QA gene is associated 
with decreased levels of C1q in patients with subacute cutaneous lupus erythematosus. 
Lupus 2003;12:124-32. 
181. Karassa FB, Trikalinos TA, Ioannidis JPA. The FcgRIIIA-F158 allele is a risk factor for 
the development of lupus nephritis: a meta-analysis. Kidney Int 2003;63:1475-82. 
182. Manger K, Repp R, Jansen M, et al. Fcγ receptor IIa, IIIa, and IIIb polymorphisms in 
German patients with systemic lupus erythematosus: association with clinical symptoms. 
Ann Rheum Dis 2002;61:786-92. 
183. Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR. Lupus erythematosus in 
the 1980s: a survey of 570 patients. Semin Arthritis Rheum 1991;21:55-64. 
184. Bywaters EGL. Jaccoud's syndrome. A sequel to the joint involvement of systemic lupus 
erythematosus. Clin Rheum Dis 1975;1:125-48. 
185. van Vugt RM, Derksen RHWM, Kater L, Bijlsma JWJ. Deforming arthropathy or lupus 
and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis 1998;57:540-4. 
186. Spronk PE, ter Borg EJ, Kallenberg CG. Patients with systemic lupus erythematosus and 
Jaccoud's arthropathy: a clinical subset with an increased C reactive protein response? Ann 
Rheum Dis 1992;51:358-61. 
187. Mediwake R, Isenberg DA, Schellekens GA, van Venrooij WJ. Use of anti-citrullinated 
peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with 
systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 2001;60:67-8. 
188. Labowitz R, Schumacher HRJ. Articular manifestations of systemic lupus erythematosus. 
Ann Intern Med 1971;74:9211-21. 
189. Alarcon-Segovia D, Abud-Mendoza C, Diaz-Jouanen E, Iglesias A, De los Reyes V, 
Hernandez-Ortiz J. Deforming arthropathy of the hands in systemic lupus erythematosus. J 
Rheumatol 1988;15:65-9. 
190. Cohen MG, Webb J. Concurrence of rheumatoid arthritis and systemic lupus 
erythematosus: report of 11 cases. Ann Rheum Dis 1987;46:853-8. 
191. Panush RS, Edwards NL, Longley S, Webster E. 'Rhupus' syndrome. Arch Intern Med 
1988;148:1633-6. 
192. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An 
American College of Rheumatology/European League Against Rheumatism collaborative 
initiative. Arthritis Rheum 2010;62:2569-81. 
193. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 
revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-
24. 
 224 
194. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an 
American College of Rheumatology/European League Against Rheumatism collaborative 
initiative. Ann Rheum Dis 2010;69:1580-8. 
195. Bridges SL. Update on autoantibodies in rheumatoid arthritis. Curr Rheumatol Rep 
2004;6:343-50. 
196. Rantapää-Dahlqvist S, de Jong BAW, Berglin E, et al. Antibodies against cyclic 
citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid 
arthritis. Arthritis Rheum 2003;48:2741-9. 
197. van der Linden MPM, van der Woude D, Ioan-Facsinay A, et al. Value of anti–modified 
citrullinated vimentin and third-generation anti–cyclic citrullinated peptide compared with 
second-generation anti–cyclic citrullinated peptide and rheumatoid factor in predicting 
disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 
2009;60:2232-41. 
198. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic 
citrullinated peptides predict progression to rheumatoid arthritis in patients with 
undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50:709-15. 
199. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid 
arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155 
- 63. 
200. Korendowych E, Owen P, Ravindran J, Carmichael C, McHugh N. The clinical and genetic 
associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. 
Rheumatology 2005;44:1056-60. 
201. Kasapcopur O, Altun S, Aslan M, et al. Diagnostic accuracy of anti-cyclic citrullinated 
peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1687-9. 
202. van der Helm-van Mil A, Verpoort K, Breedveld F, Toes R, Huizinga T. Antibodies to 
citrullinated proteins and differences in clinical progression of rheumatoid arthritis. 
Arthritis Res Ther 2005;7:R949 - R58. 
203. Martinez JB, Valero JS, Bautista AJ, et al. Erosive arthropathy: clinical variance in lupus 
erythematosus and association with anti-CCP case series and review of the literature. Clin 
Exp Rheumatol 2007;25:47-53. 
204. Mewar D, Coote A, Moore D, et al. Independent associations of anti-cyclic citrullinated 
peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. 
Arthritis Res Ther 2006;8:R128. 
205. van der Helm-van Mil AHM, Verpoort KN, Breedveld FC, Huizinga TWJ, Toes REM, de 
Vries RRP. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-
cyclic citrullinated peptide antibodies and are not an independent risk factor for 
development of rheumatoid arthritis. Arthritis Rheum 2006;54:1117-21. 
206. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. Cutting Edge: The 
conversion of arginine to citrulline allows for a high-affinity peptide interaction with the 
 225 
rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 
2003;171:538-41. 
207. Wagner U, Kaltenhäuser S, Sauer H, et al. HLA markers and prediction of clinical course 
and outcome in rheumatoid arthritis. Arthritis Rheum 1997;40:341-51. 
208. Huizinga TWJ, Amos CI, van der Helm-van Mil AHM, et al. Refining the complex 
rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for 
antibodies to citrullinated proteins. Arthritis Rheum 2005;52:3433-8. 
209. van Gaalen FA, van Aken J, Huizinga TWJ, et al. Association between HLA class II genes 
and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of 
rheumatoid arthritis. Arthritis Rheum 2004;50:2113-21. 
210. Ramos PS, Criswell LA, Moser KL, et al. A comprehensive analysis of shared loci 
between systemic lupus erythematosus (SLE) and sixteen autoimmune diseases reveals 
limited genetic overlap. PloS Genet 2011;7:e1002406. 
211. Orozco G, Eyre S, Hinks A, et al. Study of the common genetic background for rheumatoid 
arthritis and systemic lupus erythematosus. Ann Rheum Dis 2011;70:463-8. 
212. Matmati M, Jacques P, Maelfait J, et al. A20 (TNFAIP3) deficiency in myeloid cells 
triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet 2011;43:908-12. 
213. Nordang GBN, Viken MK, Amundsen SS, et al. Interferon regulatory factor 5 gene 
polymorphism confers risk to several rheumatic diseases and correlates with expression of 
alternative thymic transcripts. Rheumatology (Oxford) 
2011:doi:10.1093/rheumatology/ker364. 
214. Merrell M, Shulman LE. Determination of prognosis in chronic disease, illustrated by 
systemic lupus erythematosus. J Chronic Dis 1955;1:12-32. 
215. Ginzler EM, Diamond HS, Weiner M, et al. A multicenter study of outcome in systemic 
lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum 
1982;25:601-11. 
216. Wallace DJ, Podell T, Weiner J, Klinenberg JR, Forouzesh S, Dubois EL. Systemic lupus 
erythematosus - survival patterns: experience with 609 patients. JAMA 1981;245:934-8. 
217. Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus 
nephritis and its treatment. QJM 1999;92:211-8. 
218. Tucker LB, Menon S, Schaller JG, Isenberg DA. Adult- and childhood-onset sytemic lupus 
erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J 
Rheumatol 1995;34:866-72. 
219. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus 
erythematosus. Results from a single center. I. Causes of death. J Rheumatol 
1995;22:1259-64. 
220. Ståhl-Hallengren C, Jönsen A, Nived O, Sturfelt G. Incidence studies of systemic lupus 
erythematosus in Southern Sweden: increasing age, decreasing frequency of renal 
manifestations and good prognosis. J Rheumatol 2000;27:685-91. 
 226 
221. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus 
erythematosus during a 10-year period: a comparison of early and late manifestations in a 
cohort of 1,000 patients. Medicine (Baltimore) 2003;82:299-308. 
222. Alamanos Y, Voulgari PV, Siozos C, et al. Epidemiology of systemic lupus erythematosus 
in northwest Greece 1982-2001. J Rheumatol 2003;30:731-5. 
223. Pons-Estel BA, Catoggio LJ, Cardiel MH, et al. The GLADEL multinational Latin 
American prospective inception cohort of 1,214 patients with systemic lupus 
erythematosus: ethnic and disease heterogeneity among "Hispanics". Medicine (Baltimore) 
2004;83:1-17. 
224. Nossent J, Kiss E, Rozman B, et al. Disease activity and damage accrual during the early 
disease course in a multinational inception cohort of patients with systemic lupus 
erythematosus. Lupus 2010;19:949-56. 
225. Uramoto KM, Michet CJ, Jr, Thumboo J, Sunku J, O'Fallon WM, Gabriel SE. Trends in 
the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 
1999;42:46-50. 
226. Moss KE, Ioannou Y, Sultan SM, Haq I, Isenberg DA. Outcome of a cohort of 300 patients 
with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann 
Rheum Dis 2002;61:409-13. 
227. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. 
Arthritis Rheum 2006;54:2550-7. 
228. Campbell R, Jr., Cooper GS, Gilkeson GS. Two aspects of the clinical and humanistic 
burden of systemic lupus erythematosus: mortality risk and quality of life early in the 
course of disease. Arthritis Care Res 2008;59:458-64. 
229. Urowitz MB, Gladman DD, Tom BDM, Ibañez D, Farewell VT. Changing patterns in 
mortality and disease outcomes for patients with systemic lupus erythematosus. J 
Rheumatol 2008;35:2152-8. 
230. Rosner S, Ginzler EM, Diamond HS, et al. A multicenter study of outcome in systemic 
lupus erythematosus. II. Causes of death. Arthritis Rheum 1982;25:612-7. 
231. Urowitz MB, Bookman AAM, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The 
bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-5. 
232. Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus. Long-
term followup of an inception cohort. Arthritis Rheum 1995;38:1492-9. 
233. Ginzler E, Berg A. Mortality in systemic lupus erythematosus. J Rheumatol 1987;14:218-
22. 
234. Dubois EL. Systemic lupus erythematosus: recent advances in its diagnosis and treatment. 
Ann Intern Med 1956;45:163-84. 
235. Calvo-Alén J, Alarcón GS, Campbell R, Fernández M, Reveille JD, Cooper GS. Lack of 
recording of systemic lupus erythematosus in the death certificates of lupus patients. 
Rheumatology (Oxford) 2005;44:1186-9. 
 227 
236. Björnådal L, Yin L, Granath F, Klareskog L, Ekbom A. Cardiovascular disease a hazard 
despite improved prognosis in patients with systemic lupus erythematosus: results from a 
Swedish population based study 1964-95. J Rheumatol 2004;31:713-9. 
237. Cervera R, Khamashta MA, Shoenfeld Y, et al. Morbidity and mortality in the 
antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 
patients. Ann Rheum Dis 2009;68:1428-32. 
238. Jonsson H, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: a prospective 
study of patients from a defined population. Medicine (Baltimore) 1989;68:141-50. 
239. Jacobsen S, Petersen J, Ullman S, et al. Mortality and causes of death of 513 Danish 
patients with systemic lupus erythematosus. Scand J Rheumatol 1999;28:75-80. 
240. Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic 
lupus erythematosus. Arthritis Rheum 2005;52:1481-90. 
241. Björnådal L, Löfström B, Yin L, Lundberg IE, Ekbom A. Increased cancer incidence in a 
Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 
2002;31:66-71. 
242. Bertoli AM, Alarcón GS, Calvo-Alén J, Fernández M, Vilá LM, Reveille JD. Systemic 
lupus erythematosus in a multiethnic US cohort: clinical features, course, and outcome in 
patients with late-onset disease. Arthritis Rheum 2006;54:1580-7. 
243. Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. 
Medicine (Baltimore) 2006;85:147-56  
244. Reveille JD, Bartolucci A, Alarcón GS. Prognosis in systemic lupus erythematosus. 
Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as 
causes of death. Arthritis Rheum 1990;33:37-48. 
245. Boddaert J, Huong DLT, Amoura Z, Wechsler B, Godeau P, Piette J-C. Late-onset 
systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 
cases in the literature. Medicine (Baltimore) 2004;83:348-59. 
246. Alamanos Y, Voulgari PV, Papassava M, Tsamandouraki K, Drosos AA. Survival and 
mortality rates of systemic lupus erythematosus patients in northwest Greece. Study of a 
21-year incidence cohort. Rheumatology (Oxford) 2003;42:1122-3. 
247. Doria A, Iaccarino L, Ghirardello A, et al. Long-term prognosis and causes of death in 
systemic lupus erythematosus. Am J Med 2006;119:700-6. 
248. Studenski S, Allen NB, Caldwell DS, Rice JR, Polisson RP. Survival in systemic lupus 
erythematosus. A multivariate analysis of demographic factors. Arthritis Rheum 
1987;30:1326-32. 
249. Alarcón GS, McGwin G, Jr, Bastian HM, et al. Systemic lupus erythematosus in three 
ethnic groups. VIII. Predictors of early mortality in the LUMINA cohort. Arthritis Care 
Res 2001;45:191-202. 
 228 
250. Ward MM. Education level and mortality in systemic lupus erythematosus (SLE): evidence 
of underascertainment of deaths due to SLE in ethnic minorities with low education levels. 
Arthritis Care Res 2004;51:616-24. 
251. Andrade RM, Alarcón GS, Fernández M, et al. Accelerated damage accrual among men 
with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis 
Rheum 2007;56:622-30. 
252. Soto ME, Vallejo M, Guillén F, Simón JA, Arena E, Reyes PA. Gender impact in systemic 
lupus erythematosus. Clin Exp Rheumatol 2004;22:713-21. 
253. Ruiz-Irastorza G, Egurbide M-V, Ugalde J, Aguirre C. High impact of antiphospholipid 
syndrome on irreversible organ damage and survival of patients with systemic lupus 
erythematosus. Arch Intern Med 2004;164:77-82. 
254. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus 
erythematosus. Results from a single center. II. Predictor variables for mortality. J 
Rheumatol 1995;22:1265-70. 
255. Cook RJ, Gladman DD, Pericak D, Urowitz MB. Prediction of short term mortality in 
systemic lupus erythematosus with time dependent measures of disease activity. J 
Rheumatol 2000;27:1892-5. 
256. Ward MM, Pyun E, Studenski S. Mortality risks associated with specific clinical 
manifestations of systemic lupus erythematosus. Arch Intern Med 1996;156:1337-44. 
257. Seleznick MJ, Fries JF. Variables associated with decreased survival in systemic lupus 
erythematosus. Semin Arthritis Rheum 1991;21:73-80. 
258. Jacobsen S, Petersen J, Ullman S, et al. A multicentre study of 513 Danish patients with 
systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic 
value. Clin Rheumatol 1998;17:478-84. 
259. Drenkard C, Villa AR, Alarcón-Segovia D, Pérez-Vázquez ME. Influence of the 
antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. J 
Rheumatol 1994;21:1067-72. 
260. Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by 
the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. 
Lupus 2001;10:93-6. 
261. Chambers SA, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of 
British patients with systemic lupus erythematosus followed up for over 10 years. 
Rheumatology (Oxford) 2009;48:673-5. 
262. Danila MI, Pons-Estel GJ, Zhang J, Vila LM, Reveille JD, Alarcon GS. Renal damage is 
the most important predictor of mortality within the damage index: data from LUMINA 
LXIV, a multiethnic US cohort. Rheumatology (Oxford) 2009;48:542-5. 
263. Mok CC, Ho CTK, Wong RWS, Lau CS. Damage accrual in southern Chinese patients 
with systemic lupus erythematosus. J Rheumatol 2003;30:1513-9. 
 229 
264. Gladman DD, Goldsmith CH, Urowitz MB, et al. The Systemic Lupus International 
Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index 
for systemic lupus erythematosus international comparison. J Rheumatol 2000;27:373-6. 
265. Nived O, Jönsen A, Bengtsson AA, Bengtsson C, Sturfelt G. High predictive value of the 
Systemic Lupus International Collaborating Clinics/American College of Rheumatology 
Damage Index for survival in systemic lupus erythematosus. J Rheumatol 2002;29:1398-
400. 
266. Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and 
pulmonary organ scores are predictors of severe outcome in patients with systemic lupus 
erythematosus. Rheumatology (Oxford) 1996;35:248-54. 
267. Kiani AN, Post WS, Magder LS, Petri M. Predictors of progression in atherosclerosis over 
2 years in systemic lupus erythematosus. Rheumatology (Oxford) 2011;50:2071-9. 
268. Alarcón GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival 
of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US 
cohort (LUMINA L). Ann Rheum Dis 2007;66:1168-72. 
269. Shinjo SK, Bonfá E, Wojdyla D, et al. Antimalarial treatment may have a time-dependent 
effect on lupus survival: data from a multinational Latin American inception cohort. 
Arthritis Rheum 2010;62:855-62. 
270. Gómez J, Suárez A, Lopez P, Mozo L, Diaz JB, Gutierrez C. Systemic lupus 
erythematosus in Asturias, Spain: clinical and serologic features. Medicine (Baltimore) 
2006;85:157-68. 
271. Gulko PS, Reveille JD, Koopman WJ, Burgard SL, Bartolucci AA, Alarcón GS. 
Anticardiolipin antibodies in systemic lupus erythematosus: clinical correlates, HLA 
associations, and impact on survival. J Rheumatol 1993;20:1684-93. 
272. Houman MH, Smiti-Khanfir M, Ghorbell IB, Miled M. Systemic lupus erythematosus in 
Tunisia: demographic and clinical analysis of 100 patients. Lupus 2004;13:204-11. 
273. Jouhikainen T, Stephansson E, Leirisalo-Repo M. Lupus anticoagulant as a prognostic 
marker in systemic lupus erythematosus. Rheumatology (Oxford) 1993;32:568-73. 
274. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes 
induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med 
1975;58:243-64. 
275. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail 
to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis 
Rheum 2001;44:2331-7. 
276. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery 
disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-9. 
277. Urowitz MB, Ibañez D, Gladman DD. Atherosclerotic vascular events in a single large 
lupus cohort: prevalence and risk factors. J Rheumatol 2007;34:70-5. 
 230 
278. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial 
infarction and angina in women with systemic lupus erythematosus: comparison with the 
Framingham Study. Am J Epidemiol 1997;145:408-15. 
279. Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of rheumatoid arthritis or 
systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J 
Cardiol 2004;93:198-200. 
280. Hak AE, Karlson EW, Feskanich D, Stampfer MJ, Costenbader KH. Systemic lupus 
erythematosus and the risk of cardiovascular disease: Results from the Nurses' Health 
Study. Arthritis Care Res 2009;61:1396-402. 
281. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in 
women with systemic lupus erythematosus. Arthritis Rheum 1999;42:338-46. 
282. Shah MA, Shah AM, Krishnan E. Poor outcomes after acute myocardial infarction in 
systemic lupus erythematosus. J Rheumatol 2009;36:570-5. 
283. Urowitz MB, Gladman D, Ibañez D, et al. Atherosclerotic vascular events in a 
multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res 
2010;62:881-7. 
284. Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol 
1987;14:223-6. 
285. Bessant R, Duncan R, Ambler G, et al. Prevalence of conventional and lupus-specific risk 
factors for cardiovascular disease in patients with systemic lupus erythematosus: a case–
control study. Arthritis Care Res 2006;55:892-9. 
286. Haque S, Gordon C, Isenberg D, et al. Risk factors for clinical coronary heart disease in 
systemic lupus erythematosus: the Lupus and Atherosclerosis Evaluation of Risk (LASER) 
Study. J Rheumatol 2010;37:322-9. 
287. Mikdashi J, Handwerger B, Langenberg P, Miller M, Kittner S. Baseline disease activity, 
hyperlipidemia, and hypertension are predictive factors for iIschemic stroke and stroke 
severity in systemic lupus erythematosus. Stroke 2007;38:281-5. 
288. Goldberg RJ, Urowitz MB, Ibanez D, Nikpour M, Gladman DD. Risk factors for 
development of coronary artery disease in women with systemic lupus erythematosus. J 
Rheumatol 2009;36:2454-61. 
289. Svenungsson E, Jensen-Urstad K, Heimburger M, et al. Risk factors for cardiovascular 
disease in systemic lupus erythematosus. Circulation 2001;104:1887-93. 
290. Holvoet P, Mertens A, Verhamme P, et al. Circulating oxidized LDL is a useful marker for 
identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 
2001;21:844-8. 
291. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein and 
coronary artery disease. N Engl J Med 2005;353:46-57. 
 231 
292. Frostegård J, Svenungsson E, Wu R, et al. Lipid peroxidation is enhanced in patients with 
systemic lupus erythematosus and is associated with arterial and renal disease 
manifestations. Arthritis Rheum 2005;52:192-200. 
293. Bessant R, Hingorani A, Patel L, MacGregor A, Isenberg DA, Rahman A. Risk of coronary 
heart disease and stroke in a large British cohort of patients with systemic lupus 
erythematosus. Rheumatology (Oxford) 2004;43:924-9. 
294. Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J, Jr. Contribution of traditional 
risk factors to coronary artery disease in patients with systemic lupus erythematosus. J 
Rheumatol 1999;26:2363-8. 
295. Karp I, Abrahamowicz M, Fortin PR, et al. Recent corticosteroid use and recent disease 
activity: independent determinants of coronary heart disease risk factors in systemic lupus 
erythematosus? Arthritis Care Res 2008;59:169-75. 
296. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the 
Hopkins Lupus Cohort. Lupus 2000;9:170-5. 
297. Bruce IN, Urowitz MB, Gladman DD, Ibañez D, Steiner G. Risk factors for coronary heart 
disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. 
Arthritis Rheum 2003;48:3159-67. 
298. Chung CP, Avalos I, Oeser A, et al. High prevalence of the metabolic syndrome in patients 
with systemic lupus erythematosus: association with disease characteristics and 
cardiovascular risk factors. Ann Rheum Dis 2007;66:208-14. 
299. Telles RW, Lanna CCD, Ferreira GA, Ribeiro AL. Metabolic syndrome in patients with 
systemic lupus erythematosus: association with traditional risk factors for coronary heart 
disease and lupus characteristics. Lupus 2010;19:803-9. 
300. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a 
joint interim statement of the International Diabetes Federation Task Force on 
Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart 
Association; World Heart Federation; International Atherosclerosis Society; and 
International Association for the Study of Obesity. Circulation 2009;120:1640-5. 
301. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26. 
302. Skalen K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic 
lipoproteins in early atherosclerosis. Nature 2002;417:750-4. 
303. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin 
Invest 1991;88:1785-92. 
304. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 
2001;21:1876-90. 
305. Cockerill GW, Rye K-A, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins 
inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler 
Thromb Vasc Biol 1995;15:1987-94. 
 232 
306. Navab M, Imes SS, Hama SY, et al. Monocyte transmigration induced by modification of 
low density lipoprotein in cocultures of human aortic wall cells is due to induction of 
monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J 
Clin Invest 1991;88:2039-46. 
307. Hansson GK. Inflammation, Atherosclerosis, and Coronary Artery Disease. N Engl J Med 
2005;352:1685-95. 
308. Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and 
intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions 
of the Council on Arteriosclerosis, American Heart Association. Circulation 1994;89:2462-
78. 
309. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 
2011;17:1410-22. 
310. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J 
Intern Med 2008;263:517-27. 
311. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular 
biology. Circ Res 2004;95:343-53. 
312. Hill JM, Zalos G, Halcox JPJ, et al. Circulating endothelial progenitor cells, vascular 
function, and cardiovascular risk. N Engl J Med 2003;348:593-600. 
313. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and 
cardiovascular outcomes. N Engl J Med 2005;353:999-1007. 
314. Schmidt-Lucke C, Rossig L, Fichtlscherer S, et al. Reduced number of circulating 
endothelial progenitor cells predicts future cardiovascular events: proof of concept for the 
clinical importance of endogenous vascular repair. Circulation 2005;111:2981-7. 
315. Rajagopalan S, Somers EC, Brook RD, et al. Endothelial cell apoptosis in systemic lupus 
erythematosus: a common pathway for abnormal vascular function and thrombosis 
propensity. Blood 2004;103:3677-83. 
316. Lima DSN, Sato EI, Lima VC, Miranda FJ, Hatta FH. Brachial endothelial function is 
impaired in patients with systemic lupus erythematosus. J Rheumatol 2002;29:292-7. 
317. Piper MK, Raza K, Nuttall SL, et al. Impaired endothelial function in systemic lupus 
erythematosus. Lupus 2007;16:84-8. 
318. Valdivielso P, Gómez-Doblas JJ, Macias M, et al. Lupus-associated endothelial 
dysfunction, disease activity and arteriosclerosis. Clin Exp Rheumatol 2008;26:827-33. 
319. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator 
dysfunction on adverse long-term outcome of coronary heart disease. Circulation 
2000;101:1899-906. 
320. Al Suwaidi J, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Jr, Lerman A. Long-
term follow-up of patients with mild coronary artery disease and endothelial dysfunction. 
Circulation 2000;101:948-54. 
 233 
321. Moonen J, de Leeuw K, van Seijen X, et al. Reduced number and impaired function of 
circulating progenitor cells in patients with systemic lupus erythematosus. Arthritis Res 
Ther 2007;9:R84. 
322. Denny MF, Thacker S, Mehta H, et al. Interferon-alpha promotes abnormal vasculogenesis 
in lupus: a potential pathway for premature atherosclerosis. Blood 2007;110:2907-15. 
323. Westerweel PE, Luijten RKMAC, Hoefer IE, Koomans HA, Derksen RH, Verhaar MC. 
Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus 
erythematosus. Ann Rheum Dis 2007;66:865-70. 
324. Lee PY, Li Y, Richards HB, et al. Type I interferon as a novel risk factor for endothelial 
progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. 
Arthritis Rheum 2007;56:3759-69. 
325. Grisar J, Steiner CW, Bonelli M, et al. Systemic lupus erythematosus patients exhibit 
functional deficiencies of endothelial progenitor cells. Rheumatology (Oxford) 
2008;47:1476-83. 
326. Ferro D, Pittoni V, Quintarelli C, et al. Coexistence of anti-phospholipid antibodies and 
endothelial perturbation in systemic lupus erythematosus patients with ongoing 
prothrombotic state. Circulation 1997;95:1425-32. 
327. Renaudineau Y, Dugué C, Dueymes M, Youinou P. Antiendothelial cell antibodies in 
systemic lupus erythematosus. Autoimmun Rev 2002;1:365-72. 
328. Navarro M, Cervera R, Font J, et al. Anti-endothelial cell antibodies in systemic 
autoimmune diseases: prevalence and clinical significance. Lupus 1997;6:521-6. 
329. Dieudé M, Senécal J-L, Raymond Y. Induction of endothelial cell apoptosis by heat-shock 
protein 60–reactive antibodies from anti–endothelial cell autoantibody–positive systemic 
lupus erythematosus patients. Arthritis Rheum 2004;50:3221-31. 
330. Williams JM, Colman R, Brookes CJ, Savage CO, Harper L. Anti-endothelial cell 
antibodies from lupus patients bind to apoptotic endothelial cells promoting macrophage 
phagocytosis but do not induce apoptosis. Rheumatology (Oxford) 2005;44:879-84. 
331. Netea MG, van der Graaf C, Van der Meer JWM, Kullberg BJ. Toll-like receptors and the 
host defense against microbial pathogens: bringing specificity to the innate-immune 
system. J Leukoc Biol 2004;75:749-55. 
332. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004;16:3-9. 
333. Rahman AH, Eisenberg RA. The role of toll-like receptors in systemic lupus 
erythematosus. Springer Semin Immunopathol 2006;28:131-43. 
334. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005;17:1-14. 
335. Huang QQ, Pope RM. Toll-like receptor signaling: a potential link among rheumatoid 
arthritis, systemic lupus, and atherosclerosis. J Leukoc Biol 2010;88:253-62. 
336. Wong CK, Wong PTY, Tam LS, Li EK, Chen DP, Lam CWK. Activation profile of Toll-
like receptors of peripheral blood lymphocytes in patients with systemic lupus 
erythematosus. Clin Exp Immunol 2010;159:11-22. 
 234 
337. Edfeldt K, Swedenborg J, Hansson GK, Yan Z-q. Expression of Toll-like receptors in 
human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 
2002;105:1158-61. 
338. Bjorkbacka H, Kunjathoor VV, Moore KJ, et al. Reduced atherosclerosis in MyD88-null 
mice links elevated serum cholesterol levels to activation of innate immunity signaling 
pathways. Nat Med 2004;10:416-21. 
339. Michelsen KS, Wong MH, Shah PK, et al. Lack of Toll-like receptor 4 or myeloid 
differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice 
deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004;101:10679-84. 
340. Niessner A, Shin MS, Pryshchep O, Goronzy JJ, Chaikof EL, Weyand CM. Synergistic 
proinflammatory effects of the antiviral cytokine interferon-α and Toll-like receptor 4 
ligands in the atherosclerotic plaque. Circulation 2007;116:2043-52. 
341. Li J, Fu Q, Cui H, et al. Interferon-α priming promotes lipid uptake and macrophage-
derived foam cell formation: a novel link between interferon-α and atherosclerosis in lupus. 
Arthritis Rheum 2011;63:492-502. 
342. Sidhu PS, Desai SR. A simple and reproducible method for assessing intimal-medial 
thickness of the common carotid artery. Br J Radiol 1997;70:85-9. 
343. Li R, Duncan BB, Metcalf PA, et al. B-mode-detected carotid artery plaque in a general 
population. Stroke 1994;25:2377-83. 
344. Spence JD, Hegele RA. Noninvasive phenotypes of atherosclerosis. Stroke 2004;35:649-
53. 
345. Simon A, Megnien J-L, Chironi G. The value of carotid intima-media thickness for 
predicting cardiovascular risk. Arterioscler Thromb Vasc Biol 2010;30:182-5. 
346. Simon A, Chironi G, Levenson J. Comparative performance of subclinical atherosclerosis 
tests in predicting coronary heart disease in asymptomatic individuals. Eur Heart J 
2007;28:2967-71. 
347. Cobble M, Bale B. Carotid intima-media thickness: knowledge and application to everyday 
practice. Postgrad Med 2010;122:7-15. 
348. Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical atherosclerosis in a 
prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 
2003;62:1071-7. 
349. Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in 
women with systemic lupus erythematosus. Arthritis Rheum 1999;42:51-60. 
350. Selzer F, Sutton-Tyrrell K, Fitzgerald SG, et al. Comparison of risk factors for vascular 
disease in the carotid artery and aorta in women with systemic lupus erythematosus. 
Arthritis Rheum 2004;50:151-9. 
351. Jiménez S, García CMA, Tàssies D, et al. Preclinical vascular disease in systemic lupus 
erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) 
2005;44:756-61. 
 235 
352. Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic 
lupus erythematosus. Am J Med 2008;121:S3-S8. 
353. Thompson T, Sutton-Tyrrell K, Wildman RP, et al. Progression of carotid intima-media 
thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum 
2008;58:835-42. 
354. de Leeuw K, Smit AJ, de Groot E, van Roon AM, Kallenberg CG, Bijl M. Longitudinal 
study on premature atherosclerosis in patients with systemic lupus erythematosus. 
Atherosclerosis 2009;206:546-50. 
355. Reynolds HR, Buyon J, Kim M, et al. Association of plasma soluble E-selectin and 
adiponectin with carotid plaque in patients with systemic lupus erythematosus. 
Atherosclerosis 2010;210:569-74. 
356. Colombo BM, Murdaca G, Caiti M, et al. Intima-media thickness: a marker of accelerated 
atherosclerosis in women with systemic lupus erythematosus. Ann N Y Acad Sci 
2007;1108:121-6. 
357. Rua-Figueroa I, Arencibia-Mireles O, Elvira M, et al. Factors involved in the progress of 
preclinical atherosclerosis associated with systemic lupus erythematosus: a 2-year 
longitudinal study. Ann Rheum Dis 2010;69:1136-9. 
358. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial 
dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5. 
359. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of 
nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 
1999;399:601-5. 
360. Wright SA, O'Prey FM, Rea DJ, et al. Microcirculatory hemodynamics and endothelial 
dysfunction in systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 
2006;26:2281-7. 
361. El Magadmi M, Bodill H, Ahmad Y, et al. Systemic lupus erythematosus: an independent 
risk factor for endothelial dysfunction in women. Circulation 2004;110:399-404. 
362. McMahon M, Grossman J, Skaggs B, et al. Dysfunctional proinflammatory high-density 
lipoproteins confer increased risk of atherosclerosis in women with systemic lupus 
erythematosus. Arthritis Rheum 2009;60:2428-37. 
363. de Leeuw K, Freire B, Smit AJ, Bootsma H, Kallenberg CG, Bijl M. Traditional and non-
traditional risk factors contribute to the development of accelerated atherosclerosis in 
patients with systemic lupus erythematosus. Lupus 2006;15:675-82. 
364. Maksimowicz-McKinnon K, Magder LS, Petri M. Predictors of carotid atherosclerosis in 
systemic lupus erythematosus. J Rheumatol 2006;33:2458-63. 
365. McMahon M, Skaggs BJ, Sahakian L, et al. High plasma leptin levels confer increased risk 
of atherosclerosis in women with systemic lupus erythematosus, and are associated with 
inflammatory oxidised lipids. Ann Rheum Dis 2011;70:1619-24. 
 236 
366. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: 
insights from mechanistic studies. Lancet 2008;371:1800-9. 
367. Roman MJ, Crow MK, Lockshin MD, et al. Rate and determinants of progress of 
atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007;56:3412-19. 
368. Borba EF, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of 
disease, activity, and anticardiolipin antibodies. Lupus 1997;6:533-9. 
369. Mok CC, Wong CK, To CH, Lai JPS, Lam CS. Effects of rosuvastatin on vascular 
biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-
controlled trial. Arthritis Care Res 2011;63:875-83. 
370. Petri MA, Kiani AN, Post W, Christopher-Stine L, Magder LS. Lupus Atherosclerosis 
Prevention Study (LAPS). Ann Rheum Dis 2011;70:760-5. 
371. Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvastatin in systemic lupus 
erythematosus in children and adolescents. Arthritis Rheum 2012;64:285-96. 
372. Farzaneh-Far A, Roman MJ, Lockshin MD, et al. Relationship of antiphospholipid 
antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis 
Rheum 2006;54:3918-25. 
373. Ilowite NT, Samuel P, Ginzler E, Jacobson MS. Dyslipoproteinemia in pediatric systemic 
lupus erythematosus. Arthritis Rheum 1988;31:859-63. 
374. Batuca JR, Ames PRJ, Amaral M, Favas C, Isenberg DA, Delgado Alves J. Anti-
atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by 
specific antibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2009;48:26-
31. 
375. Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegård J. Elevated 
triglycerides and low levels of high-density lipoprotein as markers of disease activity in 
association with up-regulation of the tumor necrosis factor α/tumor necrosis factor receptor 
system in systemic lupus erythematosus. Arthritis Rheum 2003;48:2533-40. 
376. Svenungsson E, Fei GZ, Jensen-Urstad K, de Faire U, Hamsten A, Frostegard J. TNF-a: a 
link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular 
disease. Lupus 2003;12:454-61. 
377. Borba EF, Carvalho JF, Bonfá E. Mechanisms of dyslipoproteinemias in systemic lupus 
erythematosus. Clin Dev Immunol 2006;13:203-8. 
378. Sarkissian T, Beyene J, Feldman B, McCrindle B, Silverman ED. Longitudinal 
examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis Rheum 
2007;56:631-8. 
379. Formiga F, Meco JF, Pinto X, Jacob J, Moga I, Pujol R. Lipid and lipoprotein levels in 
premenopausal systemic lupus erythematosus patients. Lupus 2001;10:359-63. 
380. Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus 
erythematosus. J Rheumatol 1994;21:1264-7. 
 237 
381. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, 
low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction 
(AMORIS study): a prospective study. Lancet 2001;358:2026-33. 
382. Bruce IN, Urowitz MB, Gladman DD, Hallett D. Natural history of hypercholesterolemia 
in systemic lupus erythematosus. J Rheumatol 1999;26:2137-43. 
383. Ettinger WH, Goldberg AP, Applebaum-Bowden D, Hazzard WR. Dyslipoproteinemia in 
systemic lupus erythematosus: effect of corticosteroids. Am J Med 1987;83:503-8. 
384. Ettinger WH, Jr., Hazzard WR. Elevated apolipoprotein-B levels in corticosteroid-treated 
patients with systemic lupus erythematosus. J Clin Endocrinol Metab 1988;67:425-8. 
385. Sarkissian T, Beyenne J, Feldman B, Adeli K, Silverman E. The complex nature of the 
interaction between disease activity and therapy on the lipid profile in patients with 
pediatric systemic lupus erythematosus. Arthritis Rheum 2006;54:1283-90. 
386. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. 
Am J Cardiol 2000;86:943-9. 
387. Fruchart J-C, Duriez P. HDL and triglyceride as therapeutic targets. Curr Opin Lipidol 
2002;13:605-16. 
388. MacGregor AJ, Dhillon VB, Binder A, et al. Fasting lipids and anticardiolipin antibodies 
as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis 
1992;51:152-5. 
389. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein 
as a protective factor against coronary heart disease. The Framingham Study. Am J Med 
1977;62:707-14. 
390. Morgan J, Carey C, Lincoff A, Capuzzi D. High-density lipoprotein subfractions and risk 
of coronary artery disease. Curr Atheroscler Rep 2004;6:359-65. 
391. Jacobs DR, Jr, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA, For the Lipid Research 
Clinics Program. High density lipoprotein cholesterol as a predictor of cardiovascular 
disease mortality in men and women: the follow-up study of the Lipid Research Clinics 
Prevalence Study. Am J Epidemiol 1990;131:32-47. 
392. Warnick GR, Nauck M, Rifai N. Evolution of methods for measurement of HDL-
cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem 2001;47:1579-96. 
393. Toth P. Reverse cholesterol transport: high-density lipoprotein’s magnificent mile. Curr 
Atheroscler Rep 2003;5:386-93. 
394. Assmann G, Gotto AM. HDL cholesterol and protective factors in atherosclerosis. 
Circulation 2004;109:III-8-III-14. 
395. Mackness MI, Durrington PN, Mackness B. How high-density lipoprotein protects against 
the effects of lipid peroxidation. Curr Opin Lipidol 2000;11:383-8. 
396. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: 
atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011;8:222-32. 
 238 
397. McMahon M, Grossman J, FitzGerald J, et al. Proinflammatory high-density lipoprotein as 
a biomarker for atherosclerosis in patients with systemic lupus erythematosus and 
rheumatoid arthritis. Arthritis Rheum 2006;54:2541-9. 
398. Batuca JR, Ames PRJ, Isenberg DA, Delgado Alves J. Antibodies toward high-density 
lipoprotein components inhibit paraoxonase activity in patients with systemic lupus 
erythematosus. Ann N Y Acad Sci 2007;1108:137-46. 
399. Delgado Alves J, Kumar S, Isenberg DA. Cross-reactivity between anti-cardiolipin, anti-
high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with 
systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 
(Oxford) 2003;42:893-9. 
400. Lahita RG, Rivkin E, Cavanagh I, Romano P. Low levels of total cholesterol, high-density 
lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients 
with systemic lupus erythematosus. Arthritis Rheum 1993;36:1566-74. 
401. Dinu AR, Merrill JR, Shen C, Antonov IV, Myones BL, Lahita RG. Frequency of 
antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. 
Lupus 1998;7:355–60. 
402. Vuilleumier N, Reber G, James R, et al. Presence of autoantibodies to apolipoprotein A-1 
in patients with acute coronary syndrome further links autoimmunity to cardiovascular 
disease. J Autoimmun 2004;23:353-60. 
403. O'Neill SG, Giles I, Lambrianides A, et al. Antibodies to apolipoprotein A-I, high-density 
lipoprotein, and C-reactive protein are associated with disease activity in patients with 
systemic lupus erythematosus. Arthritis Rheum 2010;62:845-54. 
404. Borba EF, Bonfá E, Vinagre CGC, Ramires JAF, Maranhão RC. Chylomicron metabolism 
is markedly altered in systemic lupus erythematosus. Arthritis Rheum 2000;43:1033-40. 
405. Otarod J, Goldberg I. Lipoprotein lipase and its role in regulation of plasma lipoproteins 
and cardiac risk. Curr Atheroscler Rep 2004;6:335-42. 
406. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and 
atherogenesis. J Lipid Res 1996;37:693-707. 
407. Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M. Autoantibodies to 
lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 
2002;46:2957-63. 
408. de Carvalho JF, Borba EF, Viana VST, Bueno C, Leon EP, Bonfá E. Anti–lipoprotein 
lipase antibodies: A new player in the complex atherosclerotic process in systemic lupus 
erythematosus? Arthritis Rheum 2004;50:3610-5. 
409. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk 
factor: current status. Eur Heart J 2010;31:2844-53. 
410. Caplice NM, Panetta C, Peterson TE, et al. Lipoprotein (a) binds and inactivates tissue 
factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 
2001;98:2980-7. 
 239 
411. Deb A, Caplice NM. Lipoprotein(a): New insights into mechanisms of atherogenesis and 
thrombosis. Clin Cardiol 2004;27:258-64. 
412. Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for 
atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 
2004;37:333-43. 
413. Tsimikas S, Kiechl S, Willeit J, et al. Oxidized phospholipids predict the presence and 
progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: 
five-year prospective results from the Bruneck Study. J Am Coll Cardiol 2006;47:2219-28. 
414. Sari RA, Polat MF, Taysi S, Bakan E, Çapoğlu İ. Serum lipoprotein(a) level and its clinical 
significance in patients with systemic lupus erythematosus. Clin Rheumatol 2002;21:520-
4. 
415. Borba EF, Santos RD, Bonfa E, et al. Lipoprotein(a) levels in systemic lupus 
erythematosus. J Rheumatol 1994;21:220-3. 
416. Okawa-Takatsuji M, Aotsuka S, Sumiya M, Ohta H, Kawakami M, Sakurabayashi I. 
Clinical significance of the serum lipoprotein(a) level in patients with systemic lupus 
erythematosus: its elevation during disease flare. Clin Exp Rheumatol 1996;14:531-6. 
417. George J, Harats D, Gilburd B, Levy Y, Langevitz P, Shoenfeld Y. Atherosclerosis-related 
markers in systemic lupus erythematosus patients: the role of humoral immunity in 
enhanced atherogenesis. Lupus 1999;8:220-6. 
418. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary 
Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies' 
guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91:v1-
v52. 
419. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular 
disease and a target for lipid-lowering therapy – a review of the evidence. J Intern Med 
2006;259:493-519. 
420. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk 
markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control 
study. Lancet 2008;372:224-33. 
421. Hoffman IE, Peene I, Cebecauer L, et al. Presence of rheumatoid factor and antibodies to 
citrullinated peptides in systemic lupus erythematosus. Ann Rheum Dis 2005;64:330-2. 
422. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. an approach to 
understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis 
Rheum 1987;30:1205-13. 
423. Damián-Abrego GN, Cabiedes J, Cabral AR. Anti-citrullinated peptide antibodies in lupus 
patients with or without deforming arthropathy. Lupus 2008;17:300-4. 
424. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid 
arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155 
- 63. 
 240 
425. Hochberg MC. Updating the American College of Rheumatology revised criteria for the 
classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725. 
426. Richter Cohen M, Steiner G, Smolen JS, Isenberg DA. Erosive arthritis in systemic lupus 
erythematosus: analysis of a distinct clinical and serological subset. Rheumatology 
1998;37:421-4. 
427. Kaplan D, Ginzler EM, Feldman J. Arthritis and nephritis in patients with systemic lupus 
erythematosus. J Rheumatol 1991 18:233-9. 
428. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic 
citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann 
Rheum Dis 2006;65:845-51. 
429. Bennett RM, O'Connell DJ. The arthritis of mixed connective tissue disease. Ann Rheum 
Dis 1978;37:397-403. 
430. Piirainen HI. Patients with arthritis and anti-U1-RNP antibodies: a 10-year follow-up. 
Rheumatology (Oxford) 1990;29:345-8. 
431. Amezcua-Guerra L, Springall R, Marquez-Velasco R, Gomez-Garcia L, Vargas A, Bojalil 
R. Presence of antibodies against cyclic citrullinated peptides in patients with 'rhupus': a 
cross-sectional study. Arthritis Res Ther 2006;8:R144. 
432. Gorman JD, Lum RF, Chen JJ, Suarez-Almazor ME, Thomson G, Criswell LA. Impact of 
shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 
rheumatoid arthritis patients. Arthritis Rheum 2004;50:400-12. 
433. Vos K, Visser H, Schreuder GMT, et al. Human leukocyte antigen-DQ and DR 
polymorphisms predict rheumatoid arthritis outcome better than DR alone. Hum Immunol 
2001;62:1217-25. 
434. Gourraud P-A, Boyer J-F, Barnetche T, et al. A new classification of HLA-DRB1 alleles 
differentiates predisposing and protective alleles for rheumatoid arthritis structural severity. 
Arthritis Rheum 2006;54:593-9. 
435. Mattey DL, Hassell AB, Dawes PT, et al. Independent association of rheumatoid factor and 
the HLA-DRB1 shared epitope with radiographic outcome in rheumatoid arthritis. Arthritis 
Rheum 2001;44:1529-33. 
436. Verpoort KN, van Gaalen FA, van der Helm-van Mil AHM, et al. Association of HLA-
DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis 
Rheum 2005;52:3058-62. 
437. McHugh NJ, Maymo J, Skinner RP, James I, Maddison PJ. Anticardiolipin antibodies, 
livedo reticularis, and major cerebrovascular and renal disease in systemic lupus 
erythematosus. Ann Rheum Dis 1988;47:110-5. 
438. McClain MT, Arbuckle MR, Heinlen LD, et al. The prevalence, onset, and clinical 
significance of antiphospholipid antibodies prior to diagnosis of systemic lupus 
erythematosus. Arthritis Rheum 2004;50:1226-32. 
 241 
439. Gidez LI, Miller GJ, Burstein M, Slagle S, Eder HA. Separation and quantitation of 
subclasses of human plasma high density lipoproteins by a simple precipitation procedure. 
J Lipid Res 1982;23:1206-23. 
440. Parker B, Ahmad Y, Shelmerdine J, et al. An analysis of the metabolic syndrome 
phenotype in systemic lupus erythematosus. Lupus 2011;20:1459-65. 
441. Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity 
Index 2000. J Rheumatol 2002;29:288-91. 
442. Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus 
International Collaborating Clinics/American College of Rheumatology Damage Index in 
patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-13. 
443. Cervera R, Boffa M-C, Khamashta M, Hughes G. The Euro-Phospholipid project: 
epidemiology of the antiphospholipid syndrome in Europe. Lupus 2009;18:889-93. 
444. Cederholm A, Frostegard J. Annexin A5 in cardiovascular disease and systemic lupus 
erythematosus. Immunobiology 2005;210:761-8. 
445. Haque S, Rakieh C, Edlin H, Ahmad Y, Bruce IN. Atherosclerosis progression in SLE. 
Rheumatology (Oxford) 2011;50:iii40. 
446. Gladman DD, Koh D-R, Urowitz MB, Farewell VT. Lost-to-follow-up study in systemic 
lupus erythematosus (SLE). Lupus 2000;9:363-7. 
447. Zureik M, Ducimetiere P, Touboul P-J, et al. Common carotid intima-media thickness 
predicts occurrence of carotid atherosclerotic plaques: longitudinal results from the Aging 
Vascular Study (EVA) study. Arterioscler Thromb Vasc Biol 2000;20:1622-9. 
448. Zanchetti A, Bond MG, Hennig M, et al. Calcium antagonist lacidipine slows down 
progression of asymptomatic carotid atherosclerosis. Circulation 2002;106:2422-7. 
449. Zanchetti A, Crepaldi G, Bond MG, et al. Different effects of antihypertensive regimens 
based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on 
progression of asymptomatic carotid atherosclerosis. Stroke 2004;35:2807-12. 
450. Cuspidi C, Negri F, Giudici V, Capra A, Sala C. Effects of antihypertensive drugs on 
carotid intima-media thickness: focus on angiotensin II receptor blockers. A review of 
randomized, controlled trials. Integr Blood Press Control 2009;2. 
451. Out HJ, de Groot PG, Hasselaar P, dan Vliet M, Derksen RH. Fluctuations of 
anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective 
study. Ann Rheum Dis 1989;48:1023-8. 
452. Huizinga TWJ, Amos CI, van der Helm-van Mil AHM, et al. Refining the complex 
rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for 
antibodies to citrullinated proteins. Arthritis Rheum 2005;52:3433-8. 
453. Crombie IK, Smith WC, Tavendale R, Tunstall-Pedoe H. Geographical clustering of risk 
factors and lifestyle for coronary heart disease in the Scottish Heart Health Study. Br Heart 
J 1990;64:199-203. 
 242 
454. Betteridge DJ, Dodson PM, Durrington PN, et al. Management of hyperlipidaemia: 
guidelines of the British Hyperlipidaemia Association. Postgrad Med J 1993;69:359-69. 
455. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine 
on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal 




1.  Disease Classification Criteria 
1. 1.  1997 Update of the 1982 American College of Rheumatology (ACR) revised 
criteria for classification of systemic lupus erythematosus8, 425* 
1. Malar Rash  
Fixed erythema, flat or raised, over the malar eminences, tending to spare the 
nasolabial folds  
2. Discoid rash  
Erythematous raised patches with adherent keratotic scaling and follicular 
plugging; atrophic scarring may occur in older lesions  
3. Photosensitivity  
Skin rash as a result of unusual reaction to sunlight, by patient history or 
physician observation  
4. Oral ulcers  Oral or nasopharyngeal ulceration, usually painless, observed by physician 
5. Nonerosive Arthritis  
Involving 2 or more peripheral joints, characterised by tenderness, swelling, or 
effusion  
6. Pleuritis or Pericarditis  
1. Pleuritis - convincing history of pleuritic pain or rubbing heard by a physician 
or evidence of pleural effusion                                                                        OR                                                                                                                                                                                                                                     
2. Pericarditis - documented by electrocardiogram or rub or evidence of 
pericardial effusion  
7. Renal Disorder  
1. Persistent proteinuria > 0.5 grams per day or > 3+ if quantitation not 
performed                                                                                                        OR                                                                                                                                                               
2. Cellular casts - may be red cell, haemoglobin, granular, tubular, or mixed  
8. Neurologic Disorder  
1. Seizures - in the absence of offending drugs or known metabolic 
derangements; e.g., uremia, ketoacidosis, or electrolyte imbalance              OR                                                                                                                                                                
2. Psychosis - in the absence of offending drugs or known metabolic 
derangements, e.g., uraemia, ketoacidosis, or electrolyte imbalance                                      
9. Haematologic Disorder  
1. Haemolytic anemia - with reticulocytosis                                                    OR                                                                                                                                                                                                                                  
2. Leucopenia - < 4,000/mm3 on ≥ 2 occasions                                             OR                                                                                                                                                                                                                                              
3. Lymphopenia - < 1,500/ mm3 on ≥ 2 occasions                                         OR                                                                                                                                                                                                                                           
4. Thrombocytopenia - <100,000/mm3 in the absence of offending drugs  
10. Immunologic Disorder  
1.  Anti-DNA: antibody to native DNA in abnormal titre                                   OR                                                                                                                                                                          
2. Anti-Sm: presence of antibody to Sm nuclear antigen                                OR                                                                                                                                                                                                                  
3. Positive finding of antiphospholipid antibodies on:                                                                  
3.1.  an abnormal serum level of IgG or IgM anticardiolipin antibodies                             
3.2.  a positive test result for lupus anticoagulant using a standard method  OR              
3.3.  a false-positive test result for at least 6 months confirmed by Treponema      
pallidum immobilization or fluorescent treponemal antibody absorption test  
11. Positive Antinuclear 
Antibody  
An abnormal titre of antinuclear antibody by immunofluorescence or an 
equivalent assay at any point in time and in the absence of drugs  
 
* Available from: http://www.rheumatology.org/practice/clinical/forms [Accessed 9 March 2012]. 
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1.2.   2010 ACR/European League Against Rheumatism (EULAR) classification criteria 
for rheumatoid arthritis192, 194*** 
 
Score 
Target population (Who should be tested?):  
Patients                                                                                                                                                                                           
1. who have at least 1 joint with definite clinical synovitis (swelling)*                                                                                                             
2. with the synovitis not better explained by another disease† 
 
Classification criteria for RA (score-based algorithm: add score of categories A–D;      
a score of ≥ 6/10 is needed for classification of a patient as having definite RA‡  
A. Joint involvement§          
 
1 large joint¶ 0 
2 - 10 large joints  1 
1 - 3 small joints (with or without involvement of large joints)# 2 
4 - 10 small joints (with or without involvement of large joints) 3 
> 10 joints (at least 1 small joint)** 5 
B. Serology (at least 1 test result is needed for classification)†† 
 
Negative RF and negative ACPA 0 
Low-positive RF or low-positive ACPA 2 
High-positive RF or high-positive ACPA 3 
C. Acute-phase reactants (at least 1 test result is needed for classification)‡‡ 
 
Normal CRP and normal ESR 0 
Abnormal CRP or abnormal ESR 1 
D. Duration of symptoms§§ 
 
< 6 weeks 0 
≥ 6 weeks 1 
 
*  The criteria are aimed at classification of newly presenting patients. In addition, patients with erosive 
disease typical of rheumatoid arthritis (RA) with a history compatible with prior fulfillment of the 2010 criteria 
should be classified as having RA. Patients with longstanding disease, including those whose disease is 
inactive (with or without treatment) who, based on retrospectively available data, have previously fulfilled the 
2010 criteria should be classified as having RA. 
 
†  Differential diagnoses vary among patients with different presentations, but may include conditions such as 
systemic lupus erythematosus, psoriatic arthritis, and gout. If it is unclear about the relevant differential 
diagnoses to consider, an expert rheumatologist should be consulted. 
 
‡  Although patients with a score of < 6/10 are not classifiable as having RA, their status can be reassessed 
and the criteria might be fulfilled cumulatively over time. 
 
 
§  Joint involvement refers to any swollen or tender joint on examination, which may be confirmed by imaging 
evidence of synovitis. Distal interphalangeal joints, first carpometacarpal joints, and first 
 III 
metatarsophalangeal joints are excluded from assessment.  Categories of joint distribution are classified 
according to the location and number of involved joints, with placement into the highest category possible 
based on the pattern of joint involvement. 
 
¶  "Large joints" refers to shoulders, elbows, hips, knees, and ankles. 
 
# "Small joints" refers to the metacarpophalangeal joints, proximal interphalangeal joints, second through fifth 
metatarsophalangeal joints, thumb interphalangeal joints, and wrists. 
 
** In this category, at least 1 of the involved joints must be a small joint; the other joints can include any 
combination of large and additional small joints, as well as other joints not specifically listed elsewhere (e.g., 
temporomandibular, acromioclavicular, sternoclavicular, etc.). 
 
††  Negative refers to IU values that are less than or equal to the upper limit of normal (ULN) for the laboratory 
and assay; low-positive refers to IU values that are higher than the ULN but ≤3 times the ULN for the 
laboratory and assay; high-positive refers to IU values that are >3 times the ULN for the laboratory and 
assay. Where rheumatoid factor (RF) information is only available as positive or negative, a positive result 
should be scored as low-positive for RF. ACPA = anti-citrullinated protein antibody. 
 
‡‡  Normal/abnormal is determined by local laboratory standards.  CRP = C-reactive protein; ESR = erythrocyte 
sedimentation rate. 
 
§§  Duration of symptoms refers to patient self-report of the duration of signs or symptoms of synovitis (e.g. 
pain, swelling, tenderness) of joints that are clinically involved at the time of assessment, regardless of 
treatment status. 
 
*** Available from: http://www.rheumatology.org/practice/clinical/forms [Accessed 9 March 2012]. 
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1.3.  Revised 1987 ACR criteria for the classification of rheumatoid arthritis193† 
Criterion Definition 
1. Morning stiffness 
Morning stiffness in and around the joints, lasting at least 1 hour 
before maximal improvement  
2. Arthritis of 3 or more joint areas 
At least 3 joint areas simultaneously have had soft tissue swelling 
or fluid (not bony overgrowth alone) observed by a physician. The 
14 possible areas are right or left PIP, MCP, wrist, elbow, knee, 
ankle, and MTP joints  
3. Arthritis of hand joints 
At least 1 area swollen (as defined above) in a wrist, MCP, or PIP 
joint  
4. Symmetric arthritis 
Simultaneous involvement of the same joint areas (as defined in 2) 
on both sides of the body (bilateral involvement of PIPs, MCPs, or 
MTPs is acceptable without absolute symmetry)  
5. Rheumatoid nodules 
Subcutaneous nodules, over bony prominences, or extensor 
surfaces, or in juxta-articular regions, observed by a physician  
6. Serum rheumatoid factor 
Demonstration of abnormal amounts of serum rheumatoid factor 
by any method for which the result has been positive in <5% of 
normal control subjects  
7. Radiographic changes 
Radiographic changes typical of rheumatoid arthritis on 
posteroanterior hand and wrist radiographs, which must include 
erosions or unequivocal bony decalcification localised in or most 
marked adjacent to the involved joints (osteoarthritis changes 
alone do not qualify)  
 
* For classification purposes, a patient shall be said to have rheumatoid arthritis if he/she has satisfied at least 
4 or these 7 criteria. Criteria 1 through 4 must have been present for at least 6 weeks. Patients with 2 
clinical diagnoses are not excluded.  Designation as classic, definite, or probable rheumatoid arthritis is not 
to be made.  
 
†   Available from: http://www.rheumatology.org/practice/clinical/forms [Accessed 9 March 2012]. 
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1.4.  Revised 2006 classification criteria for the antiphospholipid syndrome44 
 
Antiphospholipid antibody syndrome (APS) is present if at least one of the clinical criteria and 
one of the laboratory criteria that follow are met:* 
 
Clinical criteria 
1. Vascular thrombosis† 
One or more clinical episodes‡ of arterial, venous, or small vessel thrombosis§, in any tissue or organ. 
Thrombosis must be confirmed by objective validated criteria (i.e. unequivocal findings of appropriate 
imaging studies or histopathology).  For histopathologic confirmation, thrombosis should be present 
without significant evidence of inflammation in the vessel wall. 
 
2. Pregnancy morbidity 
(a)  One or more unexplained deaths of a morphologically normal fetus at or beyond the 10th week of 
gestation, with normal fetal morphology documented by ultrasound or by direct examination of the 
fetus OR 
(b)  One or more premature births of a morphologically normal neonate before the 34th week of gestation 
because of:  
 (i)   eclampsia or severe pre-eclampsia defined according to standard definitions,    OR 
 (ii)  recognised features of placental insufficiency¶   
      OR 
(c)  Three or more unexplained consecutive spontaneous abortions before the 10th week of gestation, with 
maternal anatomic or hormonal abnormalities and paternal and maternal chromosomal causes 
excluded. 
 
In studies of populations of patients who have more than one type of pregnancy morbidity, investigators are 
strongly encouraged to stratify groups of subjects according to a, b, or c above. 
Laboratory criteria** 
1. Lupus anticoagulant (LA) present in plasma, on two or more occasions at least 12 weeks apart, detected 
according to the guidelines of the International Society on Thrombosis and Haemostasis (Scientific 
Subcommittee on LAs/phospholipid-dependent antibodies). 
2. Anticardiolipin (aCL) antibody of IgG and/or IgM isotype in serum or plasma, present in medium or high 
titre (i.e. > 40 GPL or MPL, or > the 99th percentile), on two or more occasions, at least 12 weeks apart, 
measured by a standardized ELISA.  
3. Anti-β2 glycoprotein-I antibody of IgG and/or IgM isotype in serum or plasma (in titre > the 99th percentile), 
present on two or more occasions, at least 12 weeks apart, measured by a standardized ELISA, according 
to recommended procedures. 
 
* Classification of APS should be avoided if less than 12 weeks or more than 5 years separate the positive 
aPL test and the clinical manifestation. 
 
† Coexisting inherited or acquired factors for thrombosis are not reasons for excluding patients from APS 
trials.  However, two subgroups of APS patients should be recognised, according to:  
      (a) the presence, and  
      (b) the absence of additional risk factors for thrombosis.  
      Indicative (but not exhaustive) such cases include: age (> 55 in men, and > 65 in women), and the presence 
of any of the established risk factors for cardiovascular disease (hypertension, diabetes mellitus, elevated 
LDL or low HDL cholesterol, cigarette smoking, family history of premature cardiovascular disease, body 
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mass index > 30 kg/m2, microalbuminuria, estimated GFR < 60 mL/min), inherited thrombophilias, oral 
contraceptives, nephrotic syndrome, malignancy, immobilisation, and surgery. Thus, patients who fulfil 
criteria should be stratified according to contributing causes of thrombosis.  
 
‡ A thrombotic episode in the past could be considered as a clinical criterion, provided that thrombosis is 
proved by appropriate diagnostic means and that no alternative diagnosis or cause of thrombosis is found. 
 
§    Superficial venous thrombosis is not included in the clinical criteria.  
 
¶   Generally accepted features of placental insufficiency include:  
    (i)   abnormal or non-reassuring fetal surveillance test(s), e.g. a non-reactive non-stress test, suggestive of 
fetal hypoxemia,  
    (ii)  abnormal Doppler flow velocimetry waveform analysis suggestive of fetal hypoxemia, e.g. absent end-
diastolic flow in the umbilical artery,  
    (iii) oligohydramnios, e.g. an amniotic fluid index of 5 cm or less, or  
    (iv) a postnatal birth weight less than the 10th percentile for the gestational age.  
 
** Investigators are strongly advised to classify APS patients in studies into one of the following categories:  
     I:    more than one laboratory criteria present (any combination) 
     IIa: LA present alone 
     IIb: aCL antibody present alone 
     IIc: anti-β2 glycoprotein-I antibody present alone 
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2.  Disease Activity Measure for Systemic Lupus Erythematosus 
2.1.    Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)* 
 
            Check box if descriptor is present at the time of visit, or in the proceeding 10 days. 
 
Wt Present Descriptor Definition 





Altered ability to function in normal activity due to severe 
disturbance in the perception of reality. Include hallucinations, 
incoherence, marked loose associations, impoverished thought 
content, marked illogical thinking, bizarre, disorganized, or 






□ Organic Brain 
Syndrome 
Altered mental function with impaired orientation, memory or 
other intelligent function, with rapid onset fluctuating clinical 
features. Include clouding of consciousness with reduced 
capacity to focus, and inability to sustain attention to 
environment, plus at least two of the following: perceptual 
disturbance, incoherent speech, insomnia or daytime 
drowsiness, or increased or decreased psychomotor activity. 
Exclude metabolic, infectious or drug causes. 
8 
 
□ Visual Disturbance 
Retinal changes of SLE. Include cytoid bodies, retinal 
hemorrhages, serious exodate or hemorrhages in the choroids, 
or optic neuritis. Exclude hypertension, infection, or drug causes. 
8 □ Cranial Nerve 
Disorder 
New onset of sensory or motor neuropathy involving cranial 
nerves. 
8 □ Lupus Headache Severe persistent headache: may be migrainous, but must be 
nonresponsive to narcotic analgesia. 
8 □ CVA 
New onset of cerebrovascular accident(s).  Exclude 
arteriosclerosis. 
8 □ Vasculitis 
Ulceration, gangrene, tender finger nodules, periungual, 
infarction, splinter haemorrhages, or biopsy or angiogram proof 
of vasculitis. 
4 □ Arthritis More than 2 joints with pain and signs of inflammation (i.e. 




Proximal muscle aching/weakness, associated with elevated 
creatine phosphokinase/adolase or electromyogram changes or 
a biopsy showing myositis. 
4 □ Urinary Casts Heme-granular or red blood cell casts. 
4 □ Haematuria > 5 red blood cells/high power field. Exclude stone, infection or 
other cause. 
4 □ Proteinuria > 0.5 gm/24 hours. New onset or recent increase of more than 
0.5 gm/24 hours. 
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Wt Present Descriptor Definition 
4 □ Pyuria > 5 white blood cells/high power field. Exclude infection. 
2 □ New Rash New onset or recurrence of inflammatory type rash. 
2 □ Alopecia 
New onset or recurrence of abnormal, patchy or diffuse loss of 
hair. 
2 □ Mucosal Ulcers New onset or recurrence of oral or nasal ulcerations. 
2 □ Pleurisy 
Pleuritic chest pain with pleural rub or effusion, or pleural 
thickening. 
2 □ Pericarditis Pericardial pain with at least 1 of the following: rub, effusion, or 
electrocardiogram confirmation. 
2 □ Low Complement Decrease in CH50, C3, or C4 below the lower limit of normal for 
testing laboratory. 
2 □ Increased DNA 
binding 
> 25% binding by Farr assay or above normal range for testing 
laboratory. 
1 □ Fever > 38°C. Exclude infectious cause. 
1 □ Thrombocytopenia < 100,000 platelets/mm3. 
1 □ Leukopenia < 3,000 White blood cell/mm3. Exclude drug causes. 
 
* Available from: http://www.rheumatology.org/practice/clinical/forms [Accessed 9 March 2012]. 
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3.  Damage Index for Systemic Lupus Erythematosus 
3.1   Systemic Lupus International Collaborating Clinics/ACR Damage Index for  
Systemic Lupus Erythematosus (SLICC/ACR DI)a* 
Item Score 
Ocular (either eye, by clinical assessment) 
Any cataract ever 1 
Retinal change or optic atrophy 1 
Neuropsychiatric  
Cognitive impairment (e.g. memory deficit, difficulty with calculation, poor concentration, 
difficulty in spoken or written language, impaired performance levels) or major psychosis 1 
Seizures requiring therapy for 6 months 1 
Cerebrovascular accident ever (score 2 if > 1)       1 (2) 
Cranial or peripheral neuropathy (excluding optic) 1 
Transverse myelitis 1 
Renal  
Estimated or measured glomerular filtration rate<50% 1 
Proteinuria ≥3.5 gm/24hours 1 
OR 
End-stage renal disease (regardless of dialysis or transplantation) 3 
Pulmonary  
Pulmonary hypertension (right ventricular prominence, or loud P2) 1 
Pulmonary fibrosis (physical and radiograph) 1 
Shrinking lung (radiograph) 1 
Pleural fibrosis (radiograph) 1 
Pulmonary infarction (radiograph) 1 
Cardiovascular  
Angina or coronary artery bypass 1 
Myocardial infarction ever (score 2 if > 1)       1 (2) 
Cardiomyopathy (ventricular dysfunction) 1 
Valvular disease (diastolic murmur, or systolic murmur >3/6) 1 
Pericarditis for 6 months, or pericardiectomy 1 
Peripheral vascular  
Claudication for 6 months 1 
Minor tissue loss (pulp space) 1 
Significant tissue loss ever (e.g. loss of digit or limb) (score 2 if > 1 site)       1 (2) 









Infarction or resection of bowel below duodenum spleen, liver, or gall bladder ever, for 
cause any (score 2 if > 1 site)      1 (2) 
Mesenteric insufficiency 1 
Chronic peritonitis 1 
Stricture or upper gastrointestinal tract surgery ever 1 
Musculoskeletal  
Muscle atrophy or weakness 1 
Deforming or erosive arthritis (including reducible deformities, excluding avascular 
necrosis) 1 
Osteoporosis with fracture or vertebral collapse (excluding avascular necrosis) 1 
Avascular necrosis (score 2 if > 1)       1 (2) 
Osteomyelitis 1 
Skin  
Scarring chronic alopecia 1 
Extensive scarring or panniculum other than scalp and pulp space 1 
Skin ulceration (excluding thrombosis) for > 6 months 1 
Premature gonadal failure 1 
Diabetes (regardless of treatment) 1 
Malignancy (exclude dysplasia) (score 2 if > 1 site)       1 (2) 
 
aDamage (nonreversible change, not related to active inflammation) occurring since onset of lupus, 
ascertained by clinical assessment and present for at least 6 months unless otherwise stated. Repeat 
episodes must occur at least 6 months apart to score 2. The same lesion cannot be scored twice. 
 
* Available from: http://www.rheumatology.org/practice/clinical/forms [Accessed 9 March 2012]. 
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4.  Royal National Hospital for Rheumatic Diseases SLE Questionnaire 
SYSTEMIC LUPUS ERYTHEMATOSUS QUESTIONNAIRE
Any information you give is confidential and will only be seen by the research team at the Royal National
Hospital for Rheumatic Diseases, Bath. The information that you provide will be added to a research database
and will contribute to ongoing research by the research team at the Royal National Hospital for Rheumatic
Diseases. We would like you to complete this questionnaire as we are interested in finding out about your Lupus
as well as your background, general health issues and how you manage your daily activities.
Section 1 - Background data 
Married Single Divorced Separated Widoweda) Marital status:
b) Ethnic group:
c) Current employment
When did you last work?
d) When did your symptoms start?





White & Black Caribbean
White & Black African
White & Asian
Any other white background
CTD ID:
Year Symptoms began







Any other Mixed background
Indian
Bangladeshi




Any other Black background
Any other ethnic group









by choice Student Other
a) Have any of your immediate blood relatives (parents, siblings, children) ever had:
please tick as many as apply and give relationship (E.g. Mother) and age that they were at initial event/diagnosis)
b) Please use space below to provide details of any other family history
Section 2 – Family History
Stroke Heart attackLupus
Relation and age at event/diagnosis





If you have any queries regarding our research into Lupus, we would be pleased to hear from you. We
may contact you again in the future for further studies into lupus if you do not want to receive
further correspondence then please let us know. This questionnaire and any questions or queries
should be sent to:
Bath Connective Tissue Disease Research Unit
Bath Institute for Rheumatic Diseases
FREEPOST (SN1549)
Bath – 1 Trimbridge
BA1 1XX
Or Tel:01225 448444 or Email: ctd@birdbath.org.uk
THANK YOU FOR YOUR HELP
a) Have you ever had: (please tick as many as apply)
b) Have you ever had heart problems, blood clots or a stroke?
if yes please describe below:
c) Have you ever taken:
Steroids? (If yes, please give details below:)
Oral contraceptives or had Depot injections? (If yes, please give details below)
HRT? (If yes, please give details below:)
Section 4 – Medical History
Diabetes High cholesterol High blood pressure
Yes No
a) Have you ever smoked?
b) Average time exercising a week?
Type of exercise?
c) Have you ever drunk alcohol?
Section 3 – Lifestyle
Years smoked
Average number of hours per week
Average number of units per week
Average number per day
Current smoker Ex smoker Never smoked
Currently drink Use to drink Never drunk alcohol
Age when prescribed medication
months YearsNumber of months/ years on medication
Yes No
Dose if known
Age when prescribed medication
months YearsNumber of months/ years on medication
Age when prescribed medication
months YearsNumber of months/ years on medication
Yes No
Yes No
 
